WO2018141002A2 - DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS - Google Patents

DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS Download PDF

Info

Publication number
WO2018141002A2
WO2018141002A2 PCT/AU2018/000011 AU2018000011W WO2018141002A2 WO 2018141002 A2 WO2018141002 A2 WO 2018141002A2 AU 2018000011 W AU2018000011 W AU 2018000011W WO 2018141002 A2 WO2018141002 A2 WO 2018141002A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
mmol
heterocycloalkyl
heteroaryl
Prior art date
Application number
PCT/AU2018/000011
Other languages
French (fr)
Other versions
WO2018141002A3 (en
Inventor
Shudong Wang
Sarah AL HAJ DIAB
Yi LONG
Original Assignee
University Of South Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900290A external-priority patent/AU2017900290A0/en
Application filed by University Of South Australia filed Critical University Of South Australia
Priority to CA3051604A priority Critical patent/CA3051604A1/en
Priority to SG11201907095UA priority patent/SG11201907095UA/en
Priority to EP18748523.0A priority patent/EP3577116A4/en
Priority to JP2019541271A priority patent/JP7113528B2/en
Priority to US16/482,867 priority patent/US11111245B2/en
Priority to CN201880015860.9A priority patent/CN110418789B/en
Priority to AU2018214431A priority patent/AU2018214431B2/en
Publication of WO2018141002A2 publication Critical patent/WO2018141002A2/en
Publication of WO2018141002A3 publication Critical patent/WO2018141002A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to a novel class of inhibitors of protein kinases useful in the treatment of proliferative cell diseases and conditions including cancers.
  • CDKs Cycl in-dependent kinases
  • CDKs are serine-threonine protein kinases that associated with various cyclin subunits.
  • CDKs There are more than 20 CDKs which may be classified according to their main functions. That is, CDK 1 , CDK2, CDK3, CDK4 and CDK6 and their cyclin partners (eg cyclin A, B, D 1 , D2, D3, E and F) are known to be involved in the control of cell cycle progression, and are thus considered to be cell cycle regulators.
  • CDK7, CDK8, CDK9 and CDK l 1 and their associated cyclin partners are considered to be transcriptional regulators.
  • CDKs are thus involved in the regulation of cell-cycle control, apoptosis, neuronal physiology, differentiation, and transcription.
  • CDK inhibitors in the treatment of various diseases, including cancers, cardiovascular disorders, inflammatory diseases, neurodegenerative diseases and viral diseases, is of considerable interest (Wang, S et ai, Trends Pharmacol Sci 29(6):302-313, 2008).
  • L0006J Palbociclib (6-Acetyl-8-cyclopentyl-5-methyl-2- ⁇ L5-(l-piperazinyl)-2-pyridinylJamino ⁇ pyrido L2,3-dJpyrimidin-7(8H)-one), an inhibitor of CDK4 and CDK6, is one specific example of a CDK inhibitor that is now available for the treatment of a proliferative cell disease, particularly estrogen- positive, HER2-negative advanced breast cancer.
  • numerous other CDK inhibitors have been described with potential as agents for treating proliferative cell diseases and conditions including cancers.
  • N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2- amine compounds see International Patent Publication Nos WO 2017/020065. These compounds inhibit multiple protein kinases, particularly CDKs, including CDK4/cyclin Dl and CDK6/cyclin D3.
  • N-cylcloalkyl/heterocycloalkyl-4- (imidazo[l ,2-a]pyridine)pyrirmdin-2-amine compounds for use in the prevention and/or treatment of various diseases and conditions including proliferative diseases and conditions such as cancers.
  • A is a cycloalkyl or heterocycloalkyl, optionally substituted by one or more R 6 groups such that m is an integer from 0 to 5 inclusive, and wherein said heterocycloalkyl comprises at least one but no more than two heteroatoms selected from N, O and S; and wherein
  • R, R', R 2 , R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of H, alkyl, alkyl- R 9 , heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH 2 -heteroaryl, aralkyl, halogen, N0 2 , CN, CF 3 , OH, O-alkyl, O-alkyl-R 7 , O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O- R 7 , NH 2 , NH-alkyl, NH-alkyl-R 7 , NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH- heteroaryl, NH-R 7 , NHO-aryl, NH
  • R 7 and R 8 are each independently selected from the group consisting of H, alkyl, alkyl-R 10 , heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, halogen, N0 2 , CN, CF 3 , OH, O-alkyl, O-alkyl-R 10 , O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O-R 10 , NH 2 , NH- alkyl, NH-alkyl-R 10 , NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH- R 10 , N-(alkyl) 2 , N-(heteroalkyl) 2 , N-(cycloalkyl) 2
  • heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O
  • said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, CN, OH, O-methyl, NH 2 , COOH, CONH 2 , CF 3 and S0 2 N(CH 3 ) 2 ; and
  • R 9 , R 10 and R" are independently selected from water solubilising groups
  • the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating cancer or another proliferative cell disease or condition.
  • the present invention provides a method of treating cancer or another proliferative cell disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • a pharmaceutically acceptable carrier diluent and/or excipient.
  • the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating cancer or another proliferative cell disease or condition.
  • the present invention provides a pharmaceutical composition or medicament comprising a compound as defined in the first aspect and a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the present invention provides a method for modulating protein kinase activity in a cell, comprising introducing to or contacting said cell with an effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a disease or condition.
  • the present invention provides a method of treating a disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating a disease or condition in a subject.
  • the disease or condition referred to in any of the above aspects may be characterised by over- expression of one or more CDK enzyme and/or by one or more aberrant CDK activity. Otherwise, said disease or condition may be one which may be beneficially treated by inhibiting one or more CDK (eg by inhibiting the activity and/or expression of one or more of CDK1 , CDK2, CDK4, CDK6, CDK7 and CDK9, and/or the association of one or more of such CDK enzymes with their respective cyclin/mediator complex).
  • CDK eg by inhibiting the activity and/or expression of one or more of CDK1 , CDK2, CDK4, CDK6, CDK7 and CDK9, and/or the association of one or more of such CDK enzymes with their respective cyclin/mediator complex.
  • N-cylcloalkyl/heterocycloalkyl-4- (imidazo[ l ,2-a]pyridine)pyrimidin-2-amine derivatives suitable for use in the prevention and/or treatment of various diseases and conditions including proliferative cell diseases and conditions such as cancers, which possess desirable biological activity (eg the compounds may inhibit cell proliferation by inhibiting the activity of CDKs, FMS-like tyrosine kinases (FLTs), aurora kinases and/or CDC-like kinases (CLKs)).
  • FLTs FMS-like tyrosine kinases
  • aurora kinases and/or CDC-like kinases (CLKs)
  • the present invention provides a compound of formula I shown below:
  • A is a cycloalkyl or heterocycloalkyl, optionally substituted by one or more R 6 groups such that m is an integer from 0 to 5 inclusive, and wherein said heterocycloalkyl comprises at least one but no more than two heteroatoms selected from N, O and S; and wherein
  • R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of H, alkyl, alkyl- R 7 , heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH 2 -heteroaryl, aralkyl, halogen, N0 2 , CN, CF 3 , OH, O-alkyl, O-alkyl-R 7 , O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O- R 9 , NH 2 , NH-alkyl, NH-alkyl-R 7 , NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH- heteroaryl, NH-R 7 , NHO-aryl,
  • R 7 and R 9 are each independently selected from the group consisting of H, alkyl, alkyl-R 10 , heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, halogen, N0 2 , CN, CF 3 , OH, O-alkyl, O-alkyl-R 10 , O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O-R 10 , NH 2 , NH- alkyl, NH-alkyl-R 10 , NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH- R 10 , N-(alkyl) 2 , N-(heteroalkyl) 2 , N-(cycloalkyl) 2
  • R 9 , R 10 and R 1 1 are independently selected from water solubilising groups
  • the compounds of formula I have been found to possess anti-proliferative activity and are therefore considered to be of use in the treatment of proliferative cell diseases and conditions such as cancers (including, for example, leukaemia and lymphoma) and other diseases and conditions associated with uncontrolled cell proliferation such as, for example, some cardiovascular diseases or conditions such as restenosis and cardiomyopathy, some auto-immune diseases such as glomerulonephritis and rheumatoid arthritis, dermatological conditions such as psoriasis, and fungal or parasitic disorders.
  • proliferative cell diseases and conditions such as cancers (including, for example, leukaemia and lymphoma) and other diseases and conditions associated with uncontrolled cell proliferation such as, for example, some cardiovascular diseases or conditions such as restenosis and cardiomyopathy, some auto-immune diseases such as glomerulonephritis and rheumatoid arthritis, dermatological conditions such as psoriasis, and fungal or parasitic disorders.
  • the compounds of formula I may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (GO), Gl progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2
  • the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating cancer or another proliferative cell disease or condition.
  • the present invention provides a method of treating cancer or another proliferative cell disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating cancer or another proliferative cell disease or condition.
  • the present invention provides a pharmaceutical composition or medicament comprising a compound as defined in the first aspect and a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the present invention provides a method for modulating protein kinase activity in a cell, comprising introducing to or contacting said cell with an effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a disease or condition in a subject.
  • the present invention provides a method of treating a disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating a disease or condition in a subject.
  • treating includes prophylaxis as well as the alleviation of established symptoms of a condition.
  • the act of "treating" a disease or condition therefore includes: ( 1) preventing or delaying the appearance of clinical symptoms of the disease or condition developing in a subject afflicted with or predisposed to the disease or condition; (2) inhibiting the disease or condition (ie arresting, reducing or delaying the development of the disease or condition or a relapse thereof (in case of a maintenance treatment) or at least one clinical or subclinical symptom thereof; and (3) relieving or attenuating the disease or condition (ie causing regression of the disease or condition or at least one of its clinical or subclinical symptoms).
  • alkyl includes both straight chain and branched alkyl groups having from 1 to 8 carbon atoms (eg methyl, ethyl propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl etc).
  • heteroalkyl refers to both straight chain and branched alkyl groups wherein one or more carbon atoms are replaced by an 0-, N- or S- atom (eg 1-methoxypropanyl, methyl propionate etc).
  • cycloalkyl represents cyclic versions of alkyl (cyclopropyl, cyclopentyl, cyclohexyl etc), and may include fused rings. Cycloalkyl groups are unsubstituted, but may be substituted with those groups typically suitable for alkyl group substituents.
  • heterocycloalkyl or “heterocyclic” represents a cycloalkyl containing at least one annular carbon and at least one annular heteroatom selected from the group consisting of N, O and S, wherein the ring is not aromatic but can contain unsaturations.
  • the nitrogen and sulfur atoms in a heterocyclic group can be oxidised and the nitrogen atom(s) may optionally be quaternised.
  • the heterocyclic group can be fused to an additional carbocyclic or heterocyclic ring.
  • a heterocyclic group can be attached to the remainder of the molecule at an annular carbon or annular heteroatom.
  • heterocyclic main contain fused rings, but excludes fused systems containing a heteroaryl group as part of the fused ring system.
  • heterocycloalkyl include, but are not limited to, 1- piperidinyl, 1-piperazinyl, morpholinyl, alkylpiperidinyl etc.
  • Heterocycloalkyl moieties can be unsubstituted or substituted with various substituents known in the art, eg hydroxyl, halogen, alkylamino etc.
  • aryl refers to a substituted (mono- or poly-) or unsubstituted monoaromatic or polyaromatic group, wherein said polyaromatic group may be fused or unfused.
  • the term therefore includes groups having from 6 to 10 carbon atoms (eg phenyl, naphthyl etc). It is also to be understood that the term “aryl” is synonymous with the term “aromatic”.
  • heteroaryl refers to a substituted (mono- or poly-) or unsubstituted monoaromatic or polyaromatic group wherein polyaromatic group may be fused or unfused; and wherein at least one of the rings is an aromatic ring that contains from one to four heteroatoms selected from N, O and S as ring members (i.e. it contains at least one heteroaromatic ring); and wherein the nitrogen and sulfur atoms can be oxidised and the nitrogen atom(s) can be quaternised.
  • a heteroaryl group can be attached to the remainder of the molecule through an annular carbon or annular heteroatom, and it can be attached through any ring of the heteroaryl moiety, if that moiety is bicyclic, tricyclic or a fused ring system.
  • Illustrative examples of heteroaryl groups include 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-pyrimidyl, 5- indolyl etc.
  • aralkyl is used as a conjunction of the terms alkyl and aryl as defined above.
  • alicyclic refers to a cyclic aliphatic group.
  • aliphatic takes its normal meaning in the art and includes non-aromatic groups such as alkanes, alkenes and alkynes and substituted derivatives thereof.
  • halogen refers to fluoro, chloro, bromo and iodo.
  • derivative includes any chemical modification of an entity. Illustrative of such chemical modifications is the replacement of hydrogen by a halogen group, an alkyl group, an acyl group or an amino group.
  • the phrase "manufacture of a medicament” includes the use of one or more of the compounds of formula I directly as the medicament or in any stage of the manufacture of a medicament comprising one or more of the compounds of formula I.
  • Some of the compounds of formula I may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof, are encompassed within the scope of the present invention.
  • the isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods known to those skilled in the art.
  • pharmaceutically acceptable salt refers to salts that retain the desired biological activity of the compounds of formula I, and include pharmaceutically acceptable acid addition salts and base addition salts.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic and arylsulfonic. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995.
  • Prodrug means a compound that undergoes conversion to a compound of formula 1 within a biological system, usually by metabolic means (eg by hydrolysis, reduction or oxidation).
  • metabolic means eg by hydrolysis, reduction or oxidation.
  • an ester prodrug of a compound of formula I containing a hydroxyl group may be convertible by hydrolysis in vivo to the compound of formula I.
  • Suitable esters of the compounds of formula I containing a hydroxyl group may be, for example, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-P-hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p- toluenesulfonates, cyclohexylsulfamates and quinates.
  • an ester prodrug of a compound of formula I containing a carboxy group may be convertible by hydrolysis in vivo to the compound of formula I.
  • ester prodrugs include those described by Leinweber FJ, Drug Metab Rev 18:379-439 ( 1987).
  • an acyl prodrug of a compound of formula I containing an amino group may be convertible by hydrolysis in vivo to the compound of formula I. Examples of prodrugs for these and other functional groups, including amines, are provided in Prodrugs: challenges and rewards, Valentino J Stella (ed), Springer, 2007.
  • terapéuticaally effective amount is an amount sufficient to effect beneficial or desired clinical results.
  • a therapeutically effective amount can be administered in one or more administrations.
  • a therapeutically effective amount is sufficient for treating a disease or condition or otherwise to palliate, ameliorate, stabilise, reverse, slow or delay the progression of a disease or condition such as, for example, cancer or another proliferative cell disease or condition.
  • pharmaceutically acceptable salt, solvate or prodrug thereof may comprise between about 0.1 and about 250 mg/kg body weight per day, more preferably between about 0.1 and about 100 mg/kg body weight per day and, still more preferably between about 0.1 and about 25 mg/kg body weight per day.
  • the therapeutically effective amount may vary and depend upon a variety of factors including the activity of the particular compound (or salt, solvate or prodrug thereof), the metabolic stability and length of action of the particular compound (or salt, solvate or prodrug thereof), the age, body weight, sex, health, route and time of administration, rate of excretion of the particular compound (or salt, solvate or prodrug thereof), and the severity of, for example, the cancer or other proliferative cell disease or condition to be treated.
  • the compounds of formula I, and pharmaceutically acceptable salts, solvates and prodrugs thereof are capable of inhibiting protein kinases, especially one or more of the following group: CDKs, FLT kinases, aurora kinases and/or CLKs and may show higher selectivity (to inhibit) CDKs over other protein kinases.
  • the compounds of formula I, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which are believed to inhibit CDKs have utility in both in vitro and in vivo applications (eg in vitro whole cell assays) and as the basis of a therapeutic method of treating cancer or another proliferative cell disease or condition in a subject.
  • the compounds of formula I are suitable for the treatment of other diseases or conditions in which one or more of the protein kinase targets outlined above are implicated.
  • the compounds of formula I preferably bear a fused heterocyclic group attached to the pyrimidine ring through one of the ring carbon atoms (particularly, the carbon at position 4). More specifically, compounds of formula I preferably bear an imidazo[ l ,2-a]pyridine group attached to the carbon at position 4 of the pyrimidine. Moreover, the compounds of formula I bear group A, which is preferably a 4- to 10-membered cycloalkyl or heterocycloalkyl group, attached to the pyrimidine ring at the carbon at position 3 through an amine group.
  • the group A comprises a heterocycloalkyl group
  • that heterocycloalkyl group will comprise at least one but no more than two heteroatoms selected from N, O and S as ring members.
  • the group A is optionally substituted by one or more R 6 groups.
  • the group A is a 5- to 7-membered cycloalkyl or heterocycloalkyl group optionally substituted by one or more R 6 groups, such as a 6-membered cycloalkyl or heterocycloalkyl group optionally substituted by one or more R 6 groups such as, for example, a cyclohexyl group or piperidine group.
  • the group A is a 10-membered cycloalkyl group (eg an adamantane group) or heterocycloalkyl group optionally substituted by one or more R 6 groups.
  • the compounds of formula I may preferably comprise at least one water solubilising group R 9 , R 10 or R 11 .
  • R 9 , R 10 and R 11 are preferably independently selected from water solubilising groups of the group consisting of:
  • alicyclic, aryl and heterocyclic groups comprising one or more 0-, S- or N- heteroatoms, which may further comprise an alkyl bridge (eg a -CH 2 - or -CH 2 CH 2 - bridge),
  • morpholine, piperazine or 1 ,4-diazepane groups each of which may be optionally substituted by one or more substituents selected from S0 2 -alkyl, alkyl optionally substituted by one or more OH groups, CO-alkyl, aralkyl, COO-alkyl, and an ether group optionally substituted by one or more OH groups;
  • R 17 and R 18 are each independently selected from H, alkyl and aryl, with the proviso that at least one of R 17 and R 18 is other than H, or R 17 and R 18 together form a cyclic group optionally comprising one or more heteroatoms selected from N, O and S, and wherein said alkyl, aryl or cyclic group is optionally substituted by one or more substituents selected from halogen, N0 2 , OH, alkoxy, NH 2 , COOH, CONH 2 and CF 3 .
  • R, R 1 , R 2 , R 3 and R 4 are each independently selected from the group consisting of H, alkyl (eg a Ci_ 6 alkyl or, preferably, a Ci_ 3 alkyl such as methyl), cycloalkyl,
  • heterocycloalkyl aryl (eg phenyl), heteroaryl (eg pyridinyl, pyrimidinyl), CH 2 -heteroaryl, halogen (especially Br or F), N0 2 , CF 3 , OH, O-alkyl (eg an O-Q.6 alkyl, preferably, an 0-C 1 3 alkyl such as O- CH 3 ), O-heteroalkyl, 0-C 3 .
  • aryl eg phenyl
  • heteroaryl eg pyridinyl, pyrimidinyl
  • CH 2 -heteroaryl halogen (especially Br or F)
  • N0 2 , CF 3 , OH, O-alkyl (eg an O-Q.6 alkyl, preferably, an 0-C 1 3 alkyl such as O- CH 3 ), O-heteroalkyl, 0-C 3 .
  • cycloalkyl such as 0(C 5 H 9 ); ie O-cyclopentyl
  • O-aryl O-heteroaryl
  • NH 2 NH-alkyl (eg a NH-d_ 6 alkyl, preferably, a NH-d_ 3 alkyl such as NH-CH 3 ), NH-heteroalkyl (eg N' ,N'- dimethylethane- l ,2-diamine), NH-cycloalkyl (eg a NH-C 3 .
  • NH-alkyl eg a NH-d_ 6 alkyl, preferably, a NH-d_ 3 alkyl such as NH-CH 3
  • NH-heteroalkyl eg N' ,N'- dimethylethane- l ,2-diamine
  • NH-cycloalkyl eg a NH-C 3 .
  • cycloalkyl such as NH(C 5 H 9 ); ie NH- cyclopentyl), NH-heterocycloalkyl (eg NH-C 3 . 8 heterocycloalkyl such as NH(C 5 HnN); ie NH- piperidinamine), NH-aryl (eg NH-phenyl), NH-heteroaryl, NH-Ci_ 3 0-aryl, NHO-aryl, NHO-heteroaryl, NHCH 2 -aryl, N(alkyl) 2 (such as N(CH 3 ) 2 ), N(cycloalkyl) 2 (eg N(C 5 H 9 ) 2 ), N(heterocycloalkyl) 2 (such as N-dipiperidinamine), N-(alkyl)(aryl), SH-alkyl (eg a SH-C ⁇ alkyl or, preferably, a SH-C ⁇ alkyl such as SHCH 3 and S
  • cycloalkyl such as S(C 5 H 9 ); ie S- cyclopentyl, and R 11 ; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl (eg methyl), CN, OH, O-methyl, O-ethyl, 0-CF 2 , NH 2 , COOH, CONH 2 , heterocycloalkyl, CO-heterocycloalkyl, CF 3 and S0 2 N(CH 3 ) 2 .
  • alkyl eg methyl
  • CN OH, O-methyl, O-ethyl, 0-CF 2
  • NH 2 COOH
  • CONH 2 heterocycloalkyl
  • R is H.
  • R 1 is heteroaryl (eg pyridine).
  • R, R 1 , R 3 and R 4 are all H, and R 2 is selected from the group consisting of H, alkyl (eg a C
  • _ 3 alkyl such as NH-CH 3
  • NH-heteroalkyl eg N' ⁇ -dimethylethane- l ⁇ -diamine
  • NH-cycloalkyl eg a NH-C 3 _8 cycloalkyl such as NH(C 5 H 9 ); ie NH-cyclopentyl), NH-heterocycloalkyl (eg NH-C 3 _ 8 heterocycloalkyl such as NH(C 5 HnN); ie NH-piperidinamine), NH-aryl (eg NH-phenyl), NH-heteroaryl, N(alkyl) 2 (such as N(CH 3 ) 2 ), N(cycloalkyl) 2 (eg N(C 5 H 9 ) 2 ), N(heterocycloalkyl) 2 (such as N- dipiperidinamine), N-(alkyl) 2 (such as N-
  • cycloalkyl such as S(C 5 H 9 ); ie S- cyclopentyl, and R 1 ' ; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl (eg methyl), CN, OH, O-methyl, O-ethyl, 0-CF 2 , NH 2 , COOH, CONH 2 , heterocycloalkyl, CO-heterocycloalkyl, CF 3 and S0 2 N(CH 3 ) 2 .
  • alkyl eg methyl
  • CN OH, O-methyl, O-ethyl, 0-CF 2
  • NH 2 COOH
  • CONH 2 heterocycloal
  • R, R 1 , R 2 and R 4 are all H, and R 3 is selected from the group consisting of H, alkyl (eg a Ci_ 6 alkyl or, preferably, a Cj. 3 alkyl such as methyl), cycloalkyl, heterocycloalkyl, aryl (eg phenyl), heteroaryl (eg pyridinyl, pyrimidinyl), halogen (especially Br or F), N0 2 , CF 3 , OH, O-alkyl (eg an 0-Ci_6 alkyl, preferably, an O-C ⁇ alkyl such as 0-CH 3 ), O-heteroalkyl, 0-C 3 .
  • alkyl eg a Ci_ 6 alkyl or, preferably, a Cj. 3 alkyl such as methyl
  • aryl eg phenyl
  • heteroaryl eg pyridinyl, pyrimidinyl
  • halogen especially
  • cycloalkyl such as 0(C 5 H 9 ); ie O-cyclopentyl), O-aryl, O-heteroaryl, NH 2 , NH-alkyl (eg a NH-d_ 6 alkyl, preferably, a NH- Ci -3 alkyl such as NH-CH 3 ), NH-heteroalkyl (eg NH-cycloalkyl (eg a NH-C 3 _8 cycloalkyl such as NH(C 5 H 9 ); ie NH-cyclopentyl), NH-heterocycloalkyl (eg NH-C 3 .
  • NH-alkyl eg a NH-d_ 6 alkyl, preferably, a NH- Ci -3 alkyl such as NH-CH 3
  • NH-heteroalkyl eg NH-cycloalkyl (eg a NH-C 3 _8 cycl
  • heterocycloalkyl such as NH(C 5 HnN); ie NH-piperidinamine), NH-aryl (eg NH-phenyl), NH-heteroaryl, N(alkyl) 2 (such as N(CH 3 ) 2 ), N(cycloalkyl) 2 (eg N(C 5 H 9 ) 2 ), N(heterocycloalkyl) 2 (such as N- dipiperidinamine), N-(alkyl)(aryl), SH-alkyl (eg a SH-Ci_ 6 alkyl or, preferably, a SH-C ⁇ alkyl such as SHCH 3 and SHC(CH 3 )), SH-aryl, SH-heteroaryl, S-heteroalkyl, S-C 3 .
  • SH-alkyl eg a SH-Ci_ 6 alkyl or, preferably, a SH-C ⁇ alkyl such as SHCH 3 and SHC(CH 3 )
  • cycloalkyl such as S(C 5 H 9 ); ie S- cyclopentyl, and R 11 ; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl (eg methyl), CN, OH, O-methyl, O-ethyl, 0-CF 2 , NH 2 , COOH, CONH 2 , heterocycloalkyl, CO-heterocycloalkyl, CF 3 and S0 2 N(CH 3 ) 2 .
  • alkyl eg methyl
  • CN OH, O-methyl, O-ethyl, 0-CF 2
  • NH 2 COOH
  • CONH 2 heterocycloalkyl
  • R 5 is H, alkyl (eg a C . 6 alkyl such as phenyl, or preferably, a Ci_ 3 alkyl such as methyl), O-alkyl (preferably, a C
  • alkyl eg a C . 6 alkyl such as phenyl, or preferably, a Ci_ 3 alkyl such as methyl
  • O-alkyl preferably, a C
  • CN or halogen (preferably F and CI).
  • m is an integer from 1 to 5 inclusive, but more preferably, m is an integer from 1 , 2 and 3. Most preferably, m is 1. Where m is 2, 3, 4 or 5, it is to be understood that each of the R 6 groups may be the same or different.
  • R 6 is independently selected from the group consisting of H, alkyl (eg a Ci_5 alkyl such as methyl, propyl, cyclopropylmethyl, cyclopentylmethyl), OH, halogen (preferably F), O- alkyl (preferably, a Ci_ 6 alkoxy or, more preferably, a C 1 3 alkoxy such as methoxy or ethoxy), C0 2 -alkyl, COOH, Ci_ 3 -heterocycloalkyl, O-heteroalkyl, NH 2 , NH-alkyl (preferably, a Ci_ 6 alkyl or, more preferably, an NH-Ci.3 alkyl such as NH-CH 3 ), N-(alkyl) 2 (eg N(CH 3 ) 2 and N(C 2 H 5 ) 2 ), NH-cycloalkyl (preferably, a NH-d.4 cycloalkyl such as aze
  • A is a cyclopentane, cyclohexane, cycloheptane, tetrahydrofuran or tetrahydro-2H-pyran, diazaspiro[4.5]decan-l-one, quinuclidine, quinuclidin-3-amine, piperidine, or oxepane optionally substituted with at least one of R 6 .
  • A is cyclohexane, adamantane, tetrahydro-2H-pyran or piperidine optionally substituted with at least one of R 6 .
  • the compounds of the present invention exhibit anti-proliferative activity in human cell lines, as measured by a standard cytotoxicity assay.
  • the compound exhibits an TC 50 value of less than 5 ⁇ , even more preferably less than 1 ⁇ as measured by the cell viability (MTT proliferation) assay described in Example 2 hereinafter. More preferably still, the compound exhibits an IC 50 value of less than 0.5 ⁇ .
  • the compounds of the present invention inhibit one or more protein kinases, as measured by any standard assay well known to those skilled in the art.
  • the compound exhibits an IC 50 value of less than 1 ⁇ or less than 0.5 ⁇ as measured by the kinase assay described in Example 2 hereinafter, more preferably still less than 0.1 ⁇ .
  • the compounds may be administered in combination with one or more additional agent(s) for the treatment of cancer or another proliferative disease or condition.
  • the compounds may be used in combination with other anti-cancer agents in order to inhibit more than one cancer signalling pathway simultaneously so as to make cancer cells more susceptible to anti-cancer therapies (eg treatments with other anti-cancer agents, chemotherapy, radiotherapy or a combination thereof).
  • the compounds of formula 1 may be used in combination with one or more of the following categories of anti-cancer agents:
  • alkylating agents eg cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas
  • alkylating agents eg cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas
  • antimetabolites eg gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, fludarabine and hydroxyurea
  • antitumour antibiotics eg anthracyclines such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin
  • antimitotic agents eg vinca alkaloids such as vincristine, vinblastine, vindesine and vinorelbine and taxoids including taxol and taxotere and polokinase inhibitors
  • topoisomerase inhibitors eg gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrex
  • epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan and camptothecin
  • cytostatic agents such as antioestrogens (eg tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (eg bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (eg goserelin, leuprorelin and buserelin), progestogens (eg megestrol acetate), aromatase inhibitors (eg as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;
  • antioestrogens eg tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene
  • antiandrogens e
  • anti-invasion agents eg c-Src kinase family inhibitors such as 4-(6-chloro-2,3- methylenedioxyanilino)-7-L2-(4-methylpiperazin-l-yl)ethoxyJ-5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Publication No WO 01/94341), N-(2-chloro- 6-methylphenyl)-2- ⁇ 6-[4-(2-hydroxyethyl)piperazin-l-yl]-2-methylpyrimidin-4- ylamino ⁇ thiazole-5-carboxamide (dasatinib) and bosutinib (SKI-606)), and metalloproteinase inhibitors including marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to heparanase;
  • anti-invasion agents eg c-Src kinase
  • inhibitors of growth factor function eg growth factor antibodies and growth factor receptor antibodies such as the anti-erbB2 antibody trastuzumab (HerceptinTM), the anti-EGFR antibody panitumumab, the anti-erbB 1 antibody cetuximab (Erbitux, C225) and any growth factor or growth factor receptor antibodies disclosed by Stern et al. Critical reviews in
  • Such inhibitors also include tyrosine kinase inhibitors such as inhibitors of the epidermal growth factor family (eg EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3- morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2- methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-/V-(3-chloro-4- fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the epidermal growth factor family (eg EGFR family tyrosine kinas
  • immunotherapy approaches including for example ex vivo and in vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
  • cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor
  • a compound of the present invention and the other anti-cancer agent can be administered in the same pharmaceutical composition or in separate pharmaceutical compositions. If administered in separate pharmaceutical compositions, the compound and the other anti-cancer agent may be administered simultaneously or sequentially in any order (eg within seconds or minutes or even hours (eg 2 to 48 hours).
  • the present invention is typically applied to the treatment of cancer or another proliferative cell disease or condition in a human subject.
  • the subject may also be selected from, for example, livestock animals (eg cows, horses, pigs, sheep and goats), companion animals (eg dogs and cats) and exotic animals (eg non-human primates, tigers, elephants etc).
  • Cancers and other proliferative cell diseases and conditions that may be treated in accordance with the present invention include biliary tract cancer, brain cancer (including glioblastomas and medulloblastomas), breast cancer, cervical cancer; choriocarcinoma, colonic cancer, endometrial cancer, oesophageal cancer, gastric cancer, haematological neoplasms (including acute lymphocytic leukemia (ALL)), chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML), acute myeloid leukaemia (AML), multiple myeloma, AIDS-associated leukemias and adult T-cell leukemia lymphoma, intraepithelial neoplasms (including Bowen's disease and Paget's disease), liver cancer, lung cancer, lymphomas (including Hodgkin's disease and lymphocytic lymphomas), neuroblastomas, oral cancer (including squamous cell carcinoma),
  • ALL
  • osteosarcoma skin cancer (including melanoma, Kaposi's sarcoma, basocellular cancer, and squamous cell cancer), testicular cancer (including germinal tumours such as seminoma, non-seminoma teratomas, and choriocarcinomas), stromal tumours, germ cell tumours, thyroid cancer (including thyroid adenocarcinoma and medullar carcinoma), and renal cancer (including adenocarcinoma and Wilms' tumour).
  • germinal tumours such as seminoma, non-seminoma teratomas, and choriocarcinomas
  • stromal tumours germ cell tumours
  • thyroid cancer including thyroid adenocarcinoma and medullar carcinoma
  • renal cancer including adenocarcinoma and Wilms' tumour.
  • the compounds of the present invention are used to treat cancers characterised by over-expression of CDKs, for example, chronic lymphocytic leukaemia (CLL), lymphoma, leukaemia, breast cancer, lung cancer, prostate cancer, colon cancer, melanoma, pancreatic cancer, ovarian cancer, squamous cancer, carcinoma of head and neck, endometrial cancer, and oesophageal carcinoma (reviewed in Lapenna et al., Nat Rev Drug Discov 8(7):547-66 (2009) and Asghar et al, Nat Rev Drug Discov 14(2): 130-46 (2015)).
  • CLL chronic lymphocytic leukaemia
  • lymphoma lymphoma
  • leukaemia breast cancer
  • lung cancer prostate cancer
  • colon cancer melanoma
  • pancreatic cancer pancreatic cancer
  • ovarian cancer squamous cancer
  • carcinoma of head and neck endometrial cancer
  • endometrial cancer endometrial cancer
  • CDKs and/or cyclin over-expression may be determined by, for example, assessing the amount of mRNA encoding CDK and/or cyclin in a suitable sample using any of the techniques well known to those skilled in the art (eg quantitative amplification techniques such as qPCR).
  • the compounds of the present invention are used to a disease or condition characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity.
  • said disease or condition may be one which may be beneficially treated by inhibiting one or more CDK (eg by inhibiting the activity and/or expression of one or more of CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9, and/or the association of one or more of such CDK enzymes with their respective cyclin/mediator complex).
  • the compounds of the present invention may therefore be used to treat diseases or conditions including, for example, viral disorders, eg human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV) (Yamamoto et ai, J Clin Invest 124(8): 3479-3488 (2014)), cardiovascular diseases, eg ischaemic heart disease (known also as myocardial infarction or angina), hypertension, heart failure, restenosis and cardiomyopathy (Trifonov et ai, Curr Opin Biotechnol. 24(S 1): S I 14-S 115
  • cancers eg chronic lymphocytic leukaemia (CLL) (Walsby et ai, Oncotarget 5(2):375-85
  • lymphoma (Gregory et ai, Leukemia 29(6): 1437-1441 (2015)), leukaemia (Walsby et ai, Leukemia 25(3):41 1-419 (201 1)), breast cancer (Mita et al, Clin Breast Cancer 14(3): 169-176 (2014)), lung cancer (Stephenson et al, Lung Cancer 83(2):219-223 (2014)), prostate cancer (reviewed in Rahaman et al, Endocr Relat Cancer pii: ERC- 16-0299 (2016)), melanoma (Desai et ai, PLoS One 8(3):e59588 (2013)), pancreatic cancer (Hu et al, Mol Cancer Ther 14(7): 1532-1539 (2015)), ovarian cancer (Lam et al, Oncotarget 5(17):7691-7704 (2014)), hepatocarcinoma (Li et al, Curr Cancer Drug Target 15(3): 196-204 (2015)), oesophage
  • the level of CDK may be determined by, for example, assessing the amount of mRNA encoding CDK and/or cyclin in a suitable sample using any of the techniques well known to those skilled in the art (eg quantitative amplification techniques such as qPCR).
  • the compounds of the present invention are used to treat cancers characterised by over-expression of Fit kinases such as Flt3 and/or mutations, eg acute myeloid leukaemia (reviewed in Hitoshi et al., Nagoya J Med Sci 77(l-2):7-17 (2015) and Wander et al., Ther Adv Hematol 5(3):65-77 (2014)).
  • Fit kinases such as Flt3 and/or mutations, eg acute myeloid leukaemia (reviewed in Hitoshi et al., Nagoya J Med Sci 77(l-2):7-17 (2015) and Wander et al., Ther Adv Hematol 5(3):65-77 (2014)).
  • the compounds of the present invention are used to treat conditions characterised by over-expression of CLKs, eg in Alzheimer's disease (AD) and in diseases involving abnormal pre-mRNA splicing (Jain et al, Curr Drug Targets 15(5):539-50 (2014)).
  • CLKs are serine- arginine protein kinases and are elements of the splicing machinery. Inhibitors of CLKs modulate pre- mRNA splicing, thereby impeding cell growth and inducing apoptosis (Araki et al., PLoS One 10( 1 ): eO l 16929 (2015)).
  • the compounds of the present invention are used to treat cancers characterised by over-expression of aurora kinases.
  • Aurora kinases are key mitotic regulators, they control multiple steps of mitosis, including centrosome duplication, formation of a bipolar mitotic spindle, chromosome alignment on the mitotic spindle and the fidelity-monitoring spindle checkpoint (reviewed in Macarulla et al. , Recent Pat Anticancer Drug Discov (2): 1 14-22 (2008)).
  • Aurora kinase inhibitors are used to treat cancers, eg childhood acute leukaemia (Hartsink Segers et al, Leukemia 27(3): 560-568 (2013)), lung cancer (Chinn et al, J Cancer Res Clin Oncol 140(7): 1 137- 1349 (2014)), prostate cancer (Paller et al, Cancer Med 3(5): 1322-1335 (2014)), advanced solid tumours (Schwartz et al., Invest New Drugs 31(2):370-80 (2013)), and neuroblastoma (Michaelis et al, PLoS One 9(9): el08758 (2014)).
  • the compounds of the present invention may be formulated into a pharmaceutical composition with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • suitable carriers and diluents are well known to those skilled in the art, and are described in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1995.
  • suitable excipients for the various different forms of pharmaceutical compositions described herein may be found in the Handbook of Pharmaceutical Excipients, 2 nd Edition, ( 1994), Edited by A Wade and PJ Weller.
  • suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.
  • suitable diluents include ethanol, glycerol and water. The choice of carrier, diluent and/or excipient may be made with regard to the intended route of administration and standard pharmaceutical practice.
  • a pharmaceutical composition comprising a compound of the present invention may further comprise any suitable binders, lubricants, suspending agents, coating agents and solubilising agents.
  • suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.
  • suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Preservatives, stabilising agents, dyes and even flavouring agents may be provided in the pharmaceutical composition.
  • preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.
  • Anti-oxidants and suspending agents may be also used.
  • a pharmaceutical composition comprising a compound of the present invention may be adapted for oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, subcutaneous, intradermal, intravenous, nasal, buccal or sublingual routes of administration.
  • oral administration particular use may be made of compressed tablets, pills, tablets, gellules, drops, and capsules.
  • a pharmaceutical composition may comprise solutions or emulsions which may be injected intravenously, intraarterially, intrathecally, subcutaneously, intradermally, intraperitoneally or intramuscularly, and which are prepared from sterile or sterilisable solutions.
  • a pharmaceutical composition comprising a compound of the present invention may also be in form of suppositories, pessaries, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or dusting powders.
  • a pharmaceutical composition may be formulated in unit dosage form (ie in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose).
  • the compounds of the present invention may be provided as a pharmaceutically acceptable salt including, for example, suitable acid addition or base salts thereof.
  • suitable pharmaceutical salts may be found in Berge et al., J Pharm Sci 66: 1-19 ( 1977).
  • Salts are formed, for example with strong inorganic acids such as mineral acids (eg sulfuric acid, phosphoric acid or hydrohalic acids), with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (eg by halogen), such as acetic acid, with saturated or unsaturated dicarboxylic acids (eg oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic acid), with hydroxycarboxylic acids (eg ascorbic, glycolic, lactic, malic, tartaric or citric acid), with amino acids (eg aspartic or glutamic acid), with benzoic acid, or with organic sulfonic acids (eg (C r C 4 )-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted by, for example, halogen) such as methane- or p-tolu
  • the compounds of the present invention may be provided in their various crystalline forms, polymorphic forms and (an)hydrous forms.
  • chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation from the solvents used in the synthetic preparation of such compounds.
  • the present invention further provides a method of synthesising a compound according to the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the examples hereinafter. Alternatively, necessary starting materials may be obtainable by analogous procedures to those illustrated which are within the ordinary skill of those skilled in the art. Further, it will be appreciated that during the synthesis of the compounds, in the processes described below, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. Those skilled in the art will readily recognise when such protection is required, and how such protecting groups may be put in place, and later removed. Examples of protecting groups are described in, for example, Protective Groups in Organic Synthesis by Theodora Green (publisher: John Wiley & Sons).
  • Protecting groups may be removed by any convenient method well known to those skilled in the art as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.
  • reactants include, for example, groups such as amino, carboxyl or hydroxyl, it may be desirable to protect the group in some of the reactions mentioned herein.
  • the compounds of the present invention may be prepared by, for example, the general synthetic methodologies described in International Patent Publication No WO 2010/049731, which is herein incorporated by reference.
  • a method of synthesising a compound of the present invention (or a pharmaceutically acceptable salt, solvate or prodrug thereof) is provided wherein the method comprises the steps of:
  • R 6 is as defined in the first aspect; and if necessary,
  • step b) The cyclocondensation reaction of step b) may be conducted in the presence of a suitable solvent or solvent mixture.
  • suitable solvents include dioxane, water, etc.
  • reaction conditions for the condensation reaction of step b will be readily select appropriate reaction conditions for the condensation reaction of step b). However, typically, the reaction will be carried out in anhydrous conditions and in the presence of an inert atmosphere, such as argon or nitrogen.
  • an inert atmosphere such as argon or nitrogen.
  • the bromination reaction of step a) may be carried out at room temperature for a suitable time period of, for example, 30 minutes to 2 hours, whereas the subsequent condensation reaction of step b)may be carried out at an elevated temperature, for example, within the range of 60 to 100°C for a suitable time period of, for example, 20 minutes to 10 hours.
  • the bromination reaction of step a) is carried out at room temperature for 30 minutes to 2 hours, and then the condensation reaction of step b) will be conducted by adding the required compound (ie a compound selected from pyridin-2-amines, pyridazin-3-amine, pyrazin-2-amines and 1-aminopyridin-l-iums) and normal heating at 60 to 100 °C for 20 minutes to 10 hours.
  • the required compound ie a compound selected from pyridin-2-amines, pyridazin-3-amine, pyrazin-2-amines and 1-aminopyridin-l-iums
  • the coupling reaction of step c) may be conducted in the presence of a suitable solvent or solvent mixture.
  • suitable solvents include alcohols, acetonitrile, halogenated solvents, etc.
  • suitable reaction conditions include alcohols, acetonitrile, halogenated solvents, etc.
  • the reaction will be carried out in anhydrous conditions and in the presence of an inert atmosphere, such as argon or nitrogen.
  • the reaction may also be carried out an elevated temperature, such as, for example, within the range of 80 to 180°C for a suitable time period of, for example, 20 minutes to 48 hours.
  • the reaction is carried out under microwave heating, for example, at 80 to 180 °C for 20 minutes to 1.5 hour.
  • the method of synthesising a compound of the present invention may further comprise:
  • the salt exchange may comprise immobilising the compound on a suitable solid support or resin, and eluting the compound with an appropriate acid to yield salt of the compound of formula I.
  • reaction mixture was heated under microwave at 130 °C for 60 min, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 1 % NH 3 (32% in water) to afford the desired product.
  • Compounds showing purity ⁇ 94% were further purified using preparative HPLC.
  • N-Bromosuccinimide (0.83 g, 4.67 mmol) was added to a stirred solution of (£)-4-(2- butoxyvinyl)-2-chloro-5-fluoropyrimidine (0.90 g, 3.90 mmol) in 20 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h.
  • Pyridin-2-amine (0.37 g, 3.90 mmol) was added, and the reaction mixture heated at 85 °C for 2.5 h.
  • 6-Nitro-N-phenylpyridin-3-amine Microwave tubes were charged each with 5-bromo-2-nitropyridine (0.50 g, 2.47 mmol), aniline (3.53 ⁇ , 3.74 mmol), Cs 2 C0 3 ( 1.60 g, 4.95 mmol), Pd 2 dba 3 (0.12 g, 0.12 mmol) and xantphos (0.07 g, 0.12 mmol) in dioxane (7 mL).
  • N 5 -Phenylpyridine-2,5-diamine To a solution of 6-nitro-N- phenylpyridin-3-amine ( 1.00 g, 4.65 mmol)) in MeOH (20 mL) was added 10% Pd/C (49.0 mg, 0.46 mmol). The reaction mixture was stirred and bubbled with H 2 at room temperature for 3-10 h. The solids were filtered off and washed with MeOH. The filtrate and MeOH washing were combined and concentrated under reduced pressure to give N 5 -phenylpyridine-2,5-diamine as a white powder (0.85 g, 99%).
  • N-Bromosuccinimide (0.30 g, 1.69 mmol) was added to a stirred solution of (£ ' )-4-(2-butoxyvinyl)-2-chloro-5-fluoropyrimidine (0.39 g, 1.69 mmol) in 5 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h.
  • N 5 -(4-Fluorobenzyl)pyridine-2,5- diamine (0.43 g, 19.8 mmol) was added, and the reaction mixture heated at 85 °C for 2.5 h.
  • N-Bromosuccinimide 1.67 g, 9.38 mmol was added to a stirred solution of give (£)-4-(2-butoxyvinyl)-2-chloro-5-methylpyrimidine (2.20 g, 9.73 mmol), in 10 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h.
  • 5-Bromopyridin-2-amine 1.52 g, 8.79 mmol was added, and the reaction mixture heated at 80 °C for 2 h.
  • a suspension of 5-fluoro-4-(imidazo[ l ,2-a]pyridin-3-yl)-/V-(piperidin-4- yl)pyrimidin-2-amine (350 mg, 1.12 mmol), (bromomethyl)cyclopropane (338 ⁇ L ⁇ , 3.33 mmol), triethylamine (0.25 mL, 1.78 mmol) in DMF (7 mL) was stirred at 90 °C overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 2% MeOH to give 22 as a white powder (70 mg, 17%).
  • 1,4-diamine 44.
  • ( 1 r,4r)-N l -(4-(7-Chloroimidazo[ 1 ,2-a]pyridin-3-yl)-5-fluoropyrimidin-2- yl)cyclohexane- 1,4-diamine 150 mg, 0.42 mmol
  • 4,4,5,5-tetramethyl-2-phenyl-l,3,2-dioxaborolane 85.0 mg, 0.42 mmol
  • the product was further purified by preparative HPLC to give 44 as a yellow solid (50 mg, 30%).
  • N-(3-(2-Chloro-5-fluoropyrimidin-4-yl)imidazo[l ,2-a]pyridin-6- yl)-2-phenylacetamide (300 mg, 0.79 mmol) and ( lr,4r)-cyclohexane-l,4-diamine (270 mg, 2.37 mmol) were reacted according to general synthetic procedure A(ii).
  • N-(3-(2-Chloro-5-methylpyrimidin-4-yl)imidazo[l ,2-a1pyridin- 6-yl)-4-fluorobenzamide (0.20 g, 0.52 mmol) and (lr,4r)-cyclohexane-l,4-diamine (0.12 g, 1.05 mmol) were reacted according to general synthetic procedure A(ii).
  • N l -(5-Methyl-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,3- diamine (94). N'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)cyclohexane- l ,3- diamine ( 100 mg, 0.25 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (51.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C.
  • a1pyridin-6-amine (103). 4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methyl-N-(tetrahydro-2H-pyran-4- yl)pyrimidin-2-amine ( 194 mg, 0.50 mmol) and pyridin-3-amine (47.2 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 103 as a yellow sticky liquid (70 mg, 35%).
  • N 1 -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)-N 4 -methylcyclohexane- 1 ,4-diamine 100 mg, 0.24 mmol
  • pyrimidin-5 -amine 23.0 mg, 0.24 mmol
  • the product was further purified by preparative HPLC to give 109 as a yellow solid (60 mg, 58%).
  • N-( 1 -(Cyclopropylmethyl)piperidin-4-yl)-5-fluoro-4-(6-phenylimidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-amine (145).
  • a solution of 5-fluoro-4-(6-phenylimidazo[l ,2-a]pyridin-3-yl)-N-(piperidin- 4-yl)pyrimidin-2-amine 100 mg, 0.26 mmol), (bromomethyl)cyclopropane (89 ⁇ , 0.78 mmol), Triethylamine (0.2 mL, 2.27 mmol) in DMF (5 mL) was stirred at 90 °C overnight.
  • N-(4,4-Difluorocyclohexyl)-5-methyl-4-(6-phenylimidazo[ l ,2-alpyridin-3-yl)pyrimidin- 2-amine 155.
  • 4-(6-BromoimidazoL 1 ,2-a]pyridin-3-yl)-N-(4,4-difluorocyclohexyl)-5-methylpyrimidin-2- amine 160 mg, 0.38 mmol
  • phenylboronic acid 45 mg, 0.38 mmol
  • N-(4,4-Difluorocyclohexyl)-4-(irridazo[ l ,2-a1pyridin-3-yl)-5-m (156).
  • 4-(6-Bromoirrddazo[l ,2- ]pyridin-3-yl)-N-(4,4-difluorocyclohexyl)-5-methylpyrirmdin-2-amine (240 mg, 0.57 mmol)
  • pyrimidin-5 -amine 55 mg, 0.57 mmol
  • Methyl ( lr,4r)-4-((5-methyl-4-(6-(pyrimidin-5- yl)pyrimidin-2-yl)amino)cvclohexane- l-carboxylate (157).
  • Methyl ( l r,4r)-4-((4-(6-bromoimidazo[ l ,2- a]pyridin-3-yl)-5-methylpyrimidin-2-yl)aniino)cyclohexane- l -carboxylate (600 mg, 1.35 mmol) and pyrimidin-5-amine ( 130 mg, 1 .35 mmol) were reacted according to general synthetic procedure B.
  • CDK6/D3 and CDK9/T1 were also determined in-house using ADP Glo Kinase assays (Promega Corporation, Madison, USA). Briefly, the kinase reaction for CDK4/D1 and CDK6/D3 was performed with kinase reaction buffer (40 nM Tris base pH 7.5, 20 mM MgCl 2 , 0.4 mM DTT), 0.1 mg/ml BSA and RB-CTF substrate (retinoblastoma proteinl C-terminal fraction). For CDK9/CyclinTl , the kinase reaction was performed with standard assay buffer and Kinase Dilution Buffer and RBER-IRStide substrate.
  • kinase reaction buffer 40 nM Tris base pH 7.5, 20 mM MgCl 2 , 0.4 mM DTT
  • RB-CTF substrate retinoblastoma proteinl C-terminal fraction
  • IC 50 Half-maximal inhibition
  • CDK1 B CDK2A CDK4D1 CDK6D3 CDK7H CDK9T1 MV4-1 1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).

Description

DERIVATIVES OF N CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO
[l,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
TECHNICAL FIELD
[0001 ] The present invention relates to a novel class of inhibitors of protein kinases useful in the treatment of proliferative cell diseases and conditions including cancers.
PRIORITY DOCUMENT
10002] The present application claims priority from Australian Provisional Patent Application No 2017900290 titled "Pyrimidin-2-amine derivatives as therapeutic compounds" filed on 1 February 2017, the content of which is hereby incorporated by reference in its entirety.
INCORPORATION BY REFERENCE
10003] The following publication is referred to herein and its contents are hereby incorporated by reference in their entirety:
International Patent Publication No PCT/GB2009/051447 (WO 2010/04973 1 ) titled "Pyrazolo- and imidazopyrdinylpyrimidineamines as IGF- 1 R tyrosine kinase inhibitors" in the name of AstraZeneca AB.
BACKGROUND
10004] Protein kinases regulate various biological functions, including DNA replication, transcription, translation, cell cycle progression, energy metabolism, migration, and cell growth, making them excellent targets for treating proliferative diseases and conditions including cancers. New compounds, which inhibit the activity of protein kinases and are effective as therapeutic anti-prol iferative agents, are still needed.
[0005] Cycl in-dependent kinases (CDKs) are serine-threonine protein kinases that associated with various cyclin subunits. There are more than 20 CDKs which may be classified according to their main functions. That is, CDK 1 , CDK2, CDK3, CDK4 and CDK6 and their cyclin partners (eg cyclin A, B, D 1 , D2, D3, E and F) are known to be involved in the control of cell cycle progression, and are thus considered to be cell cycle regulators. On the other hand, CDK7, CDK8, CDK9 and CDK l 1 and their associated cyclin partners (eg cyclin C, H, K, L I , L2, T l and T2), are considered to be transcriptional regulators. CDKs are thus involved in the regulation of cell-cycle control, apoptosis, neuronal physiology, differentiation, and transcription. As such, the use of CDK inhibitors in the treatment of various diseases, including cancers, cardiovascular disorders, inflammatory diseases, neurodegenerative diseases and viral diseases, is of considerable interest (Wang, S et ai, Trends Pharmacol Sci 29(6):302-313, 2008).
L0006J Palbociclib (6-Acetyl-8-cyclopentyl-5-methyl-2-{ L5-(l-piperazinyl)-2-pyridinylJamino}pyrido L2,3-dJpyrimidin-7(8H)-one), an inhibitor of CDK4 and CDK6, is one specific example of a CDK inhibitor that is now available for the treatment of a proliferative cell disease, particularly estrogen- positive, HER2-negative advanced breast cancer. However, numerous other CDK inhibitors have been described with potential as agents for treating proliferative cell diseases and conditions including cancers. For example, the present applicant has previously disclosed N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2- amine compounds (see International Patent Publication Nos WO 2017/020065). These compounds inhibit multiple protein kinases, particularly CDKs, including CDK4/cyclin Dl and CDK6/cyclin D3.
[0007] The present applicant has now identified a new class of N-cylcloalkyl/heterocycloalkyl-4- (imidazo[l ,2-a]pyridine)pyrirmdin-2-amine compounds, for use in the prevention and/or treatment of various diseases and conditions including proliferative diseases and conditions such as cancers.
SUMMARY
[0008] According to a first aspect of the present invention, there is provided a compound of formula I shown below:
Figure imgf000003_0001
wherein:
A is a cycloalkyl or heterocycloalkyl, optionally substituted by one or more R6 groups such that m is an integer from 0 to 5 inclusive, and wherein said heterocycloalkyl comprises at least one but no more than two heteroatoms selected from N, O and S; and wherein
R, R', R2, R3, R4, R5 and R6 are each independently selected from the group consisting of H, alkyl, alkyl- R9, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH2-heteroaryl, aralkyl, halogen, N02, CN, CF3, OH, O-alkyl, O-alkyl-R7, O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O- R7, NH2, NH-alkyl, NH-alkyl-R7, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH- heteroaryl, NH-R7, NHO-aryl, NH) -heteroaryl, NHCH2-aryl, N-(alkyl)2, N-(heteroalkyl)2, N- (cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N-(R7)(R8), N-(alkyl)(R7), N- (heteroalkyl)(R7), N-(cycloalkyl)(R7), N-(heterocycloalkyl)(R7), N-(aryl)(R7), N-(heteroaryl)(R7), SH- alkyl, SH-alkyl-R7, SH-heteroalkyl, SH-cycloalkyl, SH-heterocycloalkyl, SH-aryl, SH-heteroaryl, S- (alkyl)2, S-heteroalkyl, S-(cycloalkyl)2, S-(heterocycloalkyl)2, S-(aryl)2, S-(heteroaryl)2, S-(alkyl)(aryl), SH-R7, S-(R7)(R8), S-(alkyl)(R7), S-(heteroaryl)(R7), S-(cycloalkyl)(R7), S-(heterocycloalkyl)(R7), S- (aryl)(R7), S-(heteroaryl)(R7), COOH, CONH2, CONH-alkyl, CONH-aryl, CON-(alkyl)(R7),
CON(aryl)(R7), CON(heteroaryl)(R7), CONH-R7, CON-(R7)(R8), S03H, S02-alkyl, S02-alkyl-R7, S02- aryl, S02-aryl-R7, S02NH2, S02NH-R7, S02N-(R7)(R8), CO-alkyl, CO-alkyl-R7, CO-aryl, CO-aryl-R7, CO-R7, COOR7, and R9,
and wherein R7 and R8 are each independently selected from the group consisting of H, alkyl, alkyl-R10, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, halogen, N02, CN, CF3, OH, O-alkyl, O-alkyl-R10, O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O-R10, NH2, NH- alkyl, NH-alkyl-R10, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH- R10, N-(alkyl)2, N-(heteroalkyl)2, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N- (R10)(RU), N-(alkyl)(R10), N-(heteroalkyl)(R10), N-(cycloalkyl)(R10), N-(heterocycloalkyl)(R10), N- (aryl)(R10), N-(heteroaryl)(R10), SH-alkyl, SH-alkyl-R10, SH-heteroalkyl, SH-cycloalkyl, SH- heterocycloalkyl, SH-aryl, SH-heteroaryl, S-(alkyl)2, S-(cycloalkyl)2, S-(heterocycloalkyl)2, S-(aryl)2, S- (heteroaryl)2, S-(alkyl)(aryl), SH-R10, S-(R10)(Rn), S-(alkyl)(R10), S-(heteroaryl)(R10), S- (cycloalkyl)(R10), S-(heterocycloalkyl)(R10), S-(aryl)(R10), S-(heteroaryl)(R10), COOH, COO-alkyl, CONH2, CONH-alkyl, CONH-aryl, CON-(alkyl)(R10), CON(aryl)(R10), CON(heteroaryl)(R10), CONH- R10, CON-(R'°)(R"), SO3H, S02-alkyl, S02-alkyl-R10, S02-aryl, S02-aryl-R10, S02NH2, S02NH-R10, S02N-(R'°)(R"), CO-alkyl, CO-alkyl-R10, CO-aryl, CO-aryl-R10, CO-R10, COOR10, and R9,
and wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, CN, OH, O-methyl, NH2, COOH, CONH2, CF3 and S02N(CH3)2; and
R9, R10 and R" are independently selected from water solubilising groups;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0009] In a second aspect, the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating cancer or another proliferative cell disease or condition.
[0010] In a third aspect, the present invention provides a method of treating cancer or another proliferative cell disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient. [001 1] In a fourth aspect, the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating cancer or another proliferative cell disease or condition.
[0012J In a fifth aspect, the present invention provides a pharmaceutical composition or medicament comprising a compound as defined in the first aspect and a pharmaceutically acceptable carrier, diluent and/or excipient.
[0013J In a sixth aspect, the present invention provides a method for modulating protein kinase activity in a cell, comprising introducing to or contacting said cell with an effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0014] In a seventh aspect, the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a disease or condition.
[0015] In an eighth aspect, the present invention provides a method of treating a disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
[0016] In a ninth aspect, the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating a disease or condition in a subject.
[0017] The disease or condition referred to in any of the above aspects may be characterised by over- expression of one or more CDK enzyme and/or by one or more aberrant CDK activity. Otherwise, said disease or condition may be one which may be beneficially treated by inhibiting one or more CDK (eg by inhibiting the activity and/or expression of one or more of CDK1 , CDK2, CDK4, CDK6, CDK7 and CDK9, and/or the association of one or more of such CDK enzymes with their respective cyclin/mediator complex).
DETAILED DESCRIPTION
[001 8] The present applicant has now identified a new class of N-cylcloalkyl/heterocycloalkyl-4- (imidazo[ l ,2-a]pyridine)pyrimidin-2-amine derivatives suitable for use in the prevention and/or treatment of various diseases and conditions including proliferative cell diseases and conditions such as cancers, which possess desirable biological activity (eg the compounds may inhibit cell proliferation by inhibiting the activity of CDKs, FMS-like tyrosine kinases (FLTs), aurora kinases and/or CDC-like kinases (CLKs)).
[0019] In a first aspect, the present invention provides a compound of formula I shown below:
Figure imgf000006_0001
wherein:
A is a cycloalkyl or heterocycloalkyl, optionally substituted by one or more R6 groups such that m is an integer from 0 to 5 inclusive, and wherein said heterocycloalkyl comprises at least one but no more than two heteroatoms selected from N, O and S; and wherein
R, R1, R2, R3, R4, R5 and R6 are each independently selected from the group consisting of H, alkyl, alkyl- R7, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH2-heteroaryl, aralkyl, halogen, N02, CN, CF3, OH, O-alkyl, O-alkyl-R7, O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O- R9, NH2, NH-alkyl, NH-alkyl-R7, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH- heteroaryl, NH-R7, NHO-aryl, NH)-heteroaryl, NHCH2-aryl, N-(alkyl)2, N-(heteroalkyl)2, N- (cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N-(R7)(R8), N-(alkyl)(R7), N- (heteroalkyl)(R7), N-(cycloalkyl)(R7), N-(heterocycloalkyl)(R7), N-(aryl)(R7), N-(heteroaryl)(R7), SH- alkyl, SH-alkyl-R7, SH-heteroalkyl, SH-cycloalkyl, SH-heterocycloalkyl, SH-aryl, SH-heteroaryl, S- (alkyl)2, S-heteroalkyl, S-(cycloalkyl)2, S-(heterocycloalkyl)2, S-(aryl)2, S-(heteroaryl)2, S-(alkyl)(aryl), SH-R7, S-(R7)(R8), S-(alkyl)(R7), S-(heteroaryl)(R7), S-(cycloalkyl)(R7), S-(heterocycloalkyl)(R7), S- (aryl)(R7), S-(heteroaryl)(R7), COOH, CONH2, CONH-alkyl, CONH-aryl, CON-(alkyl)(R7),
CON(aryl)(R7), CON(heteroaryl)(R7), CONH-R7, CON-(R7)(R8), S03H, S02-alkyl, S02-alkyl-R7, S02- aryl, S02-aryl-R7, S02NH2, S02NH-R7, S02N-(R7)(R8), CO-alkyl, CO-alkyl-R7, CO-aryl, CO-aryl-R7, CO-R7, COOR7, and R9,
and wherein R7 and R9 are each independently selected from the group consisting of H, alkyl, alkyl-R10, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, halogen, N02, CN, CF3, OH, O-alkyl, O-alkyl-R10, O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O-R10, NH2, NH- alkyl, NH-alkyl-R10, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH- R10, N-(alkyl)2, N-(heteroalkyl)2, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N- (R10)(RU), N-(alkyl)(R10), N-(heteroalkyl)(R10), N-(cycloalkyl)(R10), N-(heterocycloalkyl)(R10), N- (aryl)(R10), N-(heteroaryl)(R10), SH-alkyl, SH-alkyl-R10, SH-heteroalkyl, SH-cycloalkyl, SH- heterocycloalkyl, SH-aryl, SH-heteroaryl, S-(alkyl)2, S-(cycloalkyl)2, S-(heterocycloalkyl)2, S-(aryl)2, S- (heteroaryl)2, S-(alkyl)(aryl), SH-R10, S-(R10)(Rn), S-(alkyl)(R10), S-(heteroaryl)(R10), S- (cycloalkyl)(R10), S-(heterocycloalkyl)(R10), S-(aryl)(R10), S-(heteroaryl)(R10), COOH, COO-alkyl, CONH2, CONH-alkyl, CONH-aryl, CON-(alkyl)(R10), CON(aryl)(R10), CON(heteroaryl)(R10), CONH- R10, CON-(R10)(RU), S03H, SOz-alkyl, S02-alkyl-R10, S02-aryl, S02-aryl-R10, S02NH2, S02NH-R10, S02N-(R'°)(R"), CO-alkyl, CO-alkyl-R10, CO-aryl, CO-aryl-R10, CO-R10, and COOR10, and R9, and wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, CN, OH, O-methyl, NH2, COOH, CONH2, CF3 and S02N(CH3)2; and
R9, R10 and R1 1 are independently selected from water solubilising groups;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0020] The compounds of formula I have been found to possess anti-proliferative activity and are therefore considered to be of use in the treatment of proliferative cell diseases and conditions such as cancers (including, for example, leukaemia and lymphoma) and other diseases and conditions associated with uncontrolled cell proliferation such as, for example, some cardiovascular diseases or conditions such as restenosis and cardiomyopathy, some auto-immune diseases such as glomerulonephritis and rheumatoid arthritis, dermatological conditions such as psoriasis, and fungal or parasitic disorders. As used herein, an anti-proliferative effect within the scope of the present invention may be demonstrated by the ability to inhibit cell proliferation in an in vitro whole cell assay. These assays, including methods for their performance, are described in more detail in the examples provided hereinafter.
[0021] The compounds of formula I may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (GO), Gl progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2
progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, and cytokinesis functions. In particular, the compounds of formula I may influence certain gene functions such as chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways. [0022] Thus, in a second aspect, the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating cancer or another proliferative cell disease or condition.
[0023] In a third aspect, the present invention provides a method of treating cancer or another proliferative cell disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
L0024J In a fourth aspect, the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating cancer or another proliferative cell disease or condition.
[0025] In a fifth aspect, the present invention provides a pharmaceutical composition or medicament comprising a compound as defined in the first aspect and a pharmaceutically acceptable carrier, diluent and/or excipient.
[0026] In a sixth aspect, the present invention provides a method for modulating protein kinase activity in a cell, comprising introducing to or contacting said cell with an effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0027] In a seventh aspect, the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a disease or condition in a subject.
[0028] In an eighth aspect, the present invention provides a method of treating a disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
[0029] In a ninth aspect, the present invention provides the use of a compound as defined in the first aspect, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating a disease or condition in a subject.
[0030] In this specification, a number of terms are used which are well known to those skilled in the art. Nevertheless, for the purposes of clarity, a number of these terms are hereinafter defined. [0031] As used herein, the term "treating" includes prophylaxis as well as the alleviation of established symptoms of a condition. As such, the act of "treating" a disease or condition therefore includes: ( 1) preventing or delaying the appearance of clinical symptoms of the disease or condition developing in a subject afflicted with or predisposed to the disease or condition; (2) inhibiting the disease or condition (ie arresting, reducing or delaying the development of the disease or condition or a relapse thereof (in case of a maintenance treatment) or at least one clinical or subclinical symptom thereof; and (3) relieving or attenuating the disease or condition (ie causing regression of the disease or condition or at least one of its clinical or subclinical symptoms).
[0032] As used herein, the term "alkyl" includes both straight chain and branched alkyl groups having from 1 to 8 carbon atoms (eg methyl, ethyl propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl etc).
[0033] As used herein, the term "heteroalkyl" refers to both straight chain and branched alkyl groups wherein one or more carbon atoms are replaced by an 0-, N- or S- atom (eg 1-methoxypropanyl, methyl propionate etc).
[0034] As used herein, the term "cycloalkyl" represents cyclic versions of alkyl (cyclopropyl, cyclopentyl, cyclohexyl etc), and may include fused rings. Cycloalkyl groups are unsubstituted, but may be substituted with those groups typically suitable for alkyl group substituents.
[0035] As used herein, the term "heterocycloalkyl" or "heterocyclic" represents a cycloalkyl containing at least one annular carbon and at least one annular heteroatom selected from the group consisting of N, O and S, wherein the ring is not aromatic but can contain unsaturations. The nitrogen and sulfur atoms in a heterocyclic group can be oxidised and the nitrogen atom(s) may optionally be quaternised. The heterocyclic group can be fused to an additional carbocyclic or heterocyclic ring. A heterocyclic group can be attached to the remainder of the molecule at an annular carbon or annular heteroatom.
Additionally, heterocyclic main contain fused rings, but excludes fused systems containing a heteroaryl group as part of the fused ring system. Examples of heterocycloalkyl include, but are not limited to, 1- piperidinyl, 1-piperazinyl, morpholinyl, alkylpiperidinyl etc. Heterocycloalkyl moieties can be unsubstituted or substituted with various substituents known in the art, eg hydroxyl, halogen, alkylamino etc.
[0036] As used herein, the term "aryl" refers to a substituted (mono- or poly-) or unsubstituted monoaromatic or polyaromatic group, wherein said polyaromatic group may be fused or unfused. The term therefore includes groups having from 6 to 10 carbon atoms (eg phenyl, naphthyl etc). It is also to be understood that the term "aryl" is synonymous with the term "aromatic". [0037] As used herein, the term "heteroaryl" refers to a substituted (mono- or poly-) or unsubstituted monoaromatic or polyaromatic group wherein polyaromatic group may be fused or unfused; and wherein at least one of the rings is an aromatic ring that contains from one to four heteroatoms selected from N, O and S as ring members (i.e. it contains at least one heteroaromatic ring); and wherein the nitrogen and sulfur atoms can be oxidised and the nitrogen atom(s) can be quaternised. A heteroaryl group can be attached to the remainder of the molecule through an annular carbon or annular heteroatom, and it can be attached through any ring of the heteroaryl moiety, if that moiety is bicyclic, tricyclic or a fused ring system. Illustrative examples of heteroaryl groups include 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-pyrimidyl, 5- indolyl etc.
[0038] As used herein, the term "aralkyl" is used as a conjunction of the terms alkyl and aryl as defined above.
[0039] As used herein, the term "alicyclic" refers to a cyclic aliphatic group.
[0040] The term "aliphatic" takes its normal meaning in the art and includes non-aromatic groups such as alkanes, alkenes and alkynes and substituted derivatives thereof.
[0041] The term "halogen" refers to fluoro, chloro, bromo and iodo.
[0042] The term "derivative" as used herein, includes any chemical modification of an entity. Illustrative of such chemical modifications is the replacement of hydrogen by a halogen group, an alkyl group, an acyl group or an amino group.
[0043] As used herein, the phrase "manufacture of a medicament" includes the use of one or more of the compounds of formula I directly as the medicament or in any stage of the manufacture of a medicament comprising one or more of the compounds of formula I.
[0044] Some of the compounds of formula I may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof, are encompassed within the scope of the present invention. The isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods known to those skilled in the art.
[0045] The term "pharmaceutically acceptable salt" as used herein, refers to salts that retain the desired biological activity of the compounds of formula I, and include pharmaceutically acceptable acid addition salts and base addition salts. Suitable pharmaceutically acceptable acid addition salts of the compounds of formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic and arylsulfonic. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995.
L0046J In the case of compounds of formula 1 that are solid, it will be understood by those skilled in the art that the compounds (or pharmaceutically acceptable salts, solvates or prodrugs thereof) may exist in different crystalline or polymorphic forms, all of which are encompassed within the scope of the present invention.
L0047J "Prodrug" means a compound that undergoes conversion to a compound of formula 1 within a biological system, usually by metabolic means (eg by hydrolysis, reduction or oxidation). For example, an ester prodrug of a compound of formula I containing a hydroxyl group may be convertible by hydrolysis in vivo to the compound of formula I. Suitable esters of the compounds of formula I containing a hydroxyl group may be, for example, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-P-hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p- toluenesulfonates, cyclohexylsulfamates and quinates. As another example, an ester prodrug of a compound of formula I containing a carboxy group may be convertible by hydrolysis in vivo to the compound of formula I. Examples of ester prodrugs include those described by Leinweber FJ, Drug Metab Rev 18:379-439 ( 1987). Similarly, an acyl prodrug of a compound of formula I containing an amino group may be convertible by hydrolysis in vivo to the compound of formula I. Examples of prodrugs for these and other functional groups, including amines, are provided in Prodrugs: challenges and rewards, Valentino J Stella (ed), Springer, 2007.
[0048] The term "therapeutically effective amount" or "effective amount" is an amount sufficient to effect beneficial or desired clinical results. A therapeutically effective amount can be administered in one or more administrations. Typically, a therapeutically effective amount is sufficient for treating a disease or condition or otherwise to palliate, ameliorate, stabilise, reverse, slow or delay the progression of a disease or condition such as, for example, cancer or another proliferative cell disease or condition. By way of example only, a therapeutically effective amount of a compound of formula I, or a
pharmaceutically acceptable salt, solvate or prodrug thereof, may comprise between about 0.1 and about 250 mg/kg body weight per day, more preferably between about 0.1 and about 100 mg/kg body weight per day and, still more preferably between about 0.1 and about 25 mg/kg body weight per day. However, notwithstanding the above, it will be understood by those skilled in the art that the therapeutically effective amount may vary and depend upon a variety of factors including the activity of the particular compound (or salt, solvate or prodrug thereof), the metabolic stability and length of action of the particular compound (or salt, solvate or prodrug thereof), the age, body weight, sex, health, route and time of administration, rate of excretion of the particular compound (or salt, solvate or prodrug thereof), and the severity of, for example, the cancer or other proliferative cell disease or condition to be treated.
L0049J The compounds of formula I, and pharmaceutically acceptable salts, solvates and prodrugs thereof, are capable of inhibiting protein kinases, especially one or more of the following group: CDKs, FLT kinases, aurora kinases and/or CLKs and may show higher selectivity (to inhibit) CDKs over other protein kinases. As such, the compounds of formula I, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which are believed to inhibit CDKs, have utility in both in vitro and in vivo applications (eg in vitro whole cell assays) and as the basis of a therapeutic method of treating cancer or another proliferative cell disease or condition in a subject. Moreover, the compounds of formula I are suitable for the treatment of other diseases or conditions in which one or more of the protein kinase targets outlined above are implicated.
[0050] The compounds of formula I preferably bear a fused heterocyclic group attached to the pyrimidine ring through one of the ring carbon atoms (particularly, the carbon at position 4). More specifically, compounds of formula I preferably bear an imidazo[ l ,2-a]pyridine group attached to the carbon at position 4 of the pyrimidine. Moreover, the compounds of formula I bear group A, which is preferably a 4- to 10-membered cycloalkyl or heterocycloalkyl group, attached to the pyrimidine ring at the carbon at position 3 through an amine group. Where the group A comprises a heterocycloalkyl group, then that heterocycloalkyl group will comprise at least one but no more than two heteroatoms selected from N, O and S as ring members. The group A is optionally substituted by one or more R6 groups. In some embodiments, the group A is a 5- to 7-membered cycloalkyl or heterocycloalkyl group optionally substituted by one or more R6 groups, such as a 6-membered cycloalkyl or heterocycloalkyl group optionally substituted by one or more R6 groups such as, for example, a cyclohexyl group or piperidine group. In other embodiments, the group A is a 10-membered cycloalkyl group (eg an adamantane group) or heterocycloalkyl group optionally substituted by one or more R6 groups.
[0051] In some embodiments, the compounds of formula I may preferably comprise at least one water solubilising group R9, R10 or R11. Where present, R9, R10 and R11 are preferably independently selected from water solubilising groups of the group consisting of:
(i) mono-, di- and poly-hydroxylated alicyclic groups, di- or poly-hydroxylated aliphatic or aryl groups; N-, O- and/or S-containing heterocyclic groups substituted with one or more hydroxyl or amino groups, aliphatic and aryl groups comprising one or more carboxamide, sulfoxide, sulfone or sulfonamide groups; and halogenated alkylcarbonyl groups;
(ii) COOH, S03H, OS03H, P03H2 and OP03H2; (iii) NHCO(CH2)m[NHCO(CH2)m-]p[NHCO(CH2)m..]qY and NHCO(CH2),NH(CH2),Y wherein p and q are each independently selected from integers 0 or 1 , and m, m', m", t and ' are each independently selected from integers 1 to 10, and Y is selected from:
(a) alicyclic, aryl and heterocyclic groups comprising one or more 0-, S- or N- heteroatoms, which may further comprise an alkyl bridge (eg a -CH2- or -CH2CH2 - bridge),
(b) alicyclic groups comprising one or more of -0-, NH2, -NH-, =N-, quaternary amine salt, and amidine, and
(c) morpholine, piperazine or 1 ,4-diazepane groups, each of which may be optionally substituted by one or more substituents selected from S02-alkyl, alkyl optionally substituted by one or more OH groups, CO-alkyl, aralkyl, COO-alkyl, and an ether group optionally substituted by one or more OH groups;
(iv) (CH2)nNR12COR13, (CH2)nNR12S02R13 and S02R14, wherein R12 is selected from H and alkyl, R13 and R14 are each independently selected from alkyl groups optionally comprising one or more heteroatoms and/or optionally substituted with one or more substituents independently selected from OH, NH2, halogen and N02, and n and n' are each independently selected from integers 0, 1 , 2 and 3;
(v) ether and polyether groups optionally substituted with one or more OH groups or one or more Y groups, wherein Y is as defined above at (iii);
(vi) (CH2)rNH2, wherein r is selected from integers 0, 1 , 2 and 3;
(vii) (CH2)rOH, wherein r' is selected from integers 0, 1 , 2 and 3;
(viii) (CH2)n NRl 5COR16, wherein R15 is H or alkyl, n" is selected from integers 0, 1 , 2 and 3, and R16 is an aryl group optionally substituted with one or more substituents selected from halogen, N02, OH, alkoxy, NH2, COOH, CONH2 and CF3; and
(ix) S02NRl7R18, wherein R17 and R18 are each independently selected from H, alkyl and aryl, with the proviso that at least one of R17 and R18 is other than H, or R17 and R18 together form a cyclic group optionally comprising one or more heteroatoms selected from N, O and S, and wherein said alkyl, aryl or cyclic group is optionally substituted by one or more substituents selected from halogen, N02, OH, alkoxy, NH2, COOH, CONH2 and CF3.
[0052] In some embodiments, R, R1 , R2, R3 and R4 are each independently selected from the group consisting of H, alkyl (eg a Ci_6 alkyl or, preferably, a Ci_3 alkyl such as methyl), cycloalkyl,
heterocycloalkyl, aryl (eg phenyl), heteroaryl (eg pyridinyl, pyrimidinyl), CH2-heteroaryl, halogen (especially Br or F), N02, CF3, OH, O-alkyl (eg an O-Q.6 alkyl, preferably, an 0-C1 3 alkyl such as O- CH3), O-heteroalkyl, 0-C3.8 cycloalkyl (such as 0(C5H9); ie O-cyclopentyl), O-aryl, O-heteroaryl, NH2, NH-alkyl (eg a NH-d_6 alkyl, preferably, a NH-d_3 alkyl such as NH-CH3), NH-heteroalkyl (eg N' ,N'- dimethylethane- l ,2-diamine), NH-cycloalkyl (eg a NH-C3.8 cycloalkyl such as NH(C5H9); ie NH- cyclopentyl), NH-heterocycloalkyl (eg NH-C3.8 heterocycloalkyl such as NH(C5HnN); ie NH- piperidinamine), NH-aryl (eg NH-phenyl), NH-heteroaryl, NH-Ci_30-aryl, NHO-aryl, NHO-heteroaryl, NHCH2-aryl, N(alkyl)2 (such as N(CH3)2), N(cycloalkyl)2 (eg N(C5H9)2), N(heterocycloalkyl)2 (such as N-dipiperidinamine), N-(alkyl)(aryl), SH-alkyl (eg a SH-C^ alkyl or, preferably, a SH-C^ alkyl such as SHCH3 and SHC(CH3)), SH-aryl, SH-heteroaryl, S-heteroalkyl, S-C3.8 cycloalkyl (such as S(C5H9); ie S- cyclopentyl), and R11 ; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl (eg methyl), CN, OH, O-methyl, O-ethyl, 0-CF2, NH2, COOH, CONH2, heterocycloalkyl, CO-heterocycloalkyl, CF3 and S02N(CH3)2.
L0053J In some embodiments, R is H.
L0054J In some embodiments, R1 is heteroaryl (eg pyridine).
[0055] In some embodiments, R, R1 , R3 and R4 are all H, and R2 is selected from the group consisting of H, alkyl (eg a C|_6 alkyl or, preferably, a Ci_3 alkyl such as methyl), cycloalkyl, heterocycloalkyl, aryl (eg phenyl), heteroaryl (eg pyridinyl, pyrimidinyl), halogen (especially Br or F), N02, CF3, OH, O-alkyl (eg an 0-Ci_6 alkyl, preferably, an 0-Ci_3 alkyl such as 0-CH3), O-heteroalkyl, 0-C3_8 cycloalkyl (such as 0(C5H9); ie O-cyclopentyl), O-aryl, O-heteroaryl, NH2, NH-alkyl (eg a NH-C,.6 alkyl, preferably, a NH- C|_3 alkyl such as NH-CH3), NH-heteroalkyl (eg N'^-dimethylethane- l ^-diamine), NH-cycloalkyl (eg a NH-C3_8 cycloalkyl such as NH(C5H9); ie NH-cyclopentyl), NH-heterocycloalkyl (eg NH-C3_8 heterocycloalkyl such as NH(C5HnN); ie NH-piperidinamine), NH-aryl (eg NH-phenyl), NH-heteroaryl, N(alkyl)2 (such as N(CH3)2), N(cycloalkyl)2 (eg N(C5H9)2), N(heterocycloalkyl)2 (such as N- dipiperidinamine), N-(alkyl)(aryl), SH-alkyl (eg a SH-C|_6 alkyl or, preferably, a SH-C^ alkyl such as SHCH3 and SHC(CH3)), SH-aryl, SH-heteroaryl, S-heteroalkyl, S-C3.8 cycloalkyl (such as S(C5H9); ie S- cyclopentyl), and R1 ' ; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl (eg methyl), CN, OH, O-methyl, O-ethyl, 0-CF2, NH2, COOH, CONH2, heterocycloalkyl, CO-heterocycloalkyl, CF3 and S02N(CH3)2.
L0056J In some embodiments, R, R1, R2 and R4 are all H, and R3 is selected from the group consisting of H, alkyl (eg a Ci_6 alkyl or, preferably, a Cj.3 alkyl such as methyl), cycloalkyl, heterocycloalkyl, aryl (eg phenyl), heteroaryl (eg pyridinyl, pyrimidinyl), halogen (especially Br or F), N02, CF3, OH, O-alkyl (eg an 0-Ci_6 alkyl, preferably, an O-C^ alkyl such as 0-CH3), O-heteroalkyl, 0-C3.8 cycloalkyl (such as 0(C5H9); ie O-cyclopentyl), O-aryl, O-heteroaryl, NH2, NH-alkyl (eg a NH-d_6 alkyl, preferably, a NH- Ci-3 alkyl such as NH-CH3), NH-heteroalkyl (eg
Figure imgf000014_0001
NH-cycloalkyl (eg a NH-C3_8 cycloalkyl such as NH(C5H9); ie NH-cyclopentyl), NH-heterocycloalkyl (eg NH-C3.8 heterocycloalkyl such as NH(C5HnN); ie NH-piperidinamine), NH-aryl (eg NH-phenyl), NH-heteroaryl, N(alkyl)2 (such as N(CH3)2), N(cycloalkyl)2 (eg N(C5H9)2), N(heterocycloalkyl)2 (such as N- dipiperidinamine), N-(alkyl)(aryl), SH-alkyl (eg a SH-Ci_6 alkyl or, preferably, a SH-C^ alkyl such as SHCH3 and SHC(CH3)), SH-aryl, SH-heteroaryl, S-heteroalkyl, S-C3.8 cycloalkyl (such as S(C5H9); ie S- cyclopentyl), and R11; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl (eg methyl), CN, OH, O-methyl, O-ethyl, 0-CF2, NH2, COOH, CONH2, heterocycloalkyl, CO-heterocycloalkyl, CF3 and S02N(CH3)2.
L0057J In some embodiments, R5 is H, alkyl (eg a C .6 alkyl such as phenyl, or preferably, a Ci_3 alkyl such as methyl), O-alkyl (preferably, a C|_6 alkoxy or, more preferably, a C|_3 alkoxy such as methoxy or ethoxy), CN, or halogen (preferably F and CI).
L0058J In some embodiments, m is an integer from 1 to 5 inclusive, but more preferably, m is an integer from 1 , 2 and 3. Most preferably, m is 1. Where m is 2, 3, 4 or 5, it is to be understood that each of the R6 groups may be the same or different.
[0059] In some embodiments, R6 is independently selected from the group consisting of H, alkyl (eg a Ci_5 alkyl such as methyl, propyl, cyclopropylmethyl, cyclopentylmethyl), OH, halogen (preferably F), O- alkyl (preferably, a Ci_6 alkoxy or, more preferably, a C1 3 alkoxy such as methoxy or ethoxy), C02-alkyl, COOH, Ci_3-heterocycloalkyl, O-heteroalkyl, NH2, NH-alkyl (preferably, a Ci_6 alkyl or, more preferably, an NH-Ci.3 alkyl such as NH-CH3), N-(alkyl)2 (eg N(CH3)2 and N(C2H5)2), NH-cycloalkyl (preferably, a NH-d.4 cycloalkyl such as azetidine), NH-heteroalkyl, NH-R7 where R7 is CO(NH-alkyl), S02-alkyl (preferably, an S02-d_3 alkyl such as S02-methyl), S02NH2, NH-alkyl-R7 where R7 is CF3, O-alkyl, CO(NH2) or C02-alkyl, preferably a C02-C,_3 alkyl (eg NH-CH2-C02CH3), N-(alkyl)(R7) where R7 is heteroalkyl such as a C2_5 heteroalkyl (eg N(CH3)(C2H40CH3), S02-alkyl (preferably, an S02-Ci_3 alkyl such as S02-methyl), alkyl-R7 where R7 is C02-alkyl, preferably a C02-C,_3 alkyl (eg CH2-C02CH3), and COOR7 where R7 is preferably a C|_3 alkyl or Ci_6 alkyl (eg /ert-butyloxycarbonyl (Boc)); and wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, CN, carbonyl, OH, O-methyl, NH2, COOH, CONH2, and CF3.
[0060] In some embodiments, A is a cyclopentane, cyclohexane, cycloheptane, tetrahydrofuran or tetrahydro-2H-pyran, diazaspiro[4.5]decan-l-one, quinuclidine, quinuclidin-3-amine, piperidine, or oxepane optionally substituted with at least one of R6.
[0061] In some embodiments, A is cyclohexane, adamantane, tetrahydro-2H-pyran or piperidine optionally substituted with at least one of R6. [0062] In some preferred embodiments, the compounds of the present invention exhibit anti-proliferative activity in human cell lines, as measured by a standard cytotoxicity assay. Preferably, the compound exhibits an TC50 value of less than 5 μΜ, even more preferably less than 1 μΜ as measured by the cell viability (MTT proliferation) assay described in Example 2 hereinafter. More preferably still, the compound exhibits an IC50 value of less than 0.5 μΜ.
[0063] In some preferred embodiments, the compounds of the present invention inhibit one or more protein kinases, as measured by any standard assay well known to those skilled in the art. Preferably, the compound exhibits an IC50 value of less than 1 μΜ or less than 0.5 μΜ as measured by the kinase assay described in Example 2 hereinafter, more preferably still less than 0.1 μΜ.
[0064] Particular examples of compounds according to the first aspect are shown in Table 1 below.
Table 1 Chemical structure of selected compounds of the present invention
No. Structure Name Mass
(lr,4r)-A'1-(5-Fluoro-4-(imidazoLl ,2-aJpyridin-3-yl)pyrimidin-2-
1 326.4 yl)cyclohexane- 1 ,4-diamine
( l r,4r)-jV'-(5-Fluoro-4-(6-fluoroimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-
2 344.4 yl)cyclohexane- 1 ,4-diamine
(lr,4r)-A'1-(5-Fluoro-4-(6-(trifluoromethyl)imidazoLl ,2-aJpyridin-3-
3 394.4 yl)pyrimidin-2-yl)cyelohexane- 1 ,4-diamine
( l r,4r)-jV'-(5-Fluoro-4-(6-methylimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-
4 340.4 yl)cyclohexane- 1 ,4-diamine
( l r,4r)-jV'-(5-Fluoro-4-(6-phenylimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-
5 402.5 yl)cyclohexane- 1 ,4-diamine
( 1 r,4r)-Nl -(5-Fluoro-4-(6-(phenylamino)imidazo [ 1 ,2-a ]pyridin-3-
6 417.5 yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine
(lr,4r)-A^l-(5-Fluoro-4-(6-((4-fluorobenzyl)amino)imidazo[l ,2-a]pyridin-
7 449.5
3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine
Cn ( 1 r,4r)-A^1-(4-(Imidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-
8 322.4 yl)cyclohexane- 1 ,4-diamine
( 1 r,4r)-N* -(5-Methyl-4-(6-(trifluoromethyl)imidazo [ 1 ,2-a]pyridin-3-
9 390.4 yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
[0065] The compounds (and pharmaceutically acceptable salts, solvates and prodrugs thereof) may be administered in combination with one or more additional agent(s) for the treatment of cancer or another proliferative disease or condition. For example, the compounds may be used in combination with other anti-cancer agents in order to inhibit more than one cancer signalling pathway simultaneously so as to make cancer cells more susceptible to anti-cancer therapies (eg treatments with other anti-cancer agents, chemotherapy, radiotherapy or a combination thereof). As such, the compounds of formula 1 may be used in combination with one or more of the following categories of anti-cancer agents:
• other anti-proliferative/antineoplastic drugs and combinations thereof, as used in medical
oncology, such as alkylating agents (eg cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas);
antimetabolites (eg gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, fludarabine and hydroxyurea); antitumour antibiotics (eg anthracyclines such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (eg vinca alkaloids such as vincristine, vinblastine, vindesine and vinorelbine and taxoids including taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors
(eg epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan and camptothecin);
• cytostatic agents such as antioestrogens (eg tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (eg bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (eg goserelin, leuprorelin and buserelin), progestogens (eg megestrol acetate), aromatase inhibitors (eg as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;
• anti-invasion agents (eg c-Src kinase family inhibitors such as 4-(6-chloro-2,3- methylenedioxyanilino)-7-L2-(4-methylpiperazin-l-yl)ethoxyJ-5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Publication No WO 01/94341), N-(2-chloro- 6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-l-yl]-2-methylpyrimidin-4- ylamino}thiazole-5-carboxamide (dasatinib) and bosutinib (SKI-606)), and metalloproteinase inhibitors including marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to heparanase;
• inhibitors of growth factor function (eg growth factor antibodies and growth factor receptor antibodies such as the anti-erbB2 antibody trastuzumab (Herceptin™), the anti-EGFR antibody panitumumab, the anti-erbB 1 antibody cetuximab (Erbitux, C225) and any growth factor or growth factor receptor antibodies disclosed by Stern et al. Critical reviews in
oncology/haematology, 2005, Vol. 54, ppl 1-29). Such inhibitors also include tyrosine kinase inhibitors such as inhibitors of the epidermal growth factor family (eg EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3- morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2- methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-/V-(3-chloro-4- fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine kinases (eg Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors including sorafenib (BAY 43-9006), tipifarnib (Rl 15777) and lonafarnib (SCH66336)), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-IR kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors (eg AZDl 152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 and AX39459) and cyclin dependent kinase inhibitors such as CDK2 and/or CDK9 inhibitors; anti-angiogenic agents such as those which inhibit the effects of vascular endothelial growth factor (eg the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as vandetanib (ZD6474), vatalanib
(PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW 786034) and 4-(4- fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-l-ylpropoxy)quinazoline (AZD2171 ; Example 240 within International Patent Publication No WO 00/47212), compounds such as those disclosed in International Patent Publication Nos W097/22596, WO 97/30035, WO 97/32856 and WO 98/13354, and compounds that work by other mechanisms (eg linomide, inhibitors of integrin ανβ3 function and angiostatin); vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Publication Nos WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; an endothelin receptor antagonist such as zibotentan (ZD4054) or atrasentan; antisense therapies such as those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense; gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA 1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
• immunotherapy approaches, including for example ex vivo and in vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
L0066J Where used in combination with other anti-cancer agents, a compound of the present invention and the other anti-cancer agent can be administered in the same pharmaceutical composition or in separate pharmaceutical compositions. If administered in separate pharmaceutical compositions, the compound and the other anti-cancer agent may be administered simultaneously or sequentially in any order (eg within seconds or minutes or even hours (eg 2 to 48 hours).
[0067] The present invention is typically applied to the treatment of cancer or another proliferative cell disease or condition in a human subject. However, the subject may also be selected from, for example, livestock animals (eg cows, horses, pigs, sheep and goats), companion animals (eg dogs and cats) and exotic animals (eg non-human primates, tigers, elephants etc).
[0068] Cancers and other proliferative cell diseases and conditions that may be treated in accordance with the present invention include biliary tract cancer, brain cancer (including glioblastomas and medulloblastomas), breast cancer, cervical cancer; choriocarcinoma, colonic cancer, endometrial cancer, oesophageal cancer, gastric cancer, haematological neoplasms (including acute lymphocytic leukemia (ALL)), chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML), acute myeloid leukaemia (AML), multiple myeloma, AIDS-associated leukemias and adult T-cell leukemia lymphoma, intraepithelial neoplasms (including Bowen's disease and Paget's disease), liver cancer, lung cancer, lymphomas (including Hodgkin's disease and lymphocytic lymphomas), neuroblastomas, oral cancer (including squamous cell carcinoma), ovarian cancer (including those arising from epithelial cells, stromal cells, germ cells, and mesenchymal cells), pancreatic cancer, prostate cancer, colorectal cancer, sarcomas (including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and
osteosarcoma), skin cancer (including melanoma, Kaposi's sarcoma, basocellular cancer, and squamous cell cancer), testicular cancer (including germinal tumours such as seminoma, non-seminoma teratomas, and choriocarcinomas), stromal tumours, germ cell tumours, thyroid cancer (including thyroid adenocarcinoma and medullar carcinoma), and renal cancer (including adenocarcinoma and Wilms' tumour). [0069] In some embodiments, the compounds of the present invention are used to treat cancers characterised by over-expression of CDKs, for example, chronic lymphocytic leukaemia (CLL), lymphoma, leukaemia, breast cancer, lung cancer, prostate cancer, colon cancer, melanoma, pancreatic cancer, ovarian cancer, squamous cancer, carcinoma of head and neck, endometrial cancer, and oesophageal carcinoma (reviewed in Lapenna et al., Nat Rev Drug Discov 8(7):547-66 (2009) and Asghar et al, Nat Rev Drug Discov 14(2): 130-46 (2015)). CDKs and/or cyclin over-expression may be determined by, for example, assessing the amount of mRNA encoding CDK and/or cyclin in a suitable sample using any of the techniques well known to those skilled in the art (eg quantitative amplification techniques such as qPCR).
[0070] In a preferred embodiment, the compounds of the present invention are used to a disease or condition characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity. Otherwise, said disease or condition may be one which may be beneficially treated by inhibiting one or more CDK (eg by inhibiting the activity and/or expression of one or more of CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9, and/or the association of one or more of such CDK enzymes with their respective cyclin/mediator complex). The compounds of the present invention may therefore be used to treat diseases or conditions including, for example, viral disorders, eg human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV) (Yamamoto et ai, J Clin Invest 124(8): 3479-3488 (2014)), cardiovascular diseases, eg ischaemic heart disease (known also as myocardial infarction or angina), hypertension, heart failure, restenosis and cardiomyopathy (Trifonov et ai, Curr Opin Biotechnol. 24(S 1): S I 14-S 115
(2013) ), cancers, eg chronic lymphocytic leukaemia (CLL) (Walsby et ai, Oncotarget 5(2):375-85
(2014) ), lymphoma (Gregory et ai, Leukemia 29(6): 1437-1441 (2015)), leukaemia (Walsby et ai, Leukemia 25(3):41 1-419 (201 1)), breast cancer (Mita et al, Clin Breast Cancer 14(3): 169-176 (2014)), lung cancer (Stephenson et al, Lung Cancer 83(2):219-223 (2014)), prostate cancer (reviewed in Rahaman et al, Endocr Relat Cancer pii: ERC- 16-0299 (2016)), melanoma (Desai et ai, PLoS One 8(3):e59588 (2013)), pancreatic cancer (Hu et al, Mol Cancer Ther 14(7): 1532-1539 (2015)), ovarian cancer (Lam et al, Oncotarget 5(17):7691-7704 (2014)), hepatocarcinoma (Li et al, Curr Cancer Drug Target 15(3): 196-204 (2015)), oesophageal carcinoma, neuroblastoma and primary neuroectodermal tumor (de Falco et al., Cancer Biol Ther 4(3):277-281 (2005)), rhabdomyosarcoma (Simone et al, Cell Death and Differ 14(1): 192-195 (2007)) and carcinoma of head and neck (Gary et al, Oncotarget 7(25):38598-3861 1 (2016)). The level of CDK may be determined by, for example, assessing the amount of mRNA encoding CDK and/or cyclin in a suitable sample using any of the techniques well known to those skilled in the art (eg quantitative amplification techniques such as qPCR).
[0071] In some embodiments, the compounds of the present invention are used to treat cancers characterised by over-expression of Fit kinases such as Flt3 and/or mutations, eg acute myeloid leukaemia (reviewed in Hitoshi et al., Nagoya J Med Sci 77(l-2):7-17 (2015) and Wander et al., Ther Adv Hematol 5(3):65-77 (2014)).
[0072] In some embodiments, the compounds of the present invention are used to treat conditions characterised by over-expression of CLKs, eg in Alzheimer's disease (AD) and in diseases involving abnormal pre-mRNA splicing (Jain et al, Curr Drug Targets 15(5):539-50 (2014)). CLKs are serine- arginine protein kinases and are elements of the splicing machinery. Inhibitors of CLKs modulate pre- mRNA splicing, thereby impeding cell growth and inducing apoptosis (Araki et al., PLoS One 10( 1 ): eO l 16929 (2015)).
[0073J In some embodiments, the compounds of the present invention are used to treat cancers characterised by over-expression of aurora kinases. Aurora kinases are key mitotic regulators, they control multiple steps of mitosis, including centrosome duplication, formation of a bipolar mitotic spindle, chromosome alignment on the mitotic spindle and the fidelity-monitoring spindle checkpoint (reviewed in Macarulla et al. , Recent Pat Anticancer Drug Discov (2): 1 14-22 (2008)). Aurora kinase inhibitors are used to treat cancers, eg childhood acute leukaemia (Hartsink Segers et al, Leukemia 27(3): 560-568 (2013)), lung cancer (Chinn et al, J Cancer Res Clin Oncol 140(7): 1 137- 1349 (2014)), prostate cancer (Paller et al, Cancer Med 3(5): 1322-1335 (2014)), advanced solid tumours (Schwartz et al., Invest New Drugs 31(2):370-80 (2013)), and neuroblastoma (Michaelis et al, PLoS One 9(9): el08758 (2014)).
[0074] The compounds of the present invention may be formulated into a pharmaceutical composition with a pharmaceutically acceptable carrier, diluent and/or excipient. Examples of suitable carriers and diluents are well known to those skilled in the art, and are described in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1995. Examples of suitable excipients for the various different forms of pharmaceutical compositions described herein may be found in the Handbook of Pharmaceutical Excipients, 2nd Edition, ( 1994), Edited by A Wade and PJ Weller. Examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like. Examples of suitable diluents include ethanol, glycerol and water. The choice of carrier, diluent and/or excipient may be made with regard to the intended route of administration and standard pharmaceutical practice.
[0075] A pharmaceutical composition comprising a compound of the present invention may further comprise any suitable binders, lubricants, suspending agents, coating agents and solubilising agents. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Preservatives, stabilising agents, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Anti-oxidants and suspending agents may be also used.
[0076] A pharmaceutical composition comprising a compound of the present invention may be adapted for oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, subcutaneous, intradermal, intravenous, nasal, buccal or sublingual routes of administration. For oral administration, particular use may be made of compressed tablets, pills, tablets, gellules, drops, and capsules. For other forms of administration, a pharmaceutical composition may comprise solutions or emulsions which may be injected intravenously, intraarterially, intrathecally, subcutaneously, intradermally, intraperitoneally or intramuscularly, and which are prepared from sterile or sterilisable solutions. A pharmaceutical composition comprising a compound of the present invention may also be in form of suppositories, pessaries, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or dusting powders. A pharmaceutical composition may be formulated in unit dosage form (ie in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose).
[0077] The compounds of the present invention may be provided as a pharmaceutically acceptable salt including, for example, suitable acid addition or base salts thereof. A review of suitable pharmaceutical salts may be found in Berge et al., J Pharm Sci 66: 1-19 ( 1977). Salts are formed, for example with strong inorganic acids such as mineral acids (eg sulfuric acid, phosphoric acid or hydrohalic acids), with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (eg by halogen), such as acetic acid, with saturated or unsaturated dicarboxylic acids (eg oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic acid), with hydroxycarboxylic acids (eg ascorbic, glycolic, lactic, malic, tartaric or citric acid), with amino acids (eg aspartic or glutamic acid), with benzoic acid, or with organic sulfonic acids (eg (CrC4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted by, for example, halogen) such as methane- or p-toluene sulfonic acid).
L0078J The compounds of the present invention may be provided in their various crystalline forms, polymorphic forms and (an)hydrous forms. In this regard, it is well known to those skilled in the art that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation from the solvents used in the synthetic preparation of such compounds.
[0079] The present invention further provides a method of synthesising a compound according to the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0080] With regard to the description of the synthetic methods described below and in the referenced synthetic methods that are used to prepare starting materials, it will be understood by those skilled in the art that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be readily selected. Moreover, it will be understood by those skilled in the art that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions utilised.
[0081] Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the examples hereinafter. Alternatively, necessary starting materials may be obtainable by analogous procedures to those illustrated which are within the ordinary skill of those skilled in the art. Further, it will be appreciated that during the synthesis of the compounds, in the processes described below, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. Those skilled in the art will readily recognise when such protection is required, and how such protecting groups may be put in place, and later removed. Examples of protecting groups are described in, for example, Protective Groups in Organic Synthesis by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method well known to those skilled in the art as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule. Thus, if reactants include, for example, groups such as amino, carboxyl or hydroxyl, it may be desirable to protect the group in some of the reactions mentioned herein.
[0082] The compounds of the present invention may be prepared by, for example, the general synthetic methodologies described in International Patent Publication No WO 2010/049731, which is herein incorporated by reference.
[0083] In a further aspect of the present invention, a method of synthesising a compound of the present invention (or a pharmaceutically acceptable salt, solvate or prodrug thereof) is provided wherein the method comprises the steps of:
a) brominating a compound of formula III
Figure imgf000034_0001
II I wherein R5 is as defined in the first aspect,
b) thereafter conducting a one pot cyclocondensation with a compound selected from pyridin-2-amines, pyridazin-3-amine, pyrazin-2-amines and 1-aminopyridin-l-iums, to form a compound of formula V;
c) animating the compound of formula V,
Figure imgf000035_0001
wherein R, R1, R2, R3, R4 and R5 are as defined in the first aspect,
by reacting the compound of formula 111 with a compound of formula VI:
Figure imgf000035_0002
VI
wherein R6 is as defined in the first aspect; and if necessary,
d) removing any protecting groups present, and/or forming a pharmaceutically acceptable salt, solvate or prodrug thereof.
L0084J The cyclocondensation reaction of step b) may be conducted in the presence of a suitable solvent or solvent mixture. Those skilled in the art will be able to readily select a suitable solvent or solvent mixture for use in this reaction. Examples of suitable solvents include dioxane, water, etc.
[0085] In addition, those skilled in the art will be able to readily select appropriate reaction conditions for the condensation reaction of step b). However, typically, the reaction will be carried out in anhydrous conditions and in the presence of an inert atmosphere, such as argon or nitrogen.
[0086] The bromination reaction of step a) may be carried out at room temperature for a suitable time period of, for example, 30 minutes to 2 hours, whereas the subsequent condensation reaction of step b)may be carried out at an elevated temperature, for example, within the range of 60 to 100°C for a suitable time period of, for example, 20 minutes to 10 hours. Suitably, the bromination reaction of step a) is carried out at room temperature for 30 minutes to 2 hours, and then the condensation reaction of step b) will be conducted by adding the required compound (ie a compound selected from pyridin-2-amines, pyridazin-3-amine, pyrazin-2-amines and 1-aminopyridin-l-iums) and normal heating at 60 to 100 °C for 20 minutes to 10 hours.
[0087] The coupling reaction of step c) may be conducted in the presence of a suitable solvent or solvent mixture. Again, those skilled in the art will be able to readily select a suitable solvent or solvent mixture for use in this reaction. Examples of suitable solvents include alcohols, acetonitrile, halogenated solvents, etc. [0088] In addition, those skilled in the art will be able to select appropriate reaction conditions to use in the coupling reaction of step c). However, typically, the reaction will be carried out in anhydrous conditions and in the presence of an inert atmosphere, such as argon or nitrogen. The reaction may also be carried out an elevated temperature, such as, for example, within the range of 80 to 180°C for a suitable time period of, for example, 20 minutes to 48 hours. Suitably, the reaction is carried out under microwave heating, for example, at 80 to 180 °C for 20 minutes to 1.5 hour.
[0089] The resultant compound of formula I can be isolated and purified using techniques well known to those skilled in the art.
[0090] The method of synthesising a compound of the present invention (or a pharmaceutically acceptable salt, solvate or prodrug thereof) may further comprise:
e) subjecting the compound of formula I to a salt exchange (particularly in situations where the compound is formed as a mixture of different salt forms).
L0091J The salt exchange may comprise immobilising the compound on a suitable solid support or resin, and eluting the compound with an appropriate acid to yield salt of the compound of formula I.
[0092] An example of a particularly suitable method for synthesising a compound of the present invention is shown as Scheme 1 below.
Scheme 1
Figure imgf000036_0001
General reaction conditions: (a) l-(vinyloxy)butane, Pd(OAc)2, base, PEG400, heating; (b) (i) N- bromosuccimide, dioxane/water, room temperature; (ii) IV, heating; (c) base, 2-methoxyethanol, heating.
[0093] The invention is hereinafter described with reference to the following, non-limiting examples.
EXAMPLES
Example 1 Synthesis
General
L0094J Ή spectra were recorded at 298 K on a Bruker A VANCE III HD 500 spectrometer and were analysed using Bruker Topspin 3.2 software. 'H-NMR signals are reported with chemical shift values δ (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet and br = broad), relative integral, coupling constants J (Hz) and assignments. High resolution mass spectra were recorded on an AB SCIEX TripleTOF 5600 mass spectrometer (Concord, ON, Canada), and ionisation of all samples was carried out using ESI.
[0095J General synthetic procedure A:
i. A suspension of 2-chloro-4-heteroarylpyrimidine ( 1.00 eq.), ( 1 r,4r)-cyclohexane- 1 ,4-diamine (3.00 eq.) and K2C03 (3.00 eq.) in 2-methoxyethan- 1 -ol was heated at 90 °C for overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 9% MeOH + 1.0% NH3 (32% in water). i. A microwave tube was charged with 2-chloro-4-heteroarylpyrimidine (1.00 eq.), (\r,4r)- cyclohexane- 1 ,4-diamine (3.00 eq.) and Et3N (1 mL.) in 2-methoxyethan- l-ol (4 mL). The reaction mixture was heated at 180 °C for 1 h, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 9% MeOH + 1 % NH3 (32% in water).
[0096] General synthetic procedure B: A microwave-tube was charged with aryl halide (1.00 eq.), amine (1.00 eq.), Cs2C03 (2.00 eq.), Pd2(dba)3 (0.05 eq.), xantphos (0.05 eq.) and dioxane (3 mL). The reaction mixture was heated under microwave at 170 °C for 2 h. Amine (1.00 eq.), Cs2C03 (2.00 eq.), Pd2(dba)3 (0.05 eq.), xantphos (0.05 eq.) were re-added for incomplete reactions and the latter were heated under microwave at 170 °C for 2 h again. The reaction mixtures were concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 1% NH3 (32% in water) to afford the desired product. Compounds showing purity <94% were further purified using preparative HPLC. [0097] General synthetic procedure C: A microwave tube was charged with aryl halide (1.00 eq.), boronic acid/ester (1.00 eq.), Na2C03 (2.00 eq.), Pd(PPh3)4 (0.05 eq.) and MeCN/water (4 mL; 3: 1). The reaction mixture was heated under microwave at 130 °C for 60 min, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 1 % NH3 (32% in water) to afford the desired product. Compounds showing purity <94% were further purified using preparative HPLC.
L0098J General synthetic procedure D: A solution of amine derivative (1.00 eq.), the corresponding ketone ( 1.00-5.00 eq.), Et3N in the amine is a salt ( 1.50 eq.) in DCE was stirred at rt for 1 h. AcOH (2.50 eq.) and sodium triacetoxyborohydride (2.00 eq.) were added. The reaction was stirred at rt overnight, quenched by adding saturated NaHC03, and extracted with DCM. Organic extracts were combined, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 0.5% NH3 (32% in water) to afford the desired product. Compounds showing purity <94% were further purified using preparative HPLC.
[0099J General synthetic procedure E: A suspension of the cyclohexane-l,4-diamine derivative (1.00 eq.), the corresponding haloalkane ( 1.10 eq), K2C03 (0.25 eq.), KI ( 1.30 eq) in MeCN was heated at reflux for 3- 1 Oh. The reaction mixture was filtered, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 0.5% NH3 (32% in water) to afford the desired product. Compounds showing purity <94% were further purified using preparative HPLC.
[00100J The following compounds were synthesised in accordance with the procedures set above:
[00101J ( 1 r,4r)-N 1 -(5-Fluoro-4-(imidazo 1 1 ,2-a |pyridin-3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (1). A suspension of the corresponding 2,4-dichloro-5-fluoropyrimidine (2.20 g, 13.2 mmol), 1- (vinyloxy)butane (5.0 mL 39 mmol), triethylamine (1.93 mL, 13.7 mmol) in PEG400 (6 mL) as stirred and degassed over 30 min. Pd(OAc)2 (150 mg, 0.67 mmol) was added and the reaction mixture stirred under nitrogen at 80 °C for 12-48 h. The mixture was cooled, diluted with Et20 and water. Organic phase was separated and the aqueous phase extracted with Et20. Organic extracts were combined, washed with brine and purified by flash column chromatography starting with 100% petroleum ether ramping to 100% DCM to give (£ -4-(2-butoxyvinyl)-2-chloro-5-fluoropyrimidine as a yellow liquid (900 mg, 30%). Ή- NMR (CDC13): δ 0.94 (t, 3H, J = 7.0 Hz), 1.39-1.46 (m, 2H), 1.68-1.74 (m, 2H), 3.98 (t, 2H, J = 6.5 Hz), 5.87 (d, 1H, / = 12.5 Hz), 7.96 (d, 1Η, / = 12.5 Hz), 8.18 (d, 1H, / = 2.0 Hz). MS (ESI) m/z [M+H]+ 231.0665. N-Bromosuccinimide (0.83 g, 4.67 mmol) was added to a stirred solution of (£)-4-(2- butoxyvinyl)-2-chloro-5-fluoropyrimidine (0.90 g, 3.90 mmol) in 20 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h. Pyridin-2-amine (0.37 g, 3.90 mmol) was added, and the reaction mixture heated at 85 °C for 2.5 h. Dioxane was evaporated and the residue was triturated with EtOAc, the resulting solid was filtered, washed with EtOAc and purified by flash column chromatography starting with 100% petroleum ether ramping to 100% DCM to give 3-(2-chloro-5-fluoropyrirnidin-4- yl)imidazo[ l ,2-a]pyridine as a white powder (0.80 g, 93%). ¾-NMR (DMSO-i¾): δ 7.35 (t, 1H, J = 7.0 Hz), 7.65 (t, 1 H, 7 = 8.0 Hz), 7.88 (d, 1 H, J = 9.0 Hz), 8.5 1 (d, 1 H, J = 4.0 Hz), 8.85 (d, 1 H, J = 3.0 Hz), 9.73 (d, 1 H, J = 7.0 Hz). HRMS (ESI) m/z [M+H]+ calcd. for CnH7ClFN4 +, 249.0338; found 249.0309. 3-(2-Chloro-5-fluoropyrimidin-4-yl)imidazo[ l ,2-a]pyridine (0.45 g, 1 .80 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine (0.64 g, 5.60 mmol) were reacted according to general synthetic procedure A(i) to give 1 as a yellow solid (0.33 g, 56%). Ή-NMR (CDC13): δ 1.30- 1 .33 (m, 4H), 1 .96- 1 .98 (m, 2H), 2.20-2.22 (m, 2H), 2.76-2.79 (m, 1H), 3.74-3.75 (m, 1H), 5.01 (s, 1H), 7.00 (d, 1H, J = 6.5 Hz), 7.40 (t, 1H, / = 7.0 Hz), 7.76 (d, 1H, J = 8.0 Hz), 8.18 (s, 1H), 8.47 (s, 1H), 10.02 (s, 1H) (two primary amine protons (NH2) signals not observed). MS (ESI) m/z [M+HJ+ 327.1851.
[00102] ( lr,4r)-N'-(5-Fluoro-4-(6-fluoroimidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2-yl)cyclohexane-
1 ,4-diamine (2). 3-(2-Chloro-5-fluoropyrimidin-4-yl)-6-fluoroimidazo[ l ,2-a]pyridine (0.30 g, 1.59 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine (0.39 g, 4.78 mmol) were reacted according to general synthetic procedure A(i) to give 2 as a yellow solid (0.22 g, 40%). 'H-NMR (CDC13): δ 1.31- 1.39 (m, 4H), 1.98 (s, 2H), 2.23 (s, 2H), 2.74-2.79 (m, 1H), 3.74-3.80 (m, 1H), 5.03 (d, 1H, J = 7.0 Hz), 7.33 (td, 1H, J = 8.0 & 2.5 Hz), 7.74 (dd, 1H, / = 9.5 & 5.0 Hz), 8.21 (d, 1H, / = 3.5 Hz), 8.49 (d, 1H, / = 3.5 Hz), 10.08 (s, 1H). HRMS (ESI) m/z | M+HJ+ 345.1582.
[00103] ( lr,4r)-N'-(5-Fluoro-4-(6-(trifluoromethyl)imidazo[ l ,2-alpyridin-3-yl)pyrimidin-2- yPcyclohexane- 1 ,4-diamine (3). 3-(2-Chloro-5-fluoropyrimidin-4-yl)-6-(trifluoromethyl)imidazo[ 1 ,2- ajpyridine (0.50 g, 1.58 mmol) and ( lr,4r)-cyclohexane- 1 ,4-diamine (0.66 g, 4.75 mmol) were reacted according to general synthetic procedure A(i) to give 3 as a yellow solid (0.20 g, 32%). Ή-NMR
(CDC13): δ 1.25- 1.37 (m, 4H), 1.95 (d, 2H, / = 8.5 Hz), 2.18 (d, 2H, / = 8.5 Hz), 2.72-2.74 (m, 1H), 3.78- 3.82 (m, 1H), 5.00 (d, 1H, J = 7.5 Hz), 7.55 (dd, 1H, J = 9.5 & 1.5 Hz), 7.87 (d, 1H, / = 9.0 Hz), 8.24 (d, 1H, J = 3.5 Hz), 8.54 (d, 1H, J = 4.0 Hz), 10.49 (s, 1H). HRMS (ESI) m/z [M+H]+ 395.2399.
[00104] ( lr,4r)-N'-(5-Fluoro-4-(6-methylimidazo[ l ,2-alpyridin-3-yl)pyrirnidin-2-yl)cyclohexane- 1 ,4-diamine (4). N-Bromosuccinimide (0.70 g, 3.91 mmol) was added to a stirred solution of (£)-4-(2- butoxyvinyl)-2-chloro-5-fluoropyrimidine (0.90 g, 3.90 mmol) in 10 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h. 5-Methylpyridin-2-amine (0.42 g, 3.91 mmol) was added, and the reaction mixture heated at 85 °C for 2.5 h. Dioxane was evaporated and the residue was triturated with EtOAc, the resulting solid was filtered, washed with EtOAc to give 3-(2-chloro-5-fluoropyrimidin-4-yl)- 6-methylimidazo[ l ,2-a]pyridine as a white powder (0.20 g, 20%). Ή-NMR (DMSO-<i6): δ 2.42 (s, 3H), 7.53 (dd, 1H, J = 9.0 & 1.0 Hz), 7.79 (d, 1H, J = 9.0 Hz), 8.45 (d, 1H, J = 4.0 Hz), 8.83 (d, 1H, J = 3.5 Hz), 9.54 (s, 1H). HRMS (ESI) m/z [M+H]+ 263.0498. 3-(2-Chloro-5-fluoropyrimidin-4-yl)-6- methylimidazo[ l ,2-a]pyridine (0.15 g, 0.57 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine (0.20 g, 1.72 mmol) were reacted according to general synthetic procedure A(ii) to give 4 as a yellow solid (0.12 g, 62%). Ή-NMR (CDC13): δ 1.29- 1.36 (m, 4H), 1.97 (d, 2H, J = 9.0 Hz), 2.23 (d, 2H, J = 9.0 Hz), 2.44 (s, 3H), 2.76-2.78 (m, 1 H), 3.78-3.80 (m, 1 H), 4.98 (d, 1 H, 7 = 7.5 Hz), 7.25 (dd, 1 H, 7 = 9.0 & 1 .0 Hz), 7.66 (d, 1 H, J = 9.0 Hz), 8. 17 (d, 1 H, J = 4.0 Hz(), 8.42 (d, 1H, J = 4.0 Hz), 9.79 (s, 1 H). HRMS (ESI) m/z [M+H]+ 341 .1830.
[00105] ( 1 r,4r)-N 1 -(5-Fluoro-4-(6-phenylimidazo [ 1 ,2-alpyridin-3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4- diamine (5). 3-(2-Chloro-5-fluoropyrimidin-4-yl)-6-phenylimidazo[ l ,2-a]pyridine (0.45 g, 1.39 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine (0.48 g, 4.17 mmol) were reacted according to general synthetic procedure A(ii) to give 5 as a white solid (0.20 g, 36%). Ή-NMR (CDC13): δ 1.07 (s, 2H), 1. 17- 1.26 (m, 4H), 1.82 (d, 2H, J = 9.5 Hz), 2.09 (d, 2H, J = 1 1.0 Hz), 2.61 (br, 1 H), 2.62 (br, 1H), 4.84 (br, 1 H), 5.83 (br, 1H), 6.94 (t, 1 H, J = 7.0 Hz), 7.02 (d, 2H, J = 6.5 Hz), 7.27-7.30 (m, 2H), 7.70 (d, 1 H, / = 9.0 Hz), 8. 16 (d, 1H, / = 3.5 Hz), 8.42 (d, 1 H, / = 4.0 Hz), 10.04 (s, 1 H). HRMS (ESI) m/z. [M+H]+ 403.1958.
[ 00106J ( lr,4r)-N1-(5-Fluoro-4-(6-(phenylamino)imidazo| l ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (6). 6-Nitro-N-phenylpyridin-3-amine: Microwave tubes were charged each with 5-bromo-2-nitropyridine (0.50 g, 2.47 mmol), aniline (3.53 μί, 3.74 mmol), Cs2C03 ( 1.60 g, 4.95 mmol), Pd2dba3 (0.12 g, 0.12 mmol) and xantphos (0.07 g, 0.12 mmol) in dioxane (7 mL). Reaction mixtures were heated under microwave at 160 °C for 1 h, combined, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 2% MeOH to give a black solid that was washed with MeOH to yield 6-nitro-/V-phenylpyridin-3-amine as a brown solid (2.00 g, 63%). Ή-NMR (DMSO-J6): δ 7.14 (t, 1H, J = 7.5 Hz), 7.30 (d, 2H, / = 7.5 Hz), 7.42 (d, 2H, J = 7.5 Hz), 7.57 (dd, 1H, / = 9.0 & 2.5 Hz), 8.20 (d, 1H, / = 9.0 Hz), 8.22 (d, 1H, J = 2.5 Hz), 9.49 (s, 1H). HRMS (ESI) m/z | M+HJ+ 216.0684. N5-Phenylpyridine-2,5-diamine: To a solution of 6-nitro-N- phenylpyridin-3-amine ( 1.00 g, 4.65 mmol)) in MeOH (20 mL) was added 10% Pd/C (49.0 mg, 0.46 mmol). The reaction mixture was stirred and bubbled with H2 at room temperature for 3-10 h. The solids were filtered off and washed with MeOH. The filtrate and MeOH washing were combined and concentrated under reduced pressure to give N5-phenylpyridine-2,5-diamine as a white powder (0.85 g, 99%). Ή-NMR (CDCI3): δ 4.35 (s, 2H), 5.33 (s, 1H), 6.52 (d, 1H, / = 8.5 Hz), 6.79-6.83 (m, 3H), 7.20 (t, 2H, J = 8.0 Hz), 7.34 (dd, 1H, J = 9.0 & 2.5 Hz), 7.96 (d, 1H, J = 2.5 Hz). HRMS (ESI) m/z [M+H]+ 186.0997. 3-(2-Chloro-5-fluoropyrimidin-4-yl)-N-phenylimidazo[ 1 ,2-a]pyridin-6-amine: N- Bromosuccinimide (0.56 g, 3.13 mmol) was added to a stirred solution of (£ -4-(2-butoxyvinyl)-2-chloro- 5-fluoropyrimidine (0.80 g, 3.48 mmol) in 10 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h. N5-Phenylpyridine-2,5-diamine (0.55 g, 2.96 mmol) was added, and the reaction mixture heated at 85 °C for 2.5 h. Dioxane was evaporated and the residue was triturated with EtOAc, the resulting solid was filtered, washed with EtOAc and used for next reaction without further purification to give 3-(2- chloro-5-fluoropyrinndin-4-yl)-N-phenylimidazo[ l ,2-a]pyridin-6-amine as a brown powder ( 1.00 g, 85%). Ή-NMR (DMSO-i/6): δ 7.01 (t, 1H, J = 7.5 Hz), 7.29 (dd, 2H, J = 8.5 & 1.0 Hz), 7.38 (dt, 2H, J = 7.5 & 1.5 Hz), 7.78 (dd, 1 H, J = 9.5 & 2.5 Hz), 7.97 (d, 1 H, 7 = 9.5 Hz), 8.83 (d, 1 H, 7 = 3.5 Hz), 8.91 (s, 1H), 9.02 (d, 1 H, J = 3.0 Hz), 9.87 (d, 1 H, J = 1.5 Hz). HRMS (ESI) m/z. [M+H]+ 340.0692.
3-(2-Chloro-5-fluoropyrirnidin-4-yl)-jV-phenylimidazo[ l ,2-a]pyridin-6-amine (0.34 g, 1 .00 mmol) and ( l r,4r)-cyclohexane- l ,4-diamine (0.34 g, 3.00 mmol) were reacted according to general synthetic procedure A(ii) to give 6 as a white solid (0.1 1 g, 27%). Ή-NMR (CDC13): δ 0.78 (s, 2H), 1 . 16- 1 .26 (m, 4H), 1.72 (d, 2H, 7 = 10.5 Hz), 2. 12 (d, 2H, / = 1 1.5 Hz), 2.49-2.54 (m, 1 H), 3.66-3.68 (m, 1 H), 4.92 (d, 1H, J = 8.0 Hz), 7.45 (t, 1H, J = 7.0 Hz), 7.54 (t, 2H, / = 7.5 Hz), 7.61-7.64 (m ,3H), 7.84 (dd, 1H, J = 9.0 & 1.0 Hz), 8.20 (d, 1H, J = 3.5 Hz), 8.50 (d, 1H, J = 3.5 Hz), 10.01 (s, 1H), 10.04 (s, 1H). HRMS (ESI) m/z [M+H]+ 418.2133.
[00107] ( lr,4r)-N'-(5-Fluoro-4-(6-((4-fluorobenzyl)amino)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-
2- yl)cyclohexane- 1 ,4-diamine (7). A solution of 5-bromo-2-nitropyridine (5.00 g, 24.6 mmol), DIPEA (8.75 mL, 50 mmol) and (4-fluorophenyl)methanamine (5.50 mL, 50 mmol) in DMSO (20 mL) was heated at 150 °C for 24 h. Water (100 mL) was added and the mixture was extracted with EtOAc (3 x 250 mL). The organic layers were combined, concentrated under reduced pressure and purified by flash column chromatography starting with 100 % DCM ramping to 20% EtOAc to give N-(4-fluorobenzyl)-6- nitropyridin-3-amine as a yellow solid (3.50 g, 58%). Ή-NMR (DMSO-J6): δ 4.44 (d, 2H, J = 6.0 Hz), 7.07 (dd, 1H, J = 9.0 & 2.0 Hz), 7.19 (t, 2H, J = 8.5 Hz), 7.39-7.42 (m, 2H), 7.93-7.94 (m, 2H), 8.10 (d, 1H, J = 9.0 Hz). HRMS (ESI) m/z [M+H\+ 248.0799. To a solution of N-(4-fluorobenzyl)-6-nitropyridin-
3- amine ( 1.21 g, 4.90 mmol) in MeOH (20 mL) was added 10% Pd/C (51.9 mg, 0.49 mmol). The reaction mixture was stirred and bubbled with H2 at room temperature for 10 h. The solids were filtered off and washed with MeOH. The filtrate and MeOH washing were combined and concentrated under reduced pressure to give N5-(4-fluorobenzyl)pyridine-2,5-diamine as a white powder ( 1.00 g, 94%). Ή-NMR (CDC13): δ 4.03 (s, 2H), 4.23 (s, 2H), 6.43 (d, 1H, J = 9.0 Hz), 6.87 (dd, 1H, J = 8.5 & 3.0 Hz), 7.02 (t, 2H, J = 8.0 Hz), 7.31 (t, 2H, J = 8.5 Hz), 7.58 (d, 1H, J = 2.5 Hz) (one secondary amine proton (NH) signal not observed). HRMS (ESI) m/z [M+H]+ 218.1056. N-Bromosuccinimide (0.30 g, 1.69 mmol) was added to a stirred solution of (£')-4-(2-butoxyvinyl)-2-chloro-5-fluoropyrimidine (0.39 g, 1.69 mmol) in 5 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h. N5-(4-Fluorobenzyl)pyridine-2,5- diamine (0.43 g, 19.8 mmol) was added, and the reaction mixture heated at 85 °C for 2.5 h. Dioxane was evaporated and the residue was triturated with EtOAc, the resulting solid was filtered, washed with EtOAc, and purified by flash column chromatography starting with 100% petroleum ether ramping to 100% DCM to give 3-(2-chloro-5-fluoropyrirnidin-4-yl)-A^-(4-fluorobenzyl)irnidazo[ l ,2-ii]pyridin-6- amine as a brown powder (0.14 g, 23%). Ή-NMR (CDC13): δ 4.17 (s, 1H), 4.39 (s, 2H), 7.02-7.08 (m, 3H), 7.46 (t, 2H, J = 8.5 Hz), 7.62 (d, 1H, J = 9.0 Hz), 8.38 (d, 1H, J = 3.5 Hz), 8.44 (d, 1H, J = 3.0 Hz), 9.28 (d, 1H, J = 2.0 Hz). HRMS (ESI) m/z [M+H]+ 372.0746. 3-(2-Chloro-5-fluoropyrimidin-4-yl)-N-(4- fluorobenzyl)imidazo[ l ,2-a]pyridin-6-amine (0.10 g, 0.26 mmol) and ( lr,4r)-cyclohexane- l ,4-diamine (0.09 g, 0.80 mmol) were reacted according to general synthetic procedure A(ii) to give 7 as a white solid (0.03 g, 26%). Ή-NMR (CDC13): ί 1.19- 1.27 (m, 4H), 1.89 (d, 2H, J = 1 1.5 Hz), 2.13 (d, 2H, J = 1 1.5 Hz), 2.67-2.71 ( , 1 H), 3.77-3.79 (m, 1 H), 3.91 (s, 1 H), 4.37 (d, 2H, J = 4.5 Hz), 4.56 (br, 1 H), 6.99 (dd, 1 H, J = 9.0 & 2.5 Hz), 7.09 (t, 2H, J = 8.5 Hz), 7.41 (t, 2H, J = 7.5 Hz), 7.60 (dd, 1 H, J = 9.0 & 0.5 Hz), 8. 15 (d, 1 H, J = 4.0 Hz), 8.34 (d, I H, J = 4.5 Hz), 9.26 (s, 1 H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z. [M+H]+ 450.2196.
[ 00108J ( lr,4r)-N1-(4-(Imidazo[ 1 ,2-alpyridin-3-yl)-5-methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (8). 3-(2-Chloro-5-methylpyrimidin-4-yl)imidazo[ l ,2-a]pyridine (0. 17 g, 0.70 mmol) and ( l r,4r)- cyclohexane- 1 ,4-diamine (0.24 g, 2.10 mmol) were reacted according to general synthetic procedure A(i) to give 8 as an orange powder (0.06 g, 27%). Ή-NMR (CDC13): δ 1.26- 1.36 (m, 4H), 1.95 (apparent s, 2H), 2.18 (br, 2H), 2.39 (s, 3H), 2.74-2.78 (m, 1 H), 3.79-3.83 (m, 1 H), 4.88 (d, 1 H, J = 7.5 Hz), 6.93 (t, 1H, / = 7.0 Hz), 7.35 (t, 1 H, 7 = 8.0 Hz), 7.73 (d, 1 H, 7 = 8.5 Hz), 8.14 (s, 1 H), 8.20 (s, 1 H), 9.76 (s, 1 H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 323. 1928.
[00109] ( lr,4r)-N'-(5-Methyl-4-(6-(trifluoromethyl)imidazor 1 ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (9). 3-(2-Chloro-5-methylpyrimidin-4-yl)-6-(trifluoromethyl)imidazo[ 1 ,2- ajpyridine (0.1 1 g, 0.35 mmol) and ( l r,4r)-cyclohexane- l ,4-diamine (0.15 g, 1.05 mmol) were reacted according to synthetic procedure A(i) to give 9 as a white powder (0.06 g, 44%). Ή-NMR (CDC13): δ 1.21 - 1.31 (m, 4H), 1.89 (d, 2H, / = 10.5 Hz), 2. 12 (d, 2H, / = 1 1.0 Hz), 2.36 (s, 3H), 2.65-2.698 (m, 1 H), 3.74-3.78 (m, 1H), 5.12 (d, 1H, J = 6.5 Hz), 7.45 (d, 1H, J = 9.5 Hz), 7.79 (d, 1H, J = 9.5 Hz), 8.17 (s, 1H), 8.20 (s, 1H), 10.14 (s, 1H). HRMS (ESI) m/z LM+HJ+ 391.1804.
[001 10] ( lr.4r)-N'-(5-Methyl-4-(6-phenylimidazon ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (10). A suspension of 2,4-dichloro-5-methylpyrimidine (5.00 g, 30.7 mmol), l-(vinyloxy)butane ( 1 1.9 mL, 92 mmol), diisopropylethylamine (5.60 mL, 32.2 mmol) in PEG400 ( 15 mL, 43.0 mmol) was stirred and degassed over 30 min. Pd(OAc)2 (482 mg, 2.15 mmol) was added and the reaction mixture stirred at 80 °C for 96 h. The mixture was cooled, diluted with Et20 and water. Organic phase was separated and the aqueous phase extracted with Et20. Organic extracts were combined, washed with brine and purified by flash column chromatography starting with 100% petroleum ether ramping to 100% DCM to give (£')-4-(2-butoxyvinyl)-2-chloro-5-methylpyrimidine as an orange liquid ( 1.00 g, 15%). Ή-NMR (CDC13): δ 0.95 (t, 3H, J = 7.0 Hz), 1.39- 1.47 (m, 2H), 1.68- 1.73 (m, 2H), 2.15 (s, 3H), 3.98 (t, 2H, J = 6.5 Hz), 5.79 (d, 1H, J = 12.0 Hz), 7.95 (d, 1H, J = 1 1.5 Hz), 8.14 (s, 1H). MS (ESI) m/z [M+H]+ 227.1035. N-Bromosuccinimide ( 1.67 g, 9.38 mmol) was added to a stirred solution of give (£)-4-(2-butoxyvinyl)-2-chloro-5-methylpyrimidine (2.20 g, 9.73 mmol), in 10 mL of dioxane/water (3: 1), and the resulting solution stirred for 1 h. 5-Bromopyridin-2-amine ( 1.52 g, 8.79 mmol) was added, and the reaction mixture heated at 80 °C for 2 h. The reaction was allowed to cool to room temperature, and the precipitate was filtered and washed with MeOH to give 6-bromo-3-(2- chloro-5-methylpyrimidin-4-yl)imidazo[ 1 ,2-a]pyridine as a beige powder ( 1 .30 g, 42%). Ή-NMR (DMSO- ): δ 7.74 (d, 1H, J = 9.5 Hz), 7.85 (d, 1H, J = 9.5 Hz), 8.50 (s, 1H), 8.74 (s, 1H), 9.83 (s, 1H). HRMS (ESI) m/z [M(8 lBr)+H]+ 325.9694. 6-Bromo-3-(2-chloro-5-methylpyrimidin-4-yl)imidazo[ l ,2- a]pyridine ( 1. 15 g, 3.58 mmol) and ( l r,4r)-cyclohexane- l ,4-diamine ( 1.02 g, 8.95 mmol) were reacted according to general synthetic procedure A(ii) to give ( l r,4r)-N'-(4-(6-bromoimidazo[ l ,2-a]pyridin-3-yl)- 5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine as a white solid ( 1.10 g, 77%). Ή-NMR (DMSO-<i6): δ 1.26-1.38 (m, 4H), 1.92 (d, 2H, J = 12.0 Hz), 2.22 (d, 2H, J = 10.5 Hz), 2.69-2.73 (m, 1H), 3.79-3.83 (m, 1H), 5.08 (d, 1H, J = 8.0 Hz), 7.38 (dd, 1H, 7 = 9.5 & 1.5 Hz), 7.60 (d, 1H, / = 9.0 Hz), 8.09 (s, 1H), 8.17 (s, 1H), 9.96 (s, 1H). HRMS (ESI) m/z. [M(81Br)+HJ+ 403.1070. ( l/-,4r)-N1-(4-(6-bromoimidazoL l ,2- aJpyridin-3-yl)-5-methylpyrimidin-2-yl)cyclohexane-l ,4-diamine (0.50 g, 12.5 mmol) and 4,4,5,5- tetramethyl-2-phenyl- l ,3,2-dioxaborolane (0.26 mg, 12.5 mmol) were reacted according to general synthetic procedure C to give 10 as a white solid (0.38 g, 76%). Ή-NMR (CDC13): δ 0.78 (s, 2H, NH2), 1.16-1.27 (m, 4H), 1.68 (d, 2H, J = 10.5 Hz), 2.08 (d, 2H, J = 1 1.5 Hz), 2.41 (s, 3H), 2.49-2.54 (m, 1H), 3.65-3.69 (m, 1H), 4.85 (d, 1H, J = 7.5 Hz), 7.42 (t, 1H, J = 7.5 Hz), 7.50 (t, 2H, / = 7.5 Hz), 7.57-7.61 (m, 3H), 7.80 (d, 1H, J = 9.5 Hz), 8.16 (s, 1H), 8.20 (s, 1H), 9.98 (s, 1H). HRMS (ESI) m/z LM+HJ+ 399.2294.
[ 001 1 1J ( lr^rVN'-^-Qmidazol l ,2-a|pyridin-3-yl)-5-methoxypyrimidin-2-yl)cyclohexane-l ,4- diamine (11). 3-(2-Chloro-5-methoxypyriniidin-4-yl)imidazoLl ,2-aJpyridine (250 mg, 0.95 mmol) and ( lr,4r)-cyclohexane-l ,4-diamine (438 mg, 3.80 mmol) were reacted according to synthetic procedure A(ii) to give 11 as a yellow powder (0.13 g, 40%). Ή-NMR (DMSO-i/6): δ 1.23-1.45 (m, 4H), 1.88-2.07 (m, 4H), 2.77 (br s, 1H), 2.93 (br s, 1H), 3.92 (s, 3H), 6.93 (d, 1H, J = 7.5 Hz), 7.14 (t, 1H, J = 6.5 Hz), 7.51 (t, 1H, 7 = 8.0 Hz), 7.77 (d, 1H, J = 9.0 Hz), 8.25 (s, 1H), 8.43 (br s, 2H), 8.56 (s, 1H), 10.24 (br s, lH). HRMS (ESI) m/z [M+H]+ 339.1928.
[ 001 12J ( 1 r,4r)-N 1 -(4-(6-Bromoimidazo 1 1 ,2-a |pyridin-3-yl)-5-chloropyrimidin-2-yl)cyclohexane- 1 ,4- diamine (12). 6-Bromo-3-(2,5-dichloropyrimidin-4-yl)imidazoLl ,2-aJpyridine (300 mg, 0.88 mmol) and ( lr,4r)-cyclohexane-l ,4-diamine (201 mg, 1.76 mmol) were reacted according to synthetic procedure A(ii) to give 12 as a white powder ( 198 mg g, 53%). 'H-NMR (DMSO-i/6): δ 1.33-1.37 (m, 4H, ), 1.94- 1.96 (m, 2H), 2.18-2.20 (m, 2H), 2.74 (br s, 1H), 3.80 (br s, 1H), 5.09 (br s, 1H), 7.45 (d, 1H, / = 9.0 Hz), 7.65 (d, 1H, / = 9.0 Hz), 8.30 (s, 1H), 8.76 (s, 1H), 9.99 (s, 1H). HRMS (ESI) m/z [M(8 lBr)+H]+
423.0510.
[001 13] ( lr,4r)-N1-(5-Chloro-4-(6-(trifluoromethyl)imidazo[ 1 ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (13). 3-(2,5-Dichloropyrimidin-4-yl)-6-(trifluoromethyl)imidazo[ 1 ,2- a]pyridine (250 mg, 0.75 mmol) and ( lr,4r)-cyclohexane- l ,4-diamine ( 171 mg, 1.50 mmol) were reacted according to synthetic procedure A(ii) to give 13 as a yellow powder ( 140 mg, 45%). Ή-NMR (DMSO- d6): δ 1.05- 1.07 (m, 2H), 1.31- 1.38 (m, 2H), 1.76- 1.78 (m, 2H), 1.90- 1.92 (m, 2H), 2.22 (br s, 2H), 2.56 (s, 1 H), 3.63 (s, 1 H), 7.55 (d, 1 H, J = 8.0 Hz), 7.75 (d, 1 H, J = 9.0 Hz), 7.99 (d, 1 H, J = 9.5 Hz), 8.46 (s, 1H), 8.67 (s, 1 H), 10.06 (s, 1 H). HRMS (ESI) m/z [M+H]+ 41 1 . 1306.
[001 14] ( lr,4r)-Nl-(4-(8-Bromo-6-(trifluoromethyl)imidazor i ,2-alpyridin-3-yl)-5- chloropyrimidin-2-yl)cyclohexane- 1 ,4-diamine (14). 8-Bromo-3-(2,5-dichloropyrimidin-4-yl)-6- (trifluoromethyl)imidazo[ l ,2-(3]pyridine (300 mg, 0.73 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine ( 167 mg, 1.46 mmol) were reacted according to synthetic procedure A(ii) to give 14 as a white powder ( 155 mg g, 43%). Ή-NMR (CDC13): δ 1.23- 1.30 (m, 4H), 1.90- 1.92 (m, 2H), 2.1 1 -2. 13 (m, 2H), 2.67-2.3 1 (m, 1H), 3.71 -3.74 (m, 1 H), 5.26 (br s, 1 H), 7.77 (s, 1 H), 8.33 (s, 1 H), 8.78 (s, 1 H), 10.09 (s, 1 H). HRMS (ESI) m/z [M(79Br)+H]+ 489.0419, m/z [M(8 lBr)+H]+ found 491.0399.
[ 001 15J Methyl (( lr,4r)-4-((5-fluoro-4-(imidazo| l ,2-a|pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexyl) glycinate (15). A solution of ( l r,4r)-jV'-(5-fluoro-4-(imidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (0. 17 g, 0.52 mmol), methyl 2-bromoacetate (0.15 mL, 1.56 mmol) and Et3N (0.13 mL, 1.56 mmol) in THF (4 mL) was stirred at rt for 48 h. The reaction mixture was concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM and ramping to 4% MeOH in DCM to give 15 as a yellow solid (42.0 mg, 20%). Ή-NMR (CDC13): δ 1.29- 1.39 (m, 5H), 2.02 (d, 2H, / = 12.0 Hz), 2.25 (d, 2H, / = 10.0 Hz), 2.52-2.55 (m, 1 H), 3.48 (s, 2H), 3.72- 3.78 (m, 4H), 5.02 (d, 1H, J = 7.5 Hz), 7.01 (t, 1H, J = 7.0 Hz), 7.41 (t, 1H, J = 7.5 Hz), 7.76 (d, 1H, J = 9.0 Hz), 8.18 (d, 1H, J = 4.0 Hz), 8.47 (d, 1H, / = 4.0 Hz), 10.02 (d, 1H, / = 7.0 Hz). HRMS (ESI) m/z [M+H]+ 399.1878.
[001 16] N-(( lr,4r)-4-((5-Fluoro-4-(irnidazor i .2-alpyridin-3-yl)pyrirnidin-2- yl)amino)cyclohexyl)methanesulfonamide (16). To a solution of ( l r,4r)-N'-(5-fluoro-4-(imidazo[ l ,2- a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine (0.20 g, 0.61 mmol) and Et3N (0.10 mL, 1.22 mmol) in DCM (5 mL) cooled in an ice bath was added methanesulfonyl chloride (0.10 mL, 1.22 mmol). The reaction mixture was stirred at rt for 48 h, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM and ramping to 3% MeOH in DCM to give 16 as a white powder (0.07 g, 28%). Ή-NMR (DMSO-<¾: δ 1.38 (s, 4H), 1.98 (s, 2H), 2.02 (s, 2H), 2.93 (s, 3H), 3.16 (s, 1H), 3.61 (s, 1H), 7.04 (d, 1H, J = 7.5 Hz), 7.18 (t, 1H, J = 7.0 Hz), 7.36 (d, 1H, J = 7.5 Hz),7.56 (t, 1H, J = 7.5 Hz), 7.82 (t, 1H, J = 9.0 Hz), 8.35 (d, 1H, J = 4.0 Hz), 8.39 (d, 1H, J = 4.0 Hz), 10.17 (s, 1H). HRMS (ESI) m/z [M+H]+ 405.1792.
[001 17] N-(( 1 r,4r)-4-( ( 4-( 6-Bromoimidazo [ 1 ,2-a1pyridin-3-yl)-5-chloropyrimidin-2- yl)amino)cyclohexyl)methanesulfonamide (17). To a solution of N1-(4-(6-bromoimidazo[ l ,2-a]pyridin-3- yl)-5-chloropyrimidin-2-yl) cyclo-hexane- 1 ,4-diamine (100 mg, 0.24 mmol) in pyridine (1 mL) and DCM (4 mL) added methanesulfonyl chloride (54.7 mg, 0.48 mmol) at 0°C and the resulting solution was stirred at room temperature for 2 h. The reaction residue was filtered and washed with DCM (5 mL) and EtOAc ( 10 mL) to give 17 as a yellow solid ( 1 10 mg, 92%). ¾-NMR (DMSO- 6): δ 1.41-1.46 (m, 2H), 1.95- 1.97 (m, 2H), 2.92 (s, 3H), 3.14 (s, 1 H), 3.66 (s, 1H), 3.71 -3.76 (m, 4H), 7.06 (br s, 1 H), 7.62 (br s, 1H), 7.72 (d, 1H, J = 9.0 Hz), 7.82 (d, 1H, 7 = 9.0 Hz), 8.43 (s, 1H), 8.74 (s, 1H), 9.95 (s, 1H). HRMS (ESI) m/z [M(79Br)+H]+ 499.0313, m/z [M(8 lBr)+H]+ 501.0283.
L00118J N-((lr,4r)-4-((4-(8-Bromo-6-(trifluoromethyl)imidazo| l,2-alpyridin-3-yl)-5- chloropyrimidin-2-yl)amino)cyclohexyl)methanesulfonamide (18). To a solution of A '-(4-(8-bromo-6- (trifluoromethyl)imidazo[ 1 ,2-a]pyridin-3-yl)-5-chloro-pyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 100 mg, 0.20 mmol) in pyridine ( 1 mL) and DCM (4 mL) added methanesulfonyl chloride (45.8 mg, 0.40 mmol) at 0°C and the resulting solution was stirred at room temperature for 2 h. The reaction residue was filtered and washed with DCM (5 mL) and EtOAc ( 10 mL) to give 18 as a pale white solid (98 mg, 86%). Ή- NMR (CDC13): δ 1.24- 1.28 (m, 2H), 1.37- 1.44 (m, 2H), 1.91 - 1.95 (m, 4H), 2.90 (s, 3H), 3.09 (s, 1H), 3.60 (s, 1H), 7.06 (d, 1H, J = 5.0 Hz), 7.77 (d, 1H, 7 = 7.0 Hz), 8.20 (s, 1H), 8.48 (s, 1H), 8.66 (s, 1H), 10.02 (s, 1H). HRMS (ESI) m/z [M+H]+ 567.0187.
[001 19] 5-Fluoro-4-(imidazo[ 1 ,2-a1pyridin-3-yl)-N-( 1 -methylpiperidin-4-yl)pyrimidin-2-amine
(19). 3-(2-Chloro-5-fluoropyrimidin-4-yl)imidazo[ l ,2-a]pyridine (0.25 g, 1.00 mmol) and 1- methylpiperidin-4-amine (0.38 mL, 3.00 mmol) were reacted according to synthetic procedure A(i) to give 19 as a yellow solid (0.19 g, 58%). Ή-NMR (CDC13): δ 1.60- 1.67 (m, 2H), 2.13-2.21 (m, 4H), 2.33 (s, 3H), 2.87 (d, 2H, 7 = 9.5 Hz), 3.81-3.82 (m, 1H), 5.07 (d, 1H, 7 = 7.0 Hz), 7.01 (t, 1H, 7 = 7.0 Hz), 7.40 (t, 1H, 7 = 7.5 Hz), 7.77 (d, 1H, 7 = 9.0 Hz), 8.20 (d, 1H, 7 = 3.5 Hz), 8.47 (d, 1H, 7 = 4.0 Hz), 10.01 (d, 1H, 7 = 7.0 Hz). HRMS (ESI) m/z [M+H]+ 327.1804.
[00120] tert-Butyl 4-((5-fluoro-4-(imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2-yl)amino)piperidine- 1 - carboxylate (20). 3-(2-Chloro-5-fluoropyrimidin-4-yl)imidazo[l,2-a]pyridine (0.55 g, 2.21 mmol) and tert-butyl 4-aminopiperidine- 1 -carboxylate (1.33 g, 6.34 mmol) were reacted according to synthetic procedure A(i) to give 20 as a white solid (0.48 g, 53%). Ή-NMR (CDC13): δ 1.48 (s, 11H), 2.12 (d, 2H, 7 = 11.0 Hz), 2.99 (t, 2H, 7 = 11.5 Hz), 3.93-3.99 (m, 1H), 4.11 (s, 2H), 5.05 (d, 1H, 7 = 7.5 Hz), 7.01 (t, 1H, 7 = 7.0 Hz), 7.40 (t, 1H, 7 = 7.5 Hz), 7.77 (d, 1H, 7 = 9.0 Hz), 8.20 (d, 1H, 7 = 3.5 Hz), 8.47 (d, 1H, 7 = 4.0 Hz), 9.99 (d, 1H, 7 = 7.0 Hz). HRMS (ESI) m/z [M+H]+ 413.2178.
[00121] 5-Fluoro-4-(imidazo[ 1 ,2-a1pyridin-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine (21). A solution of tert-butyl 4-((5-fluoro-4-(imidazo[ 1 ,2- ]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine- 1 - carboxylate (100 mg, 0.24 mmol) in 2M HC1 (2 mL) and EtOH (2 mL) was stirred at room temperature for 48 h, basified with 2M (NaOH) to pH 10, and purified by flash column chromatography starting with 100% DCM ramping to 6% MeOH + 1.0% NH3 (32% in water) to give 21 as a white solid (70 mg, 93%). Ή-NMR (CDC13): δ 1.43-1.50 (m, 2H), 2.15 (d, 2H, 7 = 10.5 Hz), 2.78 (t, 2H, 7 = 10.5 Hz), 3.17 (d, 2H, / = 12.5 Hz), 3.48 (s, 1 H), 3.88-3.96 (m, 1H), 5.09 (d, 1 H, 7 = 7.0 Hz), 7.00 (t, 1H, 7 = 7.0 Hz), 7.40 (t, 1H, / = 7.5 Hz), 7.77 (d, 1H, 7 = 8.5 Hz), 8.20 (d, 1H, 7 = 3.5 Hz), 8.47 (d, 1H, 7 = 3.5 Hz), 10.02 (d, 1H, 7 = 5.0 Hz). HRMS (ESI) m/z [M+H]+ 313.1246.
[00122] N-(l-(Cyclopropylmethyl)piperidin-4-yl)-5-fluoro-4-(irnidazo[l ,2-alpyridin-3- yl)pyrimidin-2-amine (22). A suspension of 5-fluoro-4-(imidazo[ l ,2-a]pyridin-3-yl)-/V-(piperidin-4- yl)pyrimidin-2-amine (350 mg, 1.12 mmol), (bromomethyl)cyclopropane (338 μL·, 3.33 mmol), triethylamine (0.25 mL, 1.78 mmol) in DMF (7 mL) was stirred at 90 °C overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 2% MeOH to give 22 as a white powder (70 mg, 17%). Ή-NMR (CDC13): δ 0.1 1 -0.14 (m, 2H), 0.52-0.60 (m , 2H), 0.87-0.93 (m , 2H), 1.63- 1.69 (m, 2H), 2.16 (d, 2H, J = 1 1.5 Hz), 2.22 (t, 2H, 7 = 10.5 Hz), 2.30 (d, 2H, / = 6.5 Hz), 3.08 (d, 2H, 7 = 9.0 Hz), 3.80-3.86 (m, 1H), 5.08 (d, 1H, 7 = 7.0 Hz), 7.00 (t, 1H, 7 = 7.0 Hz), 7.40 (t, 1H, 7 = 7.5 Hz), 7.77 (d, 1H, 7 = 9.0 Hz), 8.20 (d, 1H, 7 = 3.5 Hz), 8.48 (d, 1H, 7 = 4.0 Hz), 10.08 (d, 1H, 7 = 7.0 Hz). HRMS (ESI) m/z |M+H]+ 367.2450.
[00123] Methyl 2-(4-((5-fluoro-4-(imidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidin- 1 - vDacetate (23). A suspension of 5-fluoro-4-(imidazo[ l ,2-a]pyridin-3-yl)- V-(piperidin-4-yl)pyrimidin-2- amine (350 mg, 1.12 mmol), methyl 2-bromoacetate (318 μί, 3.37 mmol), triethylamine (0.25 mL, 1.78 mmol) in THF (7 mL) was stirred at room temperature overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 2% MeOH to give 23 as an orange powder (60 mg, 14%). Ή-NMR (CDC13): δ 1.67-1.74 (m, 2H), 2.15 (d, 2H, 7 = 11.0 Hz), 2.43 (t, 2H, 7 = 11.0 Hz), 2.98 (d, 2H, 7 = 12.0 Hz), 3.74 (s, 3H), 3.74 (s, 2H), 3.81-3.87 (m, 1H), 5105 (d, 1H, 7 = 7.0 Hz), 7.10 (t, 1H, 7 = 6.5 Hz), 7.40 (t, 1H, 7 = 7.0 Hz), 7.76 (d, 1H, 7 = 9.0 Hz), 8.19 (d, 1H, 7 = 3.5 Hz), 8.40 (d, 1H, 7 = 4.0 Hz), 10.0 (d, 1H, 7 = 7.0 Hz). HRMS (ESI) m/z [M+H]+ 385.2190.
[00124] 5-Fluoro-4-(irm^azo[l ,2-a1pyridin-3-yl)-N-(l-(methylsulfonyl)piperidin-4-yl)pyrimidin-2- amine (24). To a solution of 5-fluoro-4-(irm^azo[l,2-a]pyridin-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine (283 mg, 0.91 mmol) and triethylamine (133 ^L, 0.93 mmol) in DCM (7 mL) cooled on an ice bath was added methanesulfonyl chloride (105 xL, 1.82 mmol). The reaction was allowed to warm to room temperature, stirred overnight, and filtered. The filtrate was purified by flash column chromatography starting with 100% DCM ramping to 2% MeOH to give 24 as a white solid (40 mg, 11%). Ή-NMR (DMSO-i 6): δ 1.56-1.62 (m, 2H), 2.07 (d, 2H, 7 = 11.5 Hz), 2.91 (s, 5H), 3.60 (d, 2H, 7 = 12.0 Hz), 3.82- 3.85 (m, 1H), 7.24 (s, 1H), 7.48 (d, 1H, 7 = 7.5 Hz), 7.55-7.58 (m, 1H), 7.82 (d, 1H, 7 = 9.0 Hz), 8.37 (d, 1H, 7 = 4.0 Hz), 8.42 (d, 1H, 7 = 4.0 Hz), 10.13 (s, 1H). HRMS (ESI) m/z [M+H]+ 391.1777. [00125] ( lr,4r)-N1-(5-Fluoro-4-(6-((3-fluorophenyl)amino)imidazo[ l ,2-alpyridin-3-yl)pyrimi 2-vDcyclohexane- 1 ,4-diamine (25). ( 1 r,4r)-N1-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- fluoropyrimidin-2-yl)cyclohexane- 1 ,4-diamine (291 mg, 0.72 mmol) and 3-fluoroaniline (69 μί, 0.72 mmol) were coupled according to general procedure B. The product was further purified by preparative HPLC to afford 25 as a yellow solid (30.0 mg, 10%). Ή-NMR (DMSO-i¾): δ 1. 13 (s, 4H), 1 .94 (s, 4H), 2.84 (s, 1 H), 3.61 (s, 1 H), 6.59 (s, 1 H), 6.81 (dt, 1 H, J = 12.0 & 2.0 Hz), 6.85 (d, 1 H, J = 8.0 Hz), 7.13 (d, 1 H, J = 7.0 Hz), 7.24 (d, 1H, J = 8.0 Hz), 7.48 (d, 1 H, J = 9.0 Hz), 7.78 (d, 1 H, J = 9.5 Hz), 8.29 (d, 1 H, J = 4.5 Hz), 8.40 (d, 1 H, J = 4.0 Hz), 8.77 (s, 1 H, NH), 9.95 (s, 1 H). HRMS (ESI) m/z [M+H]+ 436.2059.
[00126] ( lr.4r)-N'-(5-Fluoro-4-(6-(pyridin-3-yl)imidazo[ 1 ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (26). ( l r,4r)- -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-fluoropyrimidin- 2-yl)cyclohexane- l ,4-diamine (200 mg, 0.49 mmol) and 3-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2- yl)pyridine ( 100 mg, 0.49 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 26 as a yellow solid ( 100 mg, 50%). Ή-NMR (CDC13): δ 0.90 (s, 2H), 1.23 (d, 2H, J = 10.5 Hz), 1.67- 1.75 (m, 4H), 2. 10 (d, 2H, J = 9.5 Hz), 2.57 (s, 1 H), 3.70 (s, 1H), 5.105 (d, 1H, J = 5.0 Hz), 7.47 (t, 1H, J = 6.0 Hz), 7.53 (d, 1H, J = 8.5 Hz), 7.86 (d, 1H, J = 8.5 Hz), 7.92 (d, 1H, 7 = 5.0 Hz), 8.20 (s, 1H), 8.51 (s, 1H), 8.69 (s, 1H), 8.91 (s, 1H), 10.26 (s, 1H). HRMS (ESI) m/z LM+HJ+ 404.1998.
[00127] ( lr,4r)-N'-(5-Fluoro-4-(6-(3-fluoropyridin-2-yl)imidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (27). ( l r,4r)-Af'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-fluoropyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 187 mg, 0.46 mmol) and 3-fluoro-2-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)pyridine ( 103 mg, 0.46 mmol) were reacted according to general synthetic procedure C to give 27 as a yellow solid (90 mg, 47%). Ή-NMR (CDC13): δ 1.1 1- 1.36 (m, 2H), 1.25-1.33 (m, 2H), 1.84 (d, 1H, J = 12.5 Hz), 2.23 (d, 1H, J = 11.0 Hz), 2.66-2.71 (m, 1H), 3.87-3.89 (m, 1H), 5.02 (d, 1H, J = 7.5 Hz), 6.96 (dd, 1H, J = 8.0 & 2.5 Hz), 7.66 (dd, 1H, J = 7.5 & 1.5 Hz), 7.83 (d, 1H, J = 9.5 Hz), 7.92-7.95 (m, 2H), 8.23 (d, 1H, J = 3.5 Hz), 8.47 (d, 1H, J = 3.5 Hz), 10.69 (s, 1H). HRMS (ESI) m/z [M+H]+ 422.1905.
[00128] ( lr,4r)-N'-(5-Fluoro-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2-yl)-N4-(pyridin- 2-yl)cyclohexane- 1 ,4-diamine (28). 3-(2-Chloro-5-fluoropyrimidin-4-yl)-6-phenylimidazo[ 1 ,2- ]pyridine (200 mg, 0.62 mmol) and (l ,4r)-N1-(pyridin-2-yl)cyclohexane-l ,4-diamine (236 mg, 1.20 mmol) were reacted according to general synthetic procedure A(ii) to give 28 as a yellow solid (90.0 mg, 30%). Ή- NMR (DMSO-rfe): δ 0.93 (br s, 2H), 1.37- 1.41 (m, 2H), 1.90 (br s, 2H), 2.00-2.022 (m, 2H), 3.53-3.56 (m, 1H), 3.70-3.72 (m, 1H), 6.44-6.47 (m, 2H), 7.30-7.37 (m, 2H), 7.47 (t, 1H, J = 7.5 Hz), 7.57 (t, 2H, J = 7.5 Hz), 7.76-7.85 (m, 3H), 7.92-7.95 (m, 2H), 8.38 (s, 1H), 8.45 (s, 1H), 10.15 (s, 1H) (one secondary amine proton (NH) signal not observed). HRMS (ESI) m/z [M+H]+ 480.2309. [00129] ( lr,4r)-N1-(5-Methyl-4-(6-(pyridin-3-yl)imidazo[ l ,2-a1pyridin-3-yl)pyrim
- 1 ,4-diamine (29). ( lr,4r)-N1-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrirnidin-2-yl) cyclohexane- 1 ,4-diamine ( 146 mg, 0.37 mmol) and 3-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2-yl) pyridine (76 mg, 0.37 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 29 as a yellow solid (50 mg, 34%). Ή-NMR (CDC13): δ 1.25- 1.30 (m, 4H), 1.98 (apparent s, 2H), 2.10 (apparent s, 2H), 2.41 (s, 3H), 3.00 (s, 1 H), 3.82 (s, 1 H), 5. 18 (s, 1 H), 7.46 (t, 1 H, 7 = 6.0 Hz), 7.53 (d, 1 H, 7 = 9.0 Hz), 7.85 (d, 1 H, J = 9.0 Hz), 7.89 (d, 1 H, J = 7.5 Hz), 8.17 (s, 1 H), 8.21 (s, 1 H), 8.66 (d, 1 H, 7 = 4.0 Hz), 8.87 (s, 1H), 9.80 (s, 1H) HRMS (ESI) m/z LM+HJ+ 400.2250.
[00130] ( lr,4r)-N'-(4-(6-(3-Fluoropyridin-2-yl)imidazor 1.2-alpyridin-3-yl)-5-methylpyrimidin-2- yPcyclohexane- 1 ,4-diamine (30). ( 1 r,4r)- -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- 1 ,4-diamine ( 195 mg, 0.49 mmol) and 3-fluoro-2-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)pyridine ( 162 mg, 0.73 mmol) were reacted according to general synthetic procedure C to give 30 as a white solid (40 mg, 20%). Ή-NMR (CDC13): δ 0.98 (s, 2H), 1. 18- 1.26 (m, 2H), 1.64 (s, 2H), 1.73 (d, 2H, / = 1 1.0 Hz), 2.14 (d, 2H, 7 = 1 1.0 Hz), 2.34 (s, 3H), 2.57-2.61 (m, 1H), 3.77-3.82 (m, 1H), 5.14 (d, 1H, J = 8.0 Hz), 6.87 (dd, 1H, / = 8.0 & 3.0 Hz), 7.54 (dd, 1H, / = 7.5 & 1.5 Hz), 7.73 (d, 1H, J = 9.5 Hz), 7.81-7.87 (m, 2H), 8.06 (s, 1H), 8.18 (s, 1H), 10.30 (s, 1H). HRMS (ESI) m/z, [ M+H]+ 418.2155.
[00131 ] ( 1 r,4r)-N' -(5-Methyl-4-( 6-( phenylamino)imidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2- yDcyclohexane- 1 ,4-diamine (31). ( l r,4r)-Af'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- 1 ,4-diamine (200 mg, 0.50 mmol) and aniline (47 μL·, 0.50 mmol) were reacted according to general synthetic procedure A. The product was further purified by preparative HPLC to give 31 as a yellow solid (45 mg, 22%). Ή-NMR (DMSO-<¼): δ 1.26 (apparent s, 4H), 1.88-1.92 (m, 4H), 2.31 (s, 3H), 2.80 (s, 1H), 3.60 (s, 1H), 6.69 (s, 1H), 6.84 (t, 1H, / = 7.5 Hz), 7.08 (d, 2H, J = 7.0 Hz), 7.24 (t, 2H, J = 7.5 Hz), 7.35 (d, 1H, J = 9.5 Hz), 7.70 (d, 1H, J = 9.0 Hz), 8.16 (s, 1H), 8.21 (s, 1H), 8.44 (s, 1H), 9.57 (s, 1H). HRMS (ESI) m/z [M+H]+ 414.2407.
[00132] ( lr,4r)-N'-(4-(6-((4-Fluorobenzyl)arm^o)imidazo[ l ,2-a1pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- 1 ,4-diamine (32). 3-(2-Chloro-5-methylpyrimidin-4-yl)-N-(4-fluorobenzyl)imidazo[ 1 ,2- ]pyridin-6-amine (0.25 g, 0.68 mmol) and (l r,4r)-cyclohexane- 1 ,4-diamine (0.23 g, 2.04 mmol) were reacted according to general synthetic procedure A(ii) to give 32 as a beige solid (0.90 g, 30%). 'H-NMR (CDC13): δ 1.21 (s, 4H), 1.58 (s, 2H), 1.86 (s, 2H), 2.09 (s, 2H), 2.30 (s, 3H), 2.67 (s, 1H), 3.81 (s, 1H), 3.96 (s, 1H), 4.27 (s, 2H), 4.68 (s, 1H), 6.92 (s, 1H), 7.03 (s, 2H), 7.35 (s, 2H), 7.51 (s, 1H), 7.93 (s, 1H), 8.15 (s, 1H), 8.83 (s, 1H). HRMS (ESI) m/z [M+H]+ 446.2469. [00133] ( 1 r,4r)-N 1 -(5-Fluoro-4-(irnidazo [ 1 ,2-alpyridin-3-yl)pyrimidin-2-yl)-N4-(tetrahydro-2H-pyran-4- vDcyclohexane- 1 ,4-diamine (33). To a solution ( Ιτ,4ΐ)-Ν -(5-ίΙηοτο-4-(ίτΏίάά· ζο[ 1 ,2-α]ργήάΐτι-3- yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine (80.0 mg, 0.25 mmol) in THF (6 mL) and AcOH (0.2 mL) was added tetrahydro-4H-pyran-4-one (23 μL, 0.25 mmol), and the reaction mixture stirred for 30 min at rt. Sodium triacetoxyborohydride (62.4 mg, 0.29 mmol) was added and the reaction mixture stirred at room temperature overnight. Saturated NaHC03 (20 mL) and DCM ( 100 mL) were added. Organic phase was separated and the aqueous phase was extracted with DCM (2 x 100 mL). Organic extracts were combined and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 1 % NH3 (32% in water) to afford 33 as a yellow solid (20.0 mg, 20%). Ή-NMR (CDC13): δ 1.26- 1.33 (m, 2H), 1.70-1.85 (m, 4H), 1.97 (d, 2H, 7 = 1 1.5 Hz), 2.19 (d, 2H, 7 = 1 1.5 Hz), 2.29 (d, 2H, 7 = 12.0 Hz), 3.05 (t, IH, J = 12.0 Hz), 3.22 (t, IH, 7 = 12.5 Hz), 3.38 (t, 2H, 7 = 12.0 Hz), 3.80-3.82 (m, IH), 4.01 (d, 2H, J = 1 1.5 Hz), 5.07 (s, IH), 7.11 (t, IH, 7 = 7.0 Hz), 7.41 (t, 1H, 7 = 7.5 Hz), 7.76 (d, 1H, 7 = 9.0 Hz), 8.16 (d, IH, 7 = 3.5 Hz), 8.46 (d, IH, 7 = 3.5 Hz), 9.98 (d, IH, 7 = 7.0 Hz). HRMS (ESI) m/z,
LM+HJ+ 41 1.2310.
[00134] ( lr,4r)-N'-(5-Methyl-4-(6-(pyridin-3-ylamino)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (34). ( lr,4r)-N1-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane-l ,4-diamine (225 mg, 0.56 mmol) and pyridin-3-amine (53 mg, 0.56 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 34 as an orange solid (85 mg, 37%). 'H-NMR (MeOD-J4): δ 1.37-1.42 (m, 4H), 1.99 (s, 2H), 2.10 (s, 2H), 2.38 (s, 3H), 3.08 (s, IH), 3.72 (s, IH), 7.32 (t, IH, 7 = 8.0 Hz), 7.43 (d, IH, J = 9.0 Hz), 7.56 (d, IH, 7 = 8.0 Hz), 7.68 (d, IH, 7 = 9.5 Hz), 8.05 (d, IH, 7 = 4.5 Hz), 8.12 (s, IH), 8.22 (s, IH), 8.35 (s, IH), 8.51 (s, IH), 9.70 (s, IH). HRMS (ESI) m/z [M+H]+ 415.2360.
[00135] ( lr.4r)-N'-(5-Chloro-4-(6-(pyridin-3-yl)imidazon ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (35). (lr,4r)-N1-(4-(6-BromoirrddazoL l ,2- Jpyridin-3-yl)-5-chloropyrirnidin- 2-yl)cyclohexane-l ,4-diamine ( 150 mg, 0.36 mmol) and 3-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2- yl)pyridine (74 mg, 0.36 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 35 as a white solid (100 mg, 66%). Ή-NMR (DMSO- d6): δ 0.46 (s, 2H), 1.21 (s, 2H), 1.44 (s, 2H), 1.83 (s, 2H), 2.31 (s, IH), 3.51 (s, IH), 7.47 (s, IH), 7.54 (t, IH, 7 = 5.0 Hz), 7.84 (d, IH, .7 = 9.5 Hz), 7.91 (d, IH, 7 = 9.0 Hz), 8.18 (d, IH, 7 = 7.0 Hz), 8.43 (s, IH), 8.61 (s, IH), 8.64 (d, IH, 7 = 4.0 Hz), 8.98 (s, IH), 9.88 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 420.1700.
[00136] ( lr,4r)-N1-(5-Chloro-4-(6-(pyridin-4-yl)in^dazo[ l ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (36). (lr,4r)-N1-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-chloropyrirnidin- 2-yl)cyclohexane-l ,4-diamine ( 150 mg, 0.36 mmol) and 4-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2- yl)pyridine (74 mg, 0.36 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 36 as a white solid (110 mg, 73%). Ή-NMR (DMSO- d6): δ 0.49 (s, IH), 1.25 (s, 3H), 1.49 (s, 2H), 1.88 (s, 2H), 2.35 (s, IH), 3.43 (s, IH), 7.51 (s, IH), 7.82 (s, 2H), 7.89-7.94 (m, 2H), 8.45 (s, IH), 8.61 (s, IH), 8.71 (s, 2H), 9.88 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (EST) m/z [M+H]+ 420.1700.
[00137] (lr,4r)-N'-(5-Methyl-4-(6-(pyridin-4-yl)im ^^
yl)cyclohexane-l,4-diamine (37). (lr,4r)- -(4-(6-Bromoimidazo[l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane-l,4-diamine (158 mg, 0.39 mmol) and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridine (121 mg, 0.59 mmol) were reacted according to general synthetic procedure C to give 37 as a yellow solid (74 mg, 48%). Ή-NMR (CDC13): δ 0.77 (s, 2H), 1.11-1.19 (m, 2H), 1.64 (s, 4H), 2.01 (d, 2H, / = 11.5 Hz), 2.34 (s, 3H), 2.49-2.53 (m, IH), 3.60-3.64 (m, IH), 5.23 (d, IH, /= 8.0 Hz), 7.46 (d, 2H, / = 4.5 Hz), 7.52 (d, IH, 7 = 9.0 Hz), 7.78 (d, IH, J = 9.0 Hz), 8.11 (s, IH), 8.16 (s, IH), 8.86 (d, 2H, / = 4.5 Hz), 9.96 (s, IH). HRMS (ESI) m/z [M+H]+ 400.2248.
[00138J (lr,4r)-N1-(5-Chloro-4-(6-(pyrirmdin-5-yl)imidazo|l,2-alpyridin-3-yl)pyrirmdin-2^
cyclohexane- 1 ,4-diamine (38). (lr,4r)-jV'-(4-(6-Bromoimidazo[l,2-a]pyridin-3-yl)-5-chloropyrimidin-2- yl)cyclohexane-l,4-diamine (220 mg, 0.52 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyrimidine (110 mg, 0.53 mmol) were reacted according to general synthetic procedure C to give 38 as a yellow solid (110 mg, 50%). Ή-NMR (DMSO- 6): δ 1.20-1.26 (m, 4H), 1.43 (d, 2H, J= 11.0 Hz), 1.81 (d, 2H,7= 11.0 Hz), 2.35 (m, IH), 3.65 (m, IH), 7.49 (br s, IH), 7.91 (d, IH, J = 9.0 Hz), 7.95 (d, IH,/ = 9.0 Hz), 8.44 (s, IH), 8.61 (s, IH), 9.25 (s, 2H), 9.28 (s, IH), 9.95 (s, IH). HRMS (ESI) m/z [M+H]+ 421.1667.
[00139] ( lr,4r)-N'-(5-Methyl-4-(6-(pyrimidin-5-yl)imidazor 1.2-alpyridin-3-yl)pyrimidin-2-yl) cyclohexane- 1 ,4-diamine (39). ( 1 r,4r)-Nl -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2- yl)cyclohexane-l,4-diamine (210 mg, 0.52 mmol) and 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyrimidine (110 mg, 0.53 mmol) were reacted according to general synthetic procedure C to give 39 as a yellow solid (120 mg, 58%). Ή-NMR (DMSO- 6): δ 1.22-1.28 (m, 4H), 1.55 (d, 2H, J= 11.0 Hz), 1.88 (d, 2H, J= 11.5 Hz), 2.35 (s, 3H), 2.97 (m, IH), 3.58 (m, IH), 7.02 (s, IH), 7.88 (d, IH, J= 9.0 Hz), 7.93 (d, IH, J = 9.0 Hz), 8.28 (m, 2H), 9.25 (s, 2H), 9.26 (s, IH), 9.98 (s, IH). HRMS (ESI) m/z [M+H]+ 401.2203.
[00140] (lr.4r)-N'-(5-Chloro-4-(6-(3-fluoropyridin-2-yl)imidazori,2-alpyridin-3-yl)pyrirnidin-2- yDcyclohexane- 1 ,4-diamine (40). (lr,4r)-N'-(4-(6-Bromoirddazo[l,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)cyclohexane-l,4-diamine (162 mg, 0.39 mmol) and 3-fluoro-2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)pyridine (86 mg, 0.39 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 40 as a white solid (60 mg, 35%). 'H-NMR (DMSO-<¾s): δ 0.95 (s, 2H), 1.35 (d, 2H, J = 1 1.5 Hz), 1.73 (s, 2H), 2.04 (d, 2H, J = 9.5 Hz), 2.78 (s, IH), 3.74 (s, IH), 7.21 (d, IH, J = 8.0 Hz), 7.57 (s, IH), 7.91 (d, IH, J = 9.0 Hz), 8.06 (d, IH, J = 6.5 Hz), 8.13-8.17 (m, 2H), 8.40 (s, IH), 8.50 (s, I H), 10.14 (s, I H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 438.1610.
[00141] (lr,4r)-Nl-(5-Chloro-4-(6-((4-fluorobenzyl)amino)imidazo[l,2-alpyridin-3-yl)pyrin^ 2-yl)cyclohexane- 1 ,4-diamine (41). 3-(2,5-Dichloropyrimidin-4-yl)-J'V-(4-fluorobenzyl)imidazo[ 1 ,2- a]pyridin-6-amine (200 mg, 0.52 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine ( 177 mg, 1.55 mmol) were reacted according to general synthetic procedure A(ii) to give 41 as a beige solid ( 140 mg, 58%). Ή- NMR (DMSO- ): δ 1.1 1 (s, 2H), 1.35 (d, 2H, 7 = 1 1.5 Hz), 1.56 (s, 2H), 1.79 (s, 2H), 1.94 (d, 2H, 7 = 10.5 Hz), 3.35 (s, IH), 3.75 (s, IH), 4.36 (s, 2H), 6.30 (s, IH), 7.16-7.22 (m, 4H), 7.46 (t, 2H, J = 7.0 Hz), 7.57 (d, IH, / = 9.5 Hz), 8.37 (s, 2H), 8.85 (s, IH). HRMS (ESI) m/z. [M+H]+ 466.1920.
[00142 J ( 1 r,4r)-N 1 -(5-chloro-4-(imidazo 1 1 ,2-a |pyridin-3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (42). 3-(2,5-Dichloropyrimidin-4-yl)imidazo[ l ,2-a]pyridine (0.50 g, 1.90 mmol) and ( 1 r,4r)-cyclohexane - 1 ,4-diamine (0.65 g, 5.70 mmol) were reacted according to general synthetic procedure A(ii) to give 42 as a yellow solid (0.28 g, 43%). Ή-NMR (CDC13): δ 1.25- 1.30 (m, 4H), 1.80 (d, 2H, 7 8.5), 2.08 (d, 2H, J = 8.5 Hz), 2.62 (m, IH), 3.67 (m, IH), 5.05 (s, IH), 7.56 (d, IH, / = 6.5 Hz), 7.91 (t, IH, J = 7.0 Hz), 8.34 (d, IH, / = 8.0 Hz), 8.81 (s, IH), 9.06 (s, IH), 9.96 (s, IH). HRMS (ESI) m/z [M+H]+ 343.1453.
[00143 J (lr,4r)-N1-(4-(7-Chloroimidazo| l,2-alpyridin-3-yl)-5-fluoropyrimidin-2-yl)cyclohexane-
1 ,4-diamine (43). 7-Chloro-3-(2-chloro-5-fluoropyrimidin-4-yl)imidazo[ l ,2-a]pyridine ( 1.50 g, 5.32 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine ( 1.82 g, 16.0 mmol) were reacted according to general synthetic procedure A(ii). The product was repurified by preparative HPLC to give 43 as a yellow powder (0.90 g, 47%). Ή-NMR (DMSO- ): δ 1.32- 1.48 (m, 4H), 1.99-2.07 (m, 4H), 2.95-2.98 (m, IH), 3.63- 3.67 (m, IH), 7.25 (s, IH), 7.45 (d, IH, 7 = 7.0), 8.03 (s, IH), 8.38 (s, IH), 8.44 (s, IH), 10.10 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 361.1342.
L00144J (lr,4r)-N1-(5-Fluoro-4-(7-phenylimidazo| l,2-a|pyridin-3-yl)pyrimidin-2-yl)cyclohexane-
1,4-diamine (44). ( 1 r,4r)-Nl -(4-(7-Chloroimidazo[ 1 ,2-a]pyridin-3-yl)-5-fluoropyrimidin-2- yl)cyclohexane- 1,4-diamine (150 mg, 0.42 mmol) and 4,4,5,5-tetramethyl-2-phenyl-l,3,2-dioxaborolane (85.0 mg, 0.42 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 44 as a yellow solid (50 mg, 30%). Ή-NMR (DMSO-J6): δ 1.37- 1.44 (m, 4H), 2.02-2.09 (m, 4H), 2.99-3.04 (m, IH), 3.767-3.70 (m, IH), 7.44 (d, IH, J = 6.0 Hz), 7.50 (t, IH, / = 7.0 Hz), 7.57 (t, 2H, / = 7.5 Hz), 7.95 (d, 2H, J = 7.0 Hz), 8.16 (s, IH), 8.40-8.41 (m, 3H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z, [M+H]+ 403.2046. [00145] ( lr^r N'-fS-Fluoro^-fT-fpyridin-S-yDinti
vDcyclohexane- 1 ,4-diamine (45). ( lr,4r)-N1-(4-(7-ChloroinTidazo[ l ,2-a]pyridin-3-yl)-5-fluoropyrimidin- 2-yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.42 mmol) and 3-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2- yl)pyridine (86.0 mg, 0.42 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 45 as a yellow solid ( 100 mg, 59%). 1 H-NMR (DMSO- i¾): <5 1.36- 1.55 (m, 6H), 2.01 -2.09 (m, 4H), 2.98-3.00 (m, I H), 3.65-3.68 (m, I H), 7.45 (d, I H, 7 = 7.0 Hz), 7.59 (t, 2H, 7 = 6.5 Hz), 8.31 (s, I H), 8.37-8.44 (m, 4H), 8.69 (d, I H, 7 = 4.0 Hz), 9.17 (s, I H). HRMS (ESI) m/z. [M+H]+ 404.1997.
[00146] ( lr,4r)-N'-(5-Fluoro-4-(7-(pyridin-3-ylamino)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (46). ( l r,4r)- -(4-(7-Chloroimidazo[ 1 ,2-a]pyridin-3-yl)-5-fluoropyrimidin- 2-yl)cyclohexane- l ,4-diamine (200 mg, 0.56 mmol) and pyridin-3-amine (53 mg, 0.56 mmol) were reacted according to general synthetic procedure B to give 46 as a yellow solid (75 mg, 54%). 1 H-NMR (CDC13): δ 1.326- 1.35 (m, 4H), 1.94- 1.96 (m, 2H), 2. 19-2.21 (m, 2H), 2.77-2.79 (m, I H), 3.68-3.71 (m, IH), 5.00 (d, I H, 7 = 7.5 Hz), 6.70 (d, I H, 7 = 7.5 Hz), 7.03 (s, I H), 7.19 (s, I H), 7.27-7.28 (m, I H), 7.62 (d, IH, 7 = 8.0 Hz), 8.1 1 (d, IH, 7 = 3.0 Hz), 8.32 (s, 2H), 8.51 (s, IH), 9.83 (d, IH, 7 = 7.5 Hz) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z LM+HJ+ 419.2105.
[00147] ( 1 r,4r)-N ' -(5-Fluoro-4-( 6-(4-( morpholinomethyl)phenyl)imidazo [ 1 ,2-a]pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (47). ( 1 r,4r)- -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- fluoropyrimidin-2-yl)cyclohexane- l ,4-diamine ( 100 mg, 0.25 mmol) and 4-(4-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)benzyl)morpholine (76.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 47 as a yellow solid (65.0 mg, 52%). 1 H-NMR (CDC13): δ 1.26-1.33 (m, 2H), 1.46-1.47 (m, 2H), 2.09-2.1 1 (m, 2H), 2.22 (d, 2H, 7 = 10.0 Hz), 2.55-2.58 (m, 4H), 3.03-3.07 (m, IH), 3.62-6.35 (m, 2H), 3.2-3.77 (m, 5H), 5.08-5.10 (m, IH), 7.49 (d, 2H, 7 = 7.0 Hz), 7.56 (d, 2H, 7 = 7.0 Hz), 7.60 (d, IH, 7 = 9.0 Hz), 7.81 (d, IH, 7 = 9.0 Hz), 8.17 (s, IH), 8.47 (s, IH), 10.04 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 502.2730.
[00148] 4-(3-(2-((( lr,4r)-4-Armnocyclohexyl)amino)-5-fluoropyrirmdin-4-yl)irrddazo[ l ,2- a]pyridin-6-yl)-N,N-dimethylbenzenesulfonamide (48) . ( 1 r,4r)-N1-(4-(6-Bromoimidazo[ 1 ,2- ]pyridin-3- yl)-5-fluoropyrimidin-2-yl)cyclohexane- l ,4-diamine ( 100 mg, 0.25 mmol) and N,N-dimethyl-4-(4,4,5,5- tetramethyl- l ,3,2-dioxaborolan-2-yl)benzenesulfonamide (78.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C. The product was repurified by preparative HPLC to give 48 as a yellow solid (60 mg, 47%). 1 H-NMR (DMSO-i/6): δ 1.34- 1.37 (d, 4H, 7 = 1 1.5 Hz), 1.86-1.89 (m, 2H), 1.98-2.01 (m, 2H), 2.71 (s, 7H), 3.66-3.68 (m, IH), 7.34 (s, IH), 7.91-7.97 (m, 4H), 8.08 (d, 2H, 7 = 6.5 Hz), 8.38 (s, IH), 8.47 (s, IH), 10.19 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z. [M+H]+ 510.2085.
[00149] ( ΐΓ,4Γ)-Ν'-(5-Ρ1ηοΓθ-4-(6-(ρνΓίάίη-3-νΐ3ηιίηο)ΪΓηϊά3ζο 1 ,2-a1pyridin-3-yl)pyrimidin-2- yDcyclohexane- 1 ,4-diamine (49). ( lr,4r)-N1-(4-(6-Bromoimidazo[l,2-a]pyridin-3-yl)-5-fluoropyrimidin- 2-yl)cyclohexane-l,4-diamine (200 mg, 0.50 mmol) and pyridin-3-amine (46 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 49 as a yellow solid (60 mg, 29%). H-NMR (MeOD-i¾: 5 1.38- 1.45 (m, 4H), 2.07 (d, 2H, 7 = 10.0 Hz), 2.19 (d, 2H, 7 = 10.5 Hz), 3.1 1 -3.16 (m, 1 H), 3.67-3.72 (m. IH), 7.35 (dd, IH, 7 = 7.5 & 4.5 Hz), 7.49 (d, IH, 7 = 9.5 Hz), 7.56 (d, IH, 7 = 7.0 Hz), 7.70 (d, IH, / = 9.5 Hz), 8.08 (d, IH, / = 4.0 Hz), 8.23 (d, IH, 7 = 3.0 Hz), 8.28 (d, IH, 7 = 3.5 Hz), 8.40 (s, IH), 8.48 (s, IH), 10.08 (s, IH) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 419.2105.
[00150J (lr,4r)-N1-(5-Fluoro-4-(6-(pyrinudin-5-ylamino)imidazo| l,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (50). ( lr,4r)-N'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-fluoropyrimidin- 2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and pyrimidin-5-amine (47 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 50 as a yellow solid (65 mg, 31 %). 1 H-NMR (DMSC : δ 1.24- 1.30 (m, 4H), 1.86- 1.96 (m, 4H), 2.85-2.88 (m, IH), 3.54-3.60 (m, IH), 7.26 (d, IH, 7 = 7.0 Hz), 7.53 (d, IH, 7 = 8.5 Hz), 7.81 (d, IH, 7 = 9.0 Hz), 8.30 (d, IH, 7 = 3.0 Hz), 8.41 (d, 1H, 7 = 2.0 Hz), 8.50 (s, IH), 8.57 (s, 2H), 8.65 (s, IH), 9.08 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 420.2060.
[00151J N-(3-(2-((( lr,4r)-4-Anunocyclohexyl)aniino)-5-fluoropyrirmdin-4-yl)imidazo| 1 ,2- alpyridin-6-yl)-4-fluorobenzamide (51). V-(3-(2-Chloro-5-fluoropyrimidin-4-yl)imidazo[ 1 ,2-a]pyridin-6- yl)-4-fluorobenzamide (0.20 g, 0.52 mmol) and ( lr,4r)-cyclohexane- l ,4-diamine (0.18 g, 1.55 mmol) were reacted according to general synthetic procedure A(ii). The product was further purified by preparative HPLC to give 51 as a yellow solid (0.05 g, 21%). 1 H-NMR (DMSO- 6): δ 1.19-1.29 (m, 4H), 1.73-1.74 (m, 2H), 2.01 (d, 2H, 7 = 9.5 Hz), 3.90-3.92 (m, IH), 7.15 (d, IH, 7 = 7.5 Hz), 7.42 (t, 2H, 7 = 8.0 Hz), 7.77-7.85 (m, 2H), 8.17 (t, 2H, 7 = 6.5 Hz), 8.32 (s, IH), 8.42 (s, IH), 10.60 (s, IH). HRMS (ESI) m/z [M+H]+ 464.2010.
[00152] N-(3-(2-(((lr,4r)-4-Aminocyclohexyl)anrdno)-5-fluoropyrimidin-4-yl)imidazo[ l,2- a1pyridin-6-yl)-2-phenylacetamide (52) . N-(3-(2-Chloro-5-fluoropyrimidin-4-yl)imidazo[l ,2-a]pyridin-6- yl)-2-phenylacetamide (300 mg, 0.79 mmol) and ( lr,4r)-cyclohexane-l,4-diamine (270 mg, 2.37 mmol) were reacted according to general synthetic procedure A(ii). The product was repurified by flash column chromatography to give 52 as a yellow solid (50.0 mg, 14%). 1 H-NMR (DMSO-i/6): δ 1.26-1.28 (m, 4H), 1.75-1.78 (m, 2H), 1.95-1.97 (m, 2H), 2.63-2.67 (m, IH), 3.79 (s, 2H), 3.95-3.98 (m, IH), 7.01 (s, IH), 7.27 (t, 1H, / = 6.5 Hz), 7.34-7.41 (m, 5H), 7.79 (d, 1H, J = 9.5 Hz, 8.28 (d, 1H, J = 3.5 Hz), 8.40 (d, 1H, / = 3.0 Hz), 10.56 (s, 2H). HRMS (ESI) m/z. [M+H]+ 460.2259.
[00153] ( lr,4r)-N'-(5-Methyl-4-(7-phenylimidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2- yDcyclohexane- 1 ,4-diamine (53). ( lr,4r)-N1-(4-(7-Chloroirnidazo[l ,2-a]pyridin-3-yl)-5-methylpyrirnidin- 2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.42 mmol) and 4,4,5,5-tetramethyl-2-phenyl-l ,3,2- dioxaborolane (83.0 mg, 0.42 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 53 as a yellow solid (90 mg, 67%). Ή-NMR (DMSO- 6): δ 1.34- 1.41 (m, 2H), 1.48 (s, 2H), 2.00-2.08 (m, 4H), 2.37 (s, 3H), 2.94-2.97 (m, 1 H), 3.74- 3.76 (m, 1 H), 7. 1 1 (d, 1 H, J = 7.5 Hz), 7.46-7.49 (m, 2H), 7.56 (t, 2H, J = 7.5 Hz), 7.94 (d, 2H, J = 7.0 Hz), 8.1 1 (s, 1 H), 8.26 (s, 1H), 8.32 (s, 1 H), 8.46 (s, 1H). HRMS (ESI) m/z [M+H]+ 399.2298.
[ 00154J ( lr r)-N'-(5-Methyl-4-(7-(pyridin-3-yl)imidazo| l ,2-a|pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (54). ( l r,4r)-N'-(4-(7-Chloroimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.42 mmol) and 3-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2- yl)pyridine (86.0 mg, 0.42 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 54 as a yellow solid (65.0 mg, 39%). Ή-NMR (DMSO- d6): δ 1.34- 1.41 (m, 2H), 1.47 (s, 2H), 2.00-2.08 (m, 4H), 2.37 (s, 3H), 2.97 (br, 1H), 3.72 (br, 1 H), 7.13 (d, 1 H, J = 7.5 Hz), 7.57-7.59 (m, 2H), 8.25 (s, 1 H), 8.27 (s, 1 H), 8.34-8.36 (m, 2H), 8.42 (s, 1 H), 8.67 (d, 1H, / = 4.0 Hz), 9.16 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z.
[M+H]+ 400.2250.
[ 00155J ( lr,4r)-N'-(5-Methyl-4-(7-(pyridin-3-ylamino)imidazo| l ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (55). ( l r,4r)-/V'-(4-(7-Chloroimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.42 mmol) and pyridin-3-amine (40.0 mg, 0.42 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 55 as a yellow solid (40.0 mg, 23%). 1 H-NMR (MeOD-i¾): δ 1.44- 1.57 (m, 4H), 2.1 1 (d, 2H, / = 1 1.5 Hz), 2.23 (d, 2H, / = 12.0 Hz), 2.39 (s, 3H), 3.05 (br, 1H), 3.80 (br, 1H), 6.91 (d, 1H, 7 = 7.5 Hz), 7.15 (s, 1H), 7.48 (dd, 1H, / = 7.5 & 5.0 Hz), 7.83 (d, 1H, 7 = 7.5 Hz), 8.07 (s, 1H), 8.16 (s, 1H), 8.26 (d, 1H, J = 4.5 Hz), 8.50 (s, 1H), 8.58 (s, 1H), 9.85 (d, 1H, J = 6.0 Hz) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z, [M+H]+ 415.2357.
[00156] ( lr,4r)-N'-(5-Methyl-4-(7-(pyrinrddin-5-ylamino)inrddazo[ l ,2-a1pyridin-3-yl)pyri yDcyclohexane- 1 ,4-diamine (56). ( lr,4r)-N'-(4-(7-Chloroimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine (200 mg, 0.56 mmol) and pyrimidin-5 -amine (53.0 mg, 0.56 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 56 as a yellow solid (80.0 mg, 34%). Ή-NMR (MeOD-i/4): δ 1.44-1.57 (m, 4H), 2.1 1 (d, 2H, J = 1 1.5 Hz), 2.23 (d, 2H, J = 12.0 Hz), 2.39 (s, 3H), 3.05 (br, 1H), 3.80 (br, 1H), 6.91 (d, 1H, J = 7.5 Hz), 7.15 (s, 1H), 7.48 (dd, 1H, J = 7.5 & 5.0 Hz), 7.83 (d, 1H, 7 = 7.5 Hz), 8.07 (s, 1H), 8.16 (s, 1H), 8.26 (d, 1H, 7 = 4.5 Hz), 8.50 (s, 1H), 8.58 (s, 1H), 9.85 (d, 1H, 7 = 6.0 Hz) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 416.2310.
[00157] ( lr,4r)-N'-(4-(6-(3-Methoxyphenyl)inn^azori,2-alpyri
yDcyclohexane- 1 ,4-diamine (57). ( lr,4r)-N1-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.38 mmol) and (3-methoxyphenyl)boronic acid (57 mg, 0.38 mmol) were reacted according to general synthetic procedure C to give 57 as a brown solid (70 mg, 43%). Ή-NMR (CDC13): δ 0.73 (s, 2H), 1. 10- 1. 16 (m, 2H), 1.64 (br, 2H), 1.89-2.04 (m, 4H), 2.36 (s, 3H), 2.47 (br, 1H), 3.62 (br, 1 H), 3.82 (s, 3H), 5.14 (d, 1 H, 7 = 7.5 Hz), 6.91 (d, 1 H, 7 = 8.0 Hz), 7.07 (s, 1 H), 7. 16 (d, 1 H, 7 = 7.0 Hz), 7.36 (t, 1 H, 7 = 8.0 Hz), 7.53 (d, 1H, 7 = 9.0 Hz), 7.74 (d, 1 H, 7 = 9.0 Hz), 8. 12 (s, 1H), 8.15 (s, 1 H), 9.97 (s, 1 H). HRMS (ESI) m/z [M+H]+ 429.2402
[ 00158J ( lr,4r)-N1-(4-(6-(6-Methoxypyridin-3-yl)irmdazo| l ,2-a|pyridin-3-yl)-5-methylpyrirmdm 2-yl)cyclohexane- 1 ,4-diamine (58). ( 1 r,4r)-N'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.39 mmol) and (6-methoxypyridin-3- yl)boronic acid (91 mg, 0.59 mmol) were reacted according to general synthetic procedure C to give 58 as a yellow solid ( 135 mg, 81 %). Ή-NMR (CDC13): δ 0.84 (s, 2H), 1.1 1 - 1. 18 (m, 2H), 1.69 (d, 2H, 7 = 10.0 Hz), 1.93 (br, 2H), 2.03 (d, 2H, 7 = 1 1.5 Hz), 2.34 (s, 3H), 2.49-2.53 (m, 1 H), 3.61 -3.67 (m, 1 H), 3.94 (s, 3H), 5.17 (d, 1 H, 7 = 7.5 Hz), 6.82 (d, 1 H, 7 = 8.5 Hz), 7.44 (d, 1 H, 7 = 9.0 Hz), 7.71 -7.75 (m, 2H), 8.1 1 (s, 1H), 8.14 (s, 1H), 8.34 (s, 1H), 9.88 (s, 1H). HRMS (ESI) m/z [M+H]+ 430.2355.
L00159J ( lr,4r)-Nl-(4-(6-(3,5-Dimethylisoxazol-4-yl)imidazo| l ,2-alpyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (59). ( 1 r,4r)-/V'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)- 5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine (210 mg, 0.52 mmol) and 3,5-dimethyl-4-(4,4,5,5- tetramethyl- l ,3,2-dioxaborolan-2-yl)isoxazole ( 1 16 mg, 0.52 mmol) were reacted according to general synthetic procedure C to give 59 as a pale yellow solid (92 mg, 42%). Ή-NMR (DMSO- 6): δ 1.18- 1.24 (m, 4H), 1.70 (d, 2H, 7 = 1 1.0 Hz), 1.83 (d, 2H, 7 = 1 1.0 Hz), 2.24 (s, 3H), 2.34 (s, 3H), 2.43 (s, 3H), 2.90 (m, 1H), 3.49 (m, 1H), 6.95 (s, lH), 7.51 (d, 1H, 7 = 9.0 Hz), 7.85 (d, 1H, 7 = 9.0 Hz), 8.24 (s, 1H), 8.29 (s, 1H), 9.87 (s, 1H). HRMS (ESI) m/z [M+H]+ 418.2357.
[00160] ( 1 r,4r)-N ' -(5-Methyl-4-( 6-(4-( morpholinomethyl)phenyl)imidazo [ 1 ,2-a]pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (60). ( 1 r,4r)-N' -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine and ( 150 mg, 0.38 mmol) 4-(4-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)benzyl)morpholine ( 1 14 mg, 0.38 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 60 as a yellow solid ( 130 mg, 69%). Ή-NMR (CDCI3): δ 1.19-1.30 (m, 4H), 1.93 (br, 2H), 2.05 (br, 2H), 2.31 (s, 3H), 2.72 (br, 4H), 2.97 (br, 1H), 3.74-3.81 (m, 7H), 5.81 (br, 1H), 7.44-7.51 (m, 4H), 7.54 (d, 1H, 7 = 9.0 Hz), 7.78 (d, 1H, 7 = 9.0 Hz), 8.06 (s, 1H), 8.18 (s, 1H), 9.61 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 498.2980.
[00161] ( lr,4r)-N'-(5-Methyl-4-(6-(6-morpholinopyridin-3-yl)imidazor i ,2-a1pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (61). ( l r,4A-)-N1-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.38 mmol) and 4-(5-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)pyridin-2-yl)morpholine ( 109 mg, 0.52 mmol) were reacted according to general synthetic procedure C to give 61 as a white solid (90 mg, 49%). Ή-NMR (DMSO-i¾): δ 0.66 (s, 2H), 1.22- 1.27 (m, 4H), 1.57 (br, 2H), 1.90 (d, 2H, J = 1 1.0 Hz), 2. 14 (d, 2H, J = 1 1.0 Hz), 2.35 (s, 3H), 3.49- 3.59 (m, 5H), 3.72-3.74 (m, 4H), 6.92 (d, 1 H, J = 6.0 Hz), 6.99 (d, 1 H, / = 8.5 Hz), 7.72 (d, 1 H, J = 9.5 Hz), 7.83 (d, 1H, J = 9.0 Hz), 7.93 (d, 1H, / = 8.0 Hz), 8.25 (s, 2H), 8.5 1 (s, 1 H), 9.98 (s, 1 H). HRMS (ESI) m/z [M+H]+ 485.2777.
L00162 J 4-(3-(2-((( lr,4r)-4-Arninocyclohexyl)amino)-5-methylpyrirnidin-4-yl)imidazo| 1 ,2- alpyridin-6-yl)-N,N-dimethylbenzenesulfonamide (62). ( 1 r,4r)- V'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3- yl)-5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and N,vV-dimethyl-4-(4,4,5,5- tetramethyl- l ,3,2-dioxaborolan-2-yl)benzenesulfonamide ( 156 mg, 0.50 mmol) were reacted according to general synthetic procedure C to give 62 as a white solid ( 160 mg, 67%). Ή-NMR (CDC13): δ 0.86 (s, 2H), 1.19- 1.26 (m, 2H), 1.23 (d, 2H, J = 8.0 Hz), 2.07 (d, 2H, J = 1 1.5 Hz), 2.40 (s, 3H), 2.58-2.62 (m, 1H), 2.79 (s, 6H), 3.67-3.72 (m, 1 H), 4.85 (d, 1 H, J = 7.5 Hz), 7.58 (d, 1 H, J = 9.5 Hz), 7.76 (d, 2H, J = 8.0 Hz), 7.84 (d, 1H, 7 = 9.5 Hz), 7.91 (d, 2H, J = 8.0 Hz), 8.15 (s, 1H), 8.24 (s, 1H), 9.92 (s, 1H). HRMS (ESI) m/z [M+H]+ 506.2339.
[00163] ( lr.4r)-N'-(4-(6-(Furan-3-yl)imidazon .2-a1pyridin-3-yl)-5-methylpyrimidin-2- yl)cyclohexane- l ,4-diamine (63). ( l r,4r)-Af'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 100 mg, 0.25 mmol) and 2-(furan-3-yl)-4,4,5,5-tetramethyl-l ,3,2- dioxaborolane (28 mg, 0.25 mmol) were reacted according to general synthetic procedure C to give 63 as an orange solid (80 mg, 82%). Ή-NMR (CDC13): δ 1.03- 1.05 (m, 2H), 1.21- 1.28 (m, 2H), 1.43 (s, 2H), 1.80 (d, 2H, / = 1 1.5 Hz ), 2.13 (d, 2H, J = 1 1.0 Hz ), 2.37 (s, 3H), 2.61-2.65 (m, 1H), 3.75-3.78 (m, 1H), 4.99 (d, 1H, J = 7.5 Hz ), 6.67 (s, 1H), 7.44 (d, 1H, J = 9.0 Hz), 7.52 (s, 1H), 7.70-7.72 (m, 2H), 8.08 (s, 1H), 8.20 (s, 1H), 9.76 (s, 1H). HRMS (ESI) m/z [M+H]+ 389.2091.
[00164] ( lr,4r)-N'-(5-Methyl-4-(6-((5-methylpyridin-3-yl)ar
2-yl)cyclohexane- 1 ,4-diamine (64). ( 1 r,4r)-Nl -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methyl pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (200 mg, 0.50 mmol) and 5-methylpyridin-3-amine (54 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 64 as an orange solid (65 mg, 30%). Ή-NMR (MeOD-<¾): δ 1.37- 1.42 (m, 4H), 2.03 (br, 2H), 2.08 (br, 2H), 2.31 (s, 3H), 2.36 (s, 3H), 3.10 (br, 1H), 3.71 (br, 1H), 7.36 (s, 1H), 7.44 (d, 1H, / = 9.0 Hz), 7.67 (d, 1H, J = 9.5 Hz), 7.91 (s, 1H), 8.12 (s, 1H), 8.19 (s, 2H), 8.32 (s, 2H), 9.76 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 429.251 1.
[00165] ( lr,4r)-N'-(5-Methyl-4-(6-((5-(trifluorome
alpyridin-3-yl pyrimidin-2-yl cyclohexane- 1 ,4-diamine (65). ( 1 r,4r)-N'-(4-(6-Bromoimidazo[ 1 ,2- a]pyridin-3-yl)-5-methylpyrirmdin-2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and 5- (trifluoromethyl)pyridin-3-amine (8 1 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 65 as a yellow solid (70 mg, 29%). Ή-NMR (MeOD-<¾: δ 1 .08- 1. 1 1 (m, 2H), 1.27- 1.34 (m, 2H), 1.8 1 - 1.83 (m, 2H), 2.01 (d, 2H, 7 = 1 1.0 Hz), 2.40 (s, 3H), 2.61 -2.64 (m, 1 H), 3.66-3.68 (m, 1H), 7.48 (d, 1 H, 7 = 9.0 Hz), 7.59 (s, 1 H), 7.75 (d, 1 H, 7 = 9.5 Hz), 8.18-8.21 (m, 2H), 8.30 (s, 1 H), 8.56 (s, 1 H), 9.95 (s, 1 H) (two primary amine protons (NH2) and two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 483.2229.
[ 00166J ( ΐΓ,4Γ)-Ν'-(4-(6-((5-Ε1υοΓορνηάίη-3-ν1) ηΊίηο)ίηιίά ζο| 1 ,2- Ιρνηάίη-3-ν1)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (66). ( 1 r,4r)-N'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)- 5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and 5-fluoropyridin-3-amine (56 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 66 as a yellow solid (80 mg, 37%). Ή-NMR (MeOD-i¾: δ 1.41 - 1.48 (m, 4H), 2.05-2. 16 (m, 4H), 2.40 (s, 3H), 3.10-3.14 (m, 1 H), 3.75-3.78 (m, 1 H), 7.32 (d, 1 H, J = 10.5 Hz), 7.48 (d, 1H, 7 = 9.0 Hz), 7.73 (d, 1 H, J = 9.5 Hz), 7.94 (s, 1H), 8.16 (s, 1 H), 8.22 (s, 1 H), 8.24 (s, 1 H), 8.31 (s, 2H), 9.77 (s, 1 H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 433.2268.
L00167 J ( lr,4r)-N 1 -(4-(6-(( 6-Ethoxypyridin-3-yl)amino)imidazo 1 1 ,2-a lpyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (67). ( 1 r,4r)-/V'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)- 5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine (750 mg, 1.87 mmol) and 5-ethoxypyridin-3-amine (259 mg, 1.87 mmol) were reacted according to general synthetic procedure B to give 67 as a yellow solid (200 mg, 23%). Ή-NMR (MeOD-<¾): δ 1.24- 1.33 (m, 4H), 1.40 (t, 3H, 7 = 7.0 Hz), 1.91- 1.93 (m, 2H), 2.03 (d, 2H, 7 = 8.5 Hz), 2.37 (s, 3H, CH3), 2.72-2.75 (m, 1H), 3.61 -3.64 (m, 1H), 4.30 (q, 2H, 7 = 7.0 Hz), 6.79 (d, 1H, 7 = 9.0 Hz), 7.33 (d, 1H, 7 = 9.0 Hz), 7.61 (d, 2H, 7 = 9.0 Hz), 8.00 (s, 1H), 8.06 (s, 1H), 8.18 (s, 1H), 9.54 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 459.2620.
[00168] ( lr.4r)-N'-(4-(6-((6-(Difluoromethoxy)pyridin-3-yl)amino)imidazor i ,2-alpyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (68). ( 1 r,4r)-Nl -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)- 5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and 5-(difluoromethoxy)pyridin- 3-amine (80 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 68 as a brown solid (80 mg, 33%). Ή-NMR (MeOO-d4): δ 1.38- 1.48 (m, 4H), 2.06-2.14 (m, 4H), 2.37 (s, 3H), 3.10-3.13 (m, 1H), 3.70-3.74 (m, 1H), 6.96 (d, 1H, 7 = 8.5 Hz), 7.38 (d, 1H, 7 = 8.5 Hz), 7.44 (t, 1H, 7 = 74 Hz), 7.65 (d, IH, J = 8.5 Hz), 7.69 (dd, IH, 7 = 8.5 & 1.5 Hz), 8.09 (s, 2H), 8.21 (s, IH), 8.50 (s, IH), 9.62 (s, IH) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 481.2275.
[00169] (lr,4r)-Nl-(5-Methyl-4-(6-((6-methylpyridin-3-yl)amino)irnidazori,2-a1pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (69). ( lr,4A-)-N1-(4-(6-Bromoimidazo[l,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (200 mg, 0.50 mmol) and 6-methylpyridin-3-amine (54 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 69 as a brown solid (55 mg, 26%). Ή-NMR (MeOO-d4): δ 1.37- 1.41 (m, 4H), 2.03-2.08 (m, 4H), 2.36 (s, 3H), 2.49 (s, 3H), 3.08- 3.1 1 (m, IH), 3.68-3.71 (m, IH), 7.22 (d, IH, 7 = 8.5 Hz), 7.42 (d, IH, 7 = 9.5 Hz), 7.54 (d, IH, 7 = 8.0 Hz), 7.66 (d, IH, 7 = 9.5 Hz), 8.1 1 (s, IH), 8.20 (s, IH), 8.25 (s, IH), 8.30 (s, 2H), 9.69 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 429.2515.
[00170J (lr.4r)-N1-(5-Methyl-4-(6-(pyrazin-2-ylamino)irnidazo[ l,2-alpyridin-3-yl)pyrimidin-2- yPcyclohexane- 1 ,4-diamine (70). ( lr,4r)-jV'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and pyrazin-2-amine (47 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 70 as a brown solid (60 mg, 29%). Ή-NMR (DMSC : δ 1.21 (br, 2H), 1.51 (br, 2H), 1.89 (br, 2H), 2.32 (br, 5H), 3.34 (br, IH), 3.67 (br, IH), 6.80 (s, IH), 7.47 (br, IH), 7.73 (d, IH, 7 = 9.5 Hz), 7.96 (s, IH), 8.08 (s, IH), 8.13 (s, IH), 8.26 (s, IH), 8.30 (s, IH), 9.63 (s, IH), 10.43 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 416.2310.
[00171J (lr.4r)-Nl-(5-Methyl-4-(6-(pyridazin-3-ylamino)imidazo| l,2-a|pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (71). ( lr,4r)-Af'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) and pyridazin-3-amine (47 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 71 as an orange solid (60 mg, 29%). Ή-NMR (CDC13): (5 1.18 (s, 2H), 1.39 (br, 2H), 1.83 (br, 4H), 2.10-2.12 (m, 2H), 2.36 (s, 3H), 2.68 (br, IH), 3.80 (br, IH), 6.01 (s, IH), 6.99 (d, IH, 7 = 9.0 Hz), 7.20-7.26 (m, 2H), 7.57 (d, IH, 7 = 9.0 Hz), 8.16 (s, 2H), 8.38 (s, IH), 8.66 (d, IH, 7 = 4.0 Hz), 1 1.6 (s, IH). HRMS (ESI) m/z [M+H]+ 416.2309.
[00172] N-(3-(2-(((lr,4r)-4-Arm^ocyclohexyl)anrdno)-5-methylpyrimidin-4-yl)imidazo[ l,2- a1pyridin-6-yl)-4-fluorobenzamide (72). N-(3-(2-Chloro-5-methylpyrimidin-4-yl)imidazo[l ,2-a1pyridin- 6-yl)-4-fluorobenzamide (0.20 g, 0.52 mmol) and (lr,4r)-cyclohexane-l,4-diamine (0.12 g, 1.05 mmol) were reacted according to general synthetic procedure A(ii). The product was further purified by preparative HPLC to give 72 as a yellow solid (0.06 g, 25%). Ή-NMR (DMSO-i/6): δ 1.32 (br, 4H), 1.86, 1.86 (br, 2H), 2.03 (br, 2H), 2.31 (s, 3H), 2.88 (br, IH), 3.91 (s, IH), 6.95 (s, IH), 7.40 (t, 2H, 7 = 8.5 Hz), 7.70 (d, IH, 7 = 9.0 Hz), 8.11-8.15 (m, 3H), 8.28 (s, IH), 8.40 (s, IH), 10.31 (s, IH), 10.7 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 460.2257. [00173] N-(3-(2-((( lr,4r)-4-Aminocyclohexyl)amino)-5-methylpyrimidin-4-yl)i 1 ,2- alpyridin-6-yl)-2-phenylacetamide (73) . N-(3-(2-Chloro-5-methylpyrimidin-4-yl)imidazo[ l ,2-a]pyridin- 6-yl)-2-phenylacetamide (0.20 g, 0.53 mmol) and ( lr,4r)-cyclohexane- l ,4-diamine (0.12 g, 1.05 mmol) were reacted according to general synthetic procedure A(ii) to give 73 as a yellow solid (0.70 g, 29%). Ή-NMR (MeOD-i¾: δ 1 .35- 1.50 (m, 4H), 2.00 (d, 2H, J = 8.5 Hz), 2.25 (d, 2H, J = 10.0 Hz), 2.5 1 (s, 3H), 2.79 (br, 1 H), 3.93 (s, 2H), 4.03 (s, 1 H), 7.45 (t, 1 H, J = 7.0 Hz), 7.5 1 -7.57 (m, 4H), 7.62 (d, 1 H, J = 9.0 Hz), 7.82 (d, 1 H, J = 9.5 Hz), 8.26 (s, 1 H), 8.35 (s, 1 H), 10.59 (s, 1 H) (two primary amine protons (NH2) and two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 456.2508.
[00174] ( 1 r,4r)-N 1 -(5-Methyl-4-(6-( pyridin-3-yloxy)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2-yl)cyclo hexane- 1 ,4-diamine (74). 3-(2-Chloro-5-methylpyrimidin-4-yl)-7-(pyridin-3-yloxy)imidazo[ 1 ,2-a] pyridine ( 1 10 mg, 0.33 mmol) and ( l r,4r)-cyclohexane- l ,4-diamine ( 1 14 mg, 1.00 mmol) were reacted according to synthetic procedure A(ii) to give 74 as a beige powder (80.0 mg, 58%). Ή-NMR (DMSO- d6): δ 0.91 (s, 2H), 1.24- 1.31 (m, 2H), 1.69 (br, 2H), 1.85- 1.87 (m, 2H), 2.35 (s, 3H), 2.47 (br, 2H), 3.35 (br, 1H), 3.52 (br, 1 H), 6.90 (s, 1 H), 7.41 -7.45 (m, 2H), 7.50 (d, 1 H, J = 7.5 Hz), 7.86 (d, 1 H, J = 9.0 Hz), 8.24 (s, 1H), 8.31 (s, 1H), 8.37 (d, 1H, / = 3.0 Hz), 8.49 (s, 1H), 9.86 (s, 1H). HRMS (ESI) m/z LM+HJ+ 416.2197.
[00175] ( lr,4r)-N'-(5-Methyl-4-(6-(pyrimidin-5-yloxy)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2- yPcyclohexane- 1 ,4-diamine (75). 3-(2-Chloro-5-methylpyrimidin-4-yl)-6-(pyrimidin-5-yloxy)imidazo [ l ,2-fl]pyridine (200 mg, 0.60 mmol) and ( l r,4r)-cyclohexane- l ,4-diamine ( 137 mg, 1.20 mmol) were reacted according to general synthetic procedure A(ii) to give 75 as a white powder (80.0 mg, 32%). Ή- NMR (MeOD-i¾: δ 1.45 (q, 2H, J = 12.5 Hz), 1.57 (q, 2H, / = 12.0 Hz), 2.1 1 (d, 2H, / = 1 1.0 Hz), 2.20 (d, 2H, y = 1 1.5 Hz), 2.42 (s, 3H), 3.15 (t, 1Η, / = 12.0 Hz), 3.78 (t, 1Η, / = 1 1.0 Hz), 7.51 (d, 1Η, / = 9.5 Hz), 7.83 (d, 1H, J = 9.5 Hz), 8.25 (s, 1H), 8.28 (s, 1H), 8.53 (s, 1H), 8.69 (s, 2H), 8.99 (s, 1H), 9.87 (s, 1H), (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z LM+HJ+ 417.2148.
[00176] (R)-N-(5-Methyl-4-(6-(pyrimidin-5-ylandno)imidazo[ l ,2-alpyridin-3-yl)pyrind
quinuclidin-3-amine (76). (R)-N-(4-(6-Bromoinddazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl) quinuclidin-3-amine (220 mg, 0.54 mmol) and pyrimidin-5 -amine (51.0 mg, 0.54 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 76 as a yellow solid (95.0 mg, 41 %). 'H-NMR (MeOD-J4): δ Ι Λ4- Ι ΛΊ (m, 1H), 1.79- 1.81 (m, 1H), 1.91-1.93 (m, 1H), 2.23-2.27 (s, 1H), 2.43 (s, 3H), 2.54-2.57 (m, 1H), 3.21 (t, 1H, J = 10.5 Hz), 3.37-3.46 (m, 2H), 3.71 (dd, 1H, J = 14.5 & 2.5 Hz), 3.75-3.77 (m, 1H), 4.30-4.32 (m, 1H), 4.60 (d, 1H, J = 14.5 Hz), 7.46 (t, 1H, J = 9.0 Hz), 7.76 (t, 1H, J = 9.0 Hz), 8.16 (s, 1H), 8.38 (s, 1H), 8.54 (s, 1H), 8.59 (s, 2H), 8.68 (s, 1H), 9.58 (s, 1H) (one secondary amine proton (NH) signal not observed). HRMS (ESI) m/z [M+H]+ 428.2307. [00177] ( lr^rVN'-fS-Chloro^-^-phenylimidazoi 1 ,2-a1pyridin-3-yl)pyrimidin-2-yl)cyclohexane-
1 ,4-diamine (11). ( l r,4r)-N1-(4-(7-Bromoimidazo[ 1.2-alpvridin-3-vl)-5-chloropvrimidin-2- yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.36 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (73.0 mg, 0.36 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 77 as a yellow solid ( 125 mg, 83%). Ή-NMR (DMSO-^): δ 1 .38- 1.53 (m, 4H), 2.00-2.06 (m, 4H), 2.93-2.96 (m, 1 H), 3.68-3.71 (m, 1 H), 7.49 (t, 1 H, J = 7.0 Hz), 7.57 (t, 2H, J = 7.5 Hz), 7.63 (s, 1H), 7.95 (s, 2H), 8. 15 (s, 1H), 8.43 (s, 1 H), 8.48 (s, 1H), 8.77 (s, 1 H), 9.99 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (EST) m/z [M+H]+ 419. 1749.
[00178] ( lr.4r)-N'-(5-Chloro-4-(7-(pyridin-3-yl)imidazo[ 1.2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (78). ( 1 r,4r)- -(4-(7-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.36 mmol) and 3-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2- yl)pyridine (73.0 mg, 0.36 mmol) were reacted according to general synthetic procedure C to give 78 as a yellow solid ( 135 mg, 89%). Ή-NMR (DMSO- 6): δ 1. 17- 1.23 (m, 2H), 1.34- 1.38 (m, 2H), 1.82- 1.85 (m, 2H), 1.97- 1.99 (m, 2H), 2.52-2.55 (m , 1 H), 3.65-3.68 (m, 1 H), 7.53-7.58 (m, 3H), 8.26 (s, 1 H), 8.35 (d, 1H, J = 4.5 Hz), 8.42 (s, 1H), 8.68 (s, 1H), 8.77 (s, 1H), 9.16 (s, 1H), 9.99 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z LM+HJ+ 420.1703.
[00179] ( lr,4r)-N'-(5-Chloro-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (79) and ( lr,4r)-N'-(5-Phenyl-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (80). ( lr,4r)-Af'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.36 mmol) and 4,4,5,5-tetramethyl-2-phenyl- 1 ,3,2- dioxaborolane (99.0 mg, 0.48 mmol) were reacted according to general synthetic procedure C. The products were further purified by preparative HPLC to give: 79 as a white solid (90 mg, 60%). Ή-NMR (CDC ): δ 1.19- 1.23 (m, 4H), 1.93- 1.95 (m, 2H), 2.12-2.14 (m, 2H), 2.89-2.91 (m, 1H), 3.72-3.76 (m, 1H), 5.18 (s, 1H), 7.42 (t, 1H, / = 7.0 Hz), 7.48 (t, 2H, / = 7.5 Hz), 7.56 (d, 2H, J = 7.5 Hz), 7.60 (d, 1H, J = 9.0 Hz), 7.83 (d, 1H, J = 9.0 Hz), 8.31 (s, 1H), 8.36 (s, 1H), 9.73 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z LM+HJ+ 419.1752. 80 as a white solid (25 mg, 15%). Ή- NMR (CDC13): δ 1.22-1.24 (m, 4H), 1.98-2.01 (m, 2H), 2.14-2.16 (m, 2H), 2.92-2.94 (m, 1H), 3.81-3.83 (m, 1H), 5.40 (s, 1H), 7.13 (s, 1H), 7.23 (d, 1H, J = 6.0 Hz), 7.33-7.38 (m, 4H), 7.43-7.50 (m, 5H), 7.67 (d, 1H, J = 9.0 Hz), 8.22 (s, 1H), 8.44 (s, 1H), 9.54 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z, [M+H]+ 461.2454.
[00180] ( lr,4r)-Nl-(5-Chloro-4-(6-(6-methoxypyridin-3-yl)imidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (81). (lr,4r)-N1-(4-(6-Bromoinndazo[ l ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)cyclohexane-l ,4-diamine ( 150 mg, 0.36 mmol) and 2-methoxy-5-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)pyridine (55.0 mg, 0.36 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 81 as a white solid (50 mg, 31 %). Ή- NMR (DMSO-i/6): (5 0.80-0.82 (m, 1H), 1.22-1.32 (m, 3H), 1.61-1.63 (s, 1H), 1.89-1.92 (m, 3H), 2.79- 2.81 (m, 1 H), 3.90-3.92 (m, 4H), 6.95 (d, 1H, 7 = 8.5 Hz), 7.81 (d, 1H, J = 9.0 Hz), 7.87 (d, 1 H, 7 = 9.0 Hz), 8.10 (d, 1H, 7 = 7.0 Hz), 8.40 (s, 1H), 8.45 (s, 1H), 8.52 (s, 1H), 8.57 (s, 1H), 9.69 (s, lH) (two primary amine protons (NH2) signals not observed). HRMS (EST) m/z [M+H]+ 450.1809.
[00181] (lr,4r)-Nl-(5-Chloro-4-(6-(4-methoxyphenyl)imidazori,2-a1pyridin-3-yl)pyrirmdin-2- yl)cyclohexane- l ,4-diamine (82). ( l r,4r)-jV'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)cyclohexane- l ,4-diamine (220 mg, 0.52 mmol) and 2-(4-methoxyphenyl)-4, 4,5, 5-tetramethyl- 1 ,3,2- dioxaborolane ( 122 mg, 0.52 mmol) were reacted according to general synthetic procedure C to give 82 as a yellow solid (80 mg, 34%). Ή-NMR (CDC13): δ 1.21- 1.27 (m, 4H), 1.95 (d, 2H, 7 = 10.5 Hz), 2.14 (d, 2H, 7 = 1 1.0 Hz), 2.86 (s, 1H), 3.75 (s, 1H), 3.86 (s, 3H), 5.08 (s, 1H), 7.03 (d, 2H, 7 = 7.5 Hz), 7.49 (d, 2H, 7 = 7.5 Hz), 7.56 (d, 1H, 7 = 9.0 Hz), 7.79 (d, 1H, 7 = 9.0 Hz), 8.31 (s, 1H), 8.39 (s, 1H, 7 = 4.0 Hz), 9.71 (s, 1H). HRMS (ESI) m/z [M+H]+ 449.1859.
L00182J (lr,4r)-N1-(5-Chloro-4-(6-(3,5-dimethylisoxazol-4-yl)imidazo| l,2-alpyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (83). ( 1 r,4r)-N'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- chloropyrimidin-2-yl)cyclohexane- 1 ,4-diamine (220 mg, 0.52 mmol) and 3,5-dimethyl-4-(4,4,5,5- tetramethyl- l ,3,2-dioxaborolan-2-yl)isoxazole ( 1 16 mg, 0.52 mmol) were reacted according to general synthetic procedure C to give 83 as a pale yellow solid (85 mg, 37%). Ή-NMR (DMSO- 6): δ 1.22- 1.28 (m, 4H), 1.61 (d, 2H, 7 = 10.5 Hz), 1.84 (d, 2H, 7 = 1 1.0 Hz), 2.26 (s, 3H), 2.45 (s, 3H), 2.65 (m, 1H), 3.65 (m, 1H), 7.52 (br s, 1H), 7.58 (d, 1H, 7 = 9.0 Hz), 7.90 (d, 1H, 7 = 9.0 Hz), 8.43 (s, 1H), 8.73 (s, 1H), 9.85 (s, 1H). HRMS (ESI) m/z [M+HJ+ 438.1831.
[00183] ( lr.4r)-N'-(5-Chloro-4-(6-(6-(piperazin- l -yl)pyridin-3-yl)imidazon .2-alpyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (84). ( 1 r,4r)-N' -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- chloropyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.36 mmol) and teri-butyl 4-(5-(4,4,5,5- tetramethyl-l ,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-l-carboxylate (140.0 mg, 0.36 mmol) were reacted according to general synthetic procedure C to give fcrf-butyl 4-(5-(3-(2-(((lr,4r)-4- airrinocyclohexyl)amino)-5-chloropyrirmdin-4-yl)i
carboxylate (130 mg). The latter was heated at reflux in 3M HC1 (4 mL) and MeOH (4 mL) for 6 h, basified with 2M NaOH, and extracted with DCM (3 X 100 mL). Organic extracts were combined, concentrated under reduced pressure and purified by preparative HPLC to give 84 as a yellow solid (60 mg, 33%). Ή-NMR (DMSO-J6): δ 0.98-102 (m, 1H), 1.35-1.37 (m, 2H), 1.74-1.76 (m, 1H), 1.90-1.96 (m, 3H), 2.81-2.92 (m, 5H), 3.59-3.66 (m, 5H), 6.96 (d, 1H, 7 = 8.5 Hz), 7.80-7.86 (m, 2H), 7.95 (d, 1H, 7 = 8.5 Hz), 8.38 (s, 2H), 8.47 (s, 1H), 8.54 (s, 1H), 9.63 (s, 1H) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 504.2387. [00184] ( lr,4r)-N'-(5-Chloro-4-(8-phenyl-6-(trifluoromethyl)imidazor 1 ,2-alpyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (85). ( 1 r,4r)-N1-(4-(8-Bromo-6-(trifluoromethyl)imidazo[ 1 ,2- a]pyridin-3-yl)-5-chloropyrirrudin-2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.31 mmol) and 4,4,5,5- tetramethyl-2-phenyl- 1 ,3,2-dioxaborolane (63.0 mg, 0.3 1 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 85 as a yellow solid (60 mg, 40%). 1 H-NMR (DMSO-rfe): δ 1.32- 1.43 (m, 4H), 1.96-2.02 (m, 4H), 2.89-2.91 (m, I H), 3.65- 3.68 (m, I H), 7.52 (d, I H, J = 7.5 Hz), 7.57 (t, 2H, J = 7.0 Hz), 7.66 (d, I H, J = 7.5 Hz), 7.89 (s, I H), 8. 13 (d, 2H, J = 7.0 Hz), 8.44 (s, I H), 8.51 (s, I H), 9.96 (s, I H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z LM+HJ+ 487.1623.
[00185] ( lr.4r)-N'-(5-Chloro-4-(8-(pyridin-3-yl)-6-(trifluoromethyl)imidazor 1 ,2-alpyridin-3- yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine (86). ( 1 r,4r)-A '-(4-(8-Bromo-6-(trifluoromethyl)imidazo[ 1 ,2- a]pyridin-3-yl)-5-chloropyrimidin-2-yl)cyclohexane- l ,4-diamine ( 128 mg, 0.26 mmol) and 3-(4,4,5,5- tetramethyl- 1 ,3,2-dioxaborolan-2-yl)pyridine (5 1.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C to give 86 as a yellow solid (71 mg, 56%). 1 H-NMR (DMSO-<¾): δ 1.06- 1.08 (m, 2H), 1.38 (q, 2H, J = 12.0 Hz), 1.48 (s, 2H), 1.79 (d, 2H, / = 10.5 Hz), 1.93 (d, 2H, / = 10.5 Hz), 2.53- 2.55 (m. IH), 3.65-3.68 (m, IH), 7.60-7.62 (m, 2H), 8.07 (s, IH), 8.50 (s, IH), 8.54 (d, 2H, / = 8.0 Hz), 8.71-8.72 (m, IH), 9.30 (s, IH), 10.09 (s, IH). HRMS (ESI) m/z, [ M+H]+ 488.1577.
[00186] N-(3-(2-((( lr,4r)-4-Aminocyclohexyl)amino)-5-chloropyrimidin-4-yl)imidazo[ 1 ,2-a]pyridin-6- vDbenzamide (87). /V-(3-(2,5-Dichloropyrimidin-4-yl)imidazo[ l ,2-a]pyridin-6-yl)benzamide (220 mg, 0.57 mmol) and ( 1 r,4r)-cyclohexane- 1 ,4-diamine ( 196 mg, 1.72 mmol) were reacted according to general synthetic procedure A(ii) to give 87 as a beige solid (90.0 mg, 34%). 1 H-NMR (DMSO-i/6): δ 0.93-1.02 (m, 4H), 1.24-1.26 (m, 2H), 1.56 (s, 2H), 1.95 (d, 2H, J = 1 1.0 Hz), 2.32-2.35 (m, IH), 3.87-3.90 (m, IH), 7.41 (s, IH), 7.59 (t, 2H, J = 7.5 Hz), 7.65 (t, IH, / = 7.0 Hz), 7.70 (s, IH), 7.83 (d, IH, J = 9.0 Hz), 8.05 (d, 2H, J = 7.5 Hz), 8.43 (s, IH), 8.60 (s, IH), 10.51 (s, 2H). HRMS (ESI) m/z [M+H]+ 462.1810.
[00187] ( lr,4r)-N'-(5-Chloro-4-(6-(pyrir din-5-ylamino)ir da
yl)cyclohexane- l ,4-diamine (88). ( 1 r,4r)-N[ -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)cyclohexane-l ,4-diamine (200 mg, 0.48 mmol) and pyrimidin-5 -amine (45.0 mg, 0.48 mmol) were reacted according to general synthetic procedure B to give 88 as a yellow solid (90.0 mg, 43%). 'H-NMR (DMSO-i/6): δ 1.25-1.36 (m, 4H), 1.74 (d, 2H, J = 16.5 Hz), 1.96-1.98 (m, 2H), 2.77-2.79 (m, IH), 3.50- 3.52 (m, IH), 7.45-7.48 (m, 2H), 7.79 (d, IH, J = 8.0 Hz), 8.43 (s, IH), 8.46 (s, IH), 8.60 (s, 2H), 8.65 (s, IH), 8.99 (s, IH), 9.74 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z.
[M+H]+ 436.1763.
[00188] ( lr,4r)-Nl-(5-Methoxy-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)pyrirnidin-2- yl)cyclohexane-l ,4-diamine (89). ( 1 r,4r)-N[ -(4-(6-Bromoimidazo [ 1 ,2-a]pyridin- methoxypyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 100 mg, 0.24 mmol) and 4,4,5, 5-tetramethyl-2-phenyl-
I , 3,2-dioxaborolane (50 mg, 0.24 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 89 as a yellow powder (50 mg, 50%). Ή-NMR (DMS : δ 1.12- 1.15 (m, 2H), 1.32 (q, 2H, / = 12.0 Hz), 1.84 (d, 2H, J = 1 1.5 Hz), 1.99 (d, 2H, J =
I I .5 Hz), 2.79-2.82 (m, I H), 3.62-3.64 (m, I H), 3.94 (s, 3H), 6.8 1 (d, I H, 7 = 7.5 Hz), 7.48 (t, I H, 7 = 7.0 Hz), 7.56 (t, 2H, J = 7.0 Hz), 7.77 (d, 2H, J = 7.5 Hz), 7.80 (d, I H, J = 9.5 Hz), 7.87 (d, I H, J = 9.0 Hz), 8.3 1 (s, IH), 8.5 1 (s, IH), 10.15 (s, I H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ 415.2246.
[00189] ( lr,4r)-N'-(5-Methyl-4-(6-phenylimidazon .2-alpyridin-3-yl)pyrimidin-2-yl)-N4-( l - methylpiperidin-4-yl)cyclohexane- 1 ,4-diamine (90). To a solution of ( l r,4r)-N'-(5-methyl-4-(6- phenylimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine (200 mg, 0.50 mmol) in THF (6 mL) and AcOH (0.2 mL) was added 1 -methylpiperidin-4-one (62 μL·, 0.50 mmol), and the reaction mixture stirred for 30 min at rt. Sodium triacetoxyborohydride (212 mg, 1.00 mmol) was added and the reaction mixture stirred at room temperature overnight. Saturated NaHC03 (20 mL) and DCM ( 100 mL) were added. Organic phase was separated and the aqueous phase was extracted with DCM (2 x 100 mL). Organic extracts were combined and purified by flash column chromatography starting with 100% DCM ramping to 7% MeOH + 1% NH3 (32% in water) to afford 90 as a white solid (90.0 mg, 36%). Ή-NMR (CDC13): S 0.68-0.72 (m, 2H), 1.12 (q, 2H, / = 1 1.5 Hz), 1.30 (q, 2H, / = 10.5 Hz), 1.76 (t, 4H, / = 12.5 Hz), 1.92 (t, 2H, / = 1 1.0 Hz), 2.04 (d, 2H, / = 10.5 Hz), 2.22 (s, 3H), 2.36-2.41 (m, 5H), 2.78 (d, 2H, J = 1 1.0 Hz), 3.62-3.64 (m, IH), 5.07 (d, IH, J = 7.5 Hz), 7.36 (t, IH, J = 7.0 Hz), 7.44 (t, 2H, J = 7.5 Hz), 7.52-7.55 (m, 3H), 7.74 (d, IH, J = 9.0 Hz), 8.1 1 (s, IH), 8.16 (s, IH), 9.89 (s, IH) (one secondary amine proton (NH) signal not observed). HRMS (ESI) m/z [M+H]+ calcd. for C3oH38N7 +, 496.3187.
[00190] ( l s.4s)-N'-(5-Methyl-4-(6-phenylimidazon ,2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (91). (li',45)-N1-(4-(6-BromoimidazoL l ,2- Jpyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane-l ,4-diamine (100 mg, 0.25 mmol) and 4,4,5,5-tetramethyl-2-phenyl-l ,3,2- dioxaborolane (51.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 91 as a yellow solid (70.0 mg, 70%). Ή-NMR (MeOD-<¼): δ 1.69-1.72 (m, 6H), 1.89-1.92 (m, 2H), 2.45 (s, 3H), 3.12 (br, IH), 4.05 (br, IH), 7.46 (t, IH, J = 7.0 Hz), 7.54 (t, 2H, J = 7.0 Hz), 7.68 (d, 2H, J = 7.5 Hz), 7.80 (s, 2H), 8.24, (s, IH), 8.29 (s, IH), 10.05 (s, IH) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 399.2297.
[00191] ( ls^s N'-fS-Methyl^-^-fpyridin-S-ylarnino^m
yl)cyclohexane-l ,4-diamine (92). (li,40,)-N1-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)cyclohexane-l ,4-diamine (200 mg, 0.50 mmol) and pyridin-3-amine (47.0 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 92 as a yellow solid (40 mg, 20%). Ή-NMR (O20-d2): δ 1.35 (br, 2H), 1.48-1.58 (m, 6H), 1.90 (s, 3H), 3.16 (br, 1 H), 3.32 (br, 1 H), 6.97 (d, 1 H, / = 9.5 Hz), 7.15 (t, I H, 7 = 8.0 Hz), 7.19 (d, 1 H, 7 = 7.5 Hz), 7.25 (d, IH, / = 9.5 Hz), 7.69 (s, 1H), 7.71 (s, IH), 7.92 (d, IH, J = 4.0 Hz), 8.01 (s, IH), 8.42 (s, IH), 9.16 (s, IH) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 415.2356.
[00192] (ls,4s)-Nl-(5-Methyl-4-(6-(pyrinu^in-5-ylamino)imidazo[l,2-a1pyridin-3-yl)pyri 2-yl)cyclohexane- 1 ,4-diamine (93). ( ls,4s)-N'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (200 mg, 0.50 mmol) and pyrimidin-5-amine (48.0 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to 93 as a yellow solid (60 mg, 29%). Ή-NMR (MeOD-i¾): δ 1.40- 1.44 (m, 2H), 1.54- 1.59 (m, 4H), 1.73- 1.77 (m, 2H), 2.83 (br, IH), 3.42 (s, 3H), 3.92 (br, IH), 5.42 (d, IH, 7 = 7.5 Hz), 7.21 (d, IH, 7 = 9.5 Hz), 7.32 (s, IH), 7.63 (d, IH, 7 = 9.5 Hz), 8.07 (s, IH), 8.14 (s, IH), 8.45 (s, 2H), 8.67 (s, IH), 9.75 (s, IH) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H]+ calcd. for C22H26N9 +, 416.23010.
[00193] Nl-(5-Methyl-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,3- diamine (94). N'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)cyclohexane- l ,3- diamine ( 100 mg, 0.25 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (51.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 94 as a yellow sticky liquid (40.0 mg, 40%). Ή-NMR (MeOD-i¾): δ 0.99 (s, IH), 1.22-1.29 (m, 3H), 1.69-1.75 (m, 2H), 2.04 (d, IH, 7 = 11.5 Hz), 2.39-2.42 (s, 4H), 2.55 (br, IH), 3.76 (br, IH), 7.47 (t, IH, 7 = 7.0 Hz), 7.55 (t, 2H, 7 = 7.0 Hz), 7.68 (d, 2H, 7 = 7.5 Hz), 7.77 (s, 2H), 8.21, (s, IH), 8.25 (s, IH), 10.03 (s, IH) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z LM+HJ+ calcd. for C24H27N6 +, 399.2297.
[00194] Nl-(5-Methyl-4-(6-(pyridin-3-ylamino)irmdazo[l ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane-l,3-diamine (95). Af'-(4-(6-Bromoimidazo[l,2-a]pyridin-3-yl)-5-methylpyrimidin-2- yl)cyclohexane-l,3-diamine (150 mg, 0.38 mmol) and pyridin-3-amine (36.0 mg, 0.38 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 95 as a yellow solid (45 mg, 29%). Ή-NMR (MeOD-i¾ : δ 1.26-1.36 (m, 4H), 1.84 (s, IH), 1.93 (s, IH), 2.01 (s, IH), 2.42 (s, 4H), 2.97 (br, IH), 3.78 (br, IH), 7.34 (t, IH, 7 = 6.5 Hz), 7.47 (d, IH, 7 = 9.5 Hz), 7.55 (d, 1H, 7 = 8.0 Hz), 7.73 (d, IH, 7 = 9.0 Hz), 8.07 (d, IH, 7 = 3.5 Hz), 8.18, (s, IH), 8.25 (s, IH), 8.35 (s, IH), 8.46 (s, IH), 9.87 (s, IH) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 415.2355. [00195] N1-(5-Methyl-4-(6-(pyrimidin-5-ylamino)imidazo[ l ,2-a1pyridm^
vDcyclohexane- 1 ,3-diamine (96). N1-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2- yl)cyclohexane- l ,3-diamine ( 150 mg, 0.38 mmol) and pyrimidin-5 -amine (36.0 mg, 0.38 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 96 as a yellow solid (60 mg, 38%). Ή-NMR (MeOO-d4): δ 1.26- 1 .42 (m, 4H), 1.87 (s, I H), 2.01 -2.04 (m, 2H), 2.34 (s, 3H), 2.43 (d, 1 H, 7 = 10.5 Hz), 3. 1 1 (br, I H), 3.77-3.82 (m, I H), 7.43 (d, IH, J = 9.5 Hz), 7.68 (d, IH, J = 9.5 Hz), 8.12 (s, I H), 8. 17 (s, I H), 8.52 (s, I H), 8.58 (s, 2H), 8.64 (s, IH), 9.83 (s, I H) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z LM+HJ+ 416.2310.
[00196] N' ,N'-Dimethyl-N4-(5-methyl-4-(6-phenylimidazor i ,2-a1pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (97). -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)- Λ^,Λ^-dimethylcyclohexane- 1 ,4-diamine ( 100 mg, 0.23 mmol) and 4,4,5, 5-tetramethyl-2-phenyl- 1 ,3,2- dioxaborolane (47.0 mg, 0.23 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 97 as a yellow sticky liquid (70.0 mg, 71 %). Ή-NMR (CDC13): δ 0.99-1.01 (m, 2H), 1.27 (q, 2H, / = 12.5 Hz), 1.80-1.82 (m, 2H), 2.21 (d, 2H, 7 = 10.5 Hz), 2.42 (s, 9H), 2.91-2.93 (m, IH), 3.68-3.70 (m, IH), 5.42 (s, IH), 7.43 (t, IH, / = 7.0 Hz), 7.50 (t, 2H, J = 7.0 Hz), 7.59-7.63 (m, 3H), 7.83 (d, IH, / = 9.0 Hz), 8.16 (s, IH), 8.19 (s, IH), 9.88 (s, 1H).HRMS (ESI) m/z | M+HJ+ 427.2609.
[00197] Nl ,Nl-Dimethyl-N4-(5-Methyl-4-(6-(pyridin-3-ylamino)imidazor i .2-a1pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (98). N'-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)-N4,N4-dimethylcyclohexane-l ,4-diamine (200 mg, 0.47 mmol) and pyridin-3- amine (44.0 mg, 0.47 mmol) were reacted according to general synthetic procedure B to give 98 as an orange solid ( 100 mg, 48%). Ή-NMR (CDC13): δ 1.21-1.329 (m, 4H), 2.14-2.21 (m, 10H), 2.38 (s, 3H), 3.68-3.70 (m, IH), 4.90 (d, IH, J = 8.0 Hz), 5.78 (d, IH, J = 4.5 Hz), 7.18 (t, IH, J = 7.5 Hz), 7.21-7.24 (m, 2H), 7.70 (d, IH, 7 = 9.0 Hz), 8.13 (s, IH), 8.17 (d, IH, 7 = 4.0 Hz), 8.19 (s, IH), 8.44 (s, IH), 9.78 (s, IH) (one carbon proton (CH) signal not observed). HRMS (ESI) m/z [M+H]+ 443.2230.
[00198] N N'-Dimethyl-N4-(5-Methyl-4-(6-(pyrimidin-5-ylamino)imidazor i .2-a1pyridin-3- yl)pyrimidin-2-yl)cyclohexane-l ,4-diamine (99). N1-(4-(6-Bromoimidazo[ 1 ,2- ]pyridin-3-yl)-5- methylpyrirrudin-2-yl)-N4,N4-dimethylcyclohexane-l ,4-diamine (200 mg, 0.47 mmol) and pyrimidin-5- amine (45.0 mg, 0.47 mmol) were reacted according to general synthetic procedure B to give 99 as an orange solid ( 100 mg, 48%). Ή-NMR (DMSO-i/6): δ 1.06- 1.19 (m, 2H), 1.54- 1.56 (m, 2H), 1.92-2.00 (m, 10H), 2.34 (s, 3H), 3.51-3.53 (m, IH), 4.12-4.13 (m, IH), 6.89 (s, IH), 7.41(d, IH, J = 9.0 Hz), 7.76 (d, IH, J = 9.5 Hz), 8.20 (s, IH), 8.24 (s, IH), 8.54 (s, 2H), 8.61 (s, IH), 8.64 (s, IH), 9.80 (s, IH). HRMS (ESI) m/z [M+H]+ 444.2623. [00199] ( ls R.5SJr)-3.5-Dimethyl-7-((5-methyl-4-(6-phenylirnidazo[ 1.2-alpyridin-3- yl)pyrimidin-2-yl)amino)adamantan- l-ol (100). ( li,3^5/?,7S)-3-((4-(6-Bromoimidazo[ l ,2-a]pyridin-3- yl)-5-methylpyrimidin-2-yl)amino)adamantan- l-ol ( 100 mg, 0.22 mmol) and 4,4,5,5-tetramethyl-2- phenyl- 1 ,3,2-dioxaborolane (45.0 mg, 0.22 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 100 as a yellow solid (80.0 mg, 76%). Ή-NMR (DMSO-<¾): δ 1. 13- 1 . 16 (m, 2H), 1.34 (br, 4H), 1 .76- 1 .83 (m, 4H), 1 .83 (br, 2H), 1.98 (br, 1 H), 2.00 (br, 1 H), 2.33 (s, 3H), 4.34 (s, 1 H), 6.63 (s, 1 H), 7.42 (t, 1 H, J = 7.0 Hz), 7.50 (t, 2H, J = 7.0 Hz), 7.72 (d, 2H, J = 7.5 Hz), 7.77 (d, \ U, J = 9.0 Hz), 7.84 (d, 1 H, J = 9.0 Hz), 8.17, (s, 1 H), 8.29 (s, 1 H), 9.54 (s, 1H). HRMS (ESI) m/z LM+H]+ 480.2763.
[00200] ( 1 s,3R,5S,7r)-3,5-Dimethyl-7-((5-methyl-4-(6-(pyridin-3-ylamino)imidazo[ 1 ,2-alpyridin-
3-yl)pyrimidin-2-yl)amino)adamantan- 1 -ol (101). ( ls,3r,5R,7S)-3-((4-(6-Bromoimidazo[ l ,2-a]pyridin-3- yl)-5-methylpyrimidin-2-yl)amino)adamantan- l -ol ( 160 mg, 0.35 mmol) and pyridin-3-amine (33.0 mg, 0.35 mmol) were reacted according to general synthetic procedure B to give 101 as a yellow solid (60.0 mg, 35%). Ή-NMR (DMSO- 6): δ 1.38- 1.52 (m, 6H), 1.88-2.02 (m, 9H), 2.3 1 (s, 3H), 4.57 (s, 1 H), 6.32 (s, 1H), 7.25 (t, 1H, J = 7.5 Hz), 7.37 (d, 1H, J = 9.5 Hz), 7.46 (d, 1H, J = 7.5 Hz), 7.72 (d, 1H, J = 9.5 Hz), 8.1 1 (s, 1H), 8.24 (s, 1H), 8.37 (s, 2H), 9.45 (s, 1H). HRMS (ESI) m/z LM+H]+ 496.2822.
[00201 ] ( 1 s.3R.5S.7r)-3.5-Dimethyl-7-((5-methyl-4-(6-(pyrimidin-5-ylamino)imidazor 1.2- a]pyridin-3-yl)pyrimidin-2-yl)amino)adamantan- 1 -ol (102). ( l 5,3r,5/?,7S)-3-((4-(6-Bromoimidazo[ l ,2- a]pyridin-3-yl)-5-methylpyrimidin-2-yl)amino)adamantan- l -ol ( 160 mg, 0.35 mmol) and pyrimidin-5- amine (35.0 mg, 0.35 mmol) were reacted according to general synthetic procedure B to give 102 as a yellow solid (80.0 mg, 46%). Ή-NMR (DMSO-J6): δ 1.38-1.52 (m, 6H), 1.86-2.01 (m, 9H), 2.32 (s, 3H), 4.56 (s, 1H), 6.37 (s, 1H), 7.42 (d, 1H, J = 9.5 Hz), 7.75 (d, 1H, J = 9.5 Hz), 8.14 (s, 1H), 8.25 (s, 1H), 8.56 (s, 3H), 8.66 (s, 1H), 9.50 (s, 1H). HRMS (ESI) m/z LM+HJ+ 497.2777.
[00202] 3-(5-Methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyri
a1pyridin-6-amine (103). 4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methyl-N-(tetrahydro-2H-pyran-4- yl)pyrimidin-2-amine ( 194 mg, 0.50 mmol) and pyridin-3-amine (47.2 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 103 as a yellow sticky liquid (70 mg, 35%). 'H-NMR (CDC13): δ 1.64- 1.70 (m, 2H), 1.93 (d, 2H, J = 1 1.0 Hz), 2.39 (s, 3H), 3.39 (br, 2H), 3.92-3.94 (m, 3H), 6.07 (s, 1H), 7.23-7.30 (m, 3H), 7.77 (d, 1H, J = 9.5 Hz), 8.16-8.17 (m, 3H), 8.25 (s, 1H), 8.46 (s, 1H), 9.82 (s, 1H). HRMS (ESI) m/z [M+H]+ 402.2042.
[00203] 3-(5-Methyl-2-((tetrahydro-2H-pyran-4-yl)armno)pyrirmdin-4-yl)-N-(pyrimidin-5- yl)imidazo[ 1 ,2-a]pyridin-6-amine (104). 4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methyl-N-(tetrahydro- 2H-pyran-4-yl)pyrimidin-2-amine (180 mg, 0.46 mmol) and pyrimidin-5 -amine (45.0 mg, 0.46 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 104 as a yellow sticky liquid (30 mg, 16%). ¾-NMR (CDC13): δ 1.70- 1.72 (m, 2H), 1.92 (d, 2H, J = 1 1.0 Hz), 2.35 (s, 3H), 3.42 (br, 2H), 3.89-3.96 (m, 3H), 6.60 (s, 1H), 7.25 (br, 1H), 7.74 (d,
I H, / = 9.5 Hz), 8.14 (s, 1 H), 8. 15 (s, 1 H), 8.24 (s, 1 H), 8.54 (s, 2H), 8.76 (s, 1 H), 9.8 1 (s, 1 H). HRMS (ESI) m/z [M+H]+ calcd. for C21H23N80+, 403.1991.
[00204] ( lr,4r)-4-((5-Methyl-4-(6-phenylimidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2- yl)amino)cyclohexan- 1 -ol (105). ( 1 r,4r)-4-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)amino)cyclohexan- 1 -ol ( 100 mg, 0.25 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (5 1.0 mg, 0.25 mmol) were reacted according to general synthetic procedure C to give 105 as a white solid (70.0 mg, 70%). 1 H-NMR (CDC13): δ 1. 19- 1.25 (m, 4H), 1.80 (d, 2H, J = 10.0 Hz), 2.10 (d, 2H, J =
I I .5 Hz), 2.41 (s, 3H), 3.49-3.52 (m, 2H), 3.71 -3.73 (m, 1 H), 4.89 (d, 1 H, 7 = 7.0 Hz), 7.42 (t, 1 H, 7 = 7.0 Hz), 7.50 (t, 2H, J = 7.0 Hz), 7.56-7.60 (m, 3H), 7.79 (d, 1 H, / = 9.5 Hz), 8. 15 (s, 1 H), 8.20 (s, 1 H), 9.95 (s, 1 H). HRMS (ESI) m/z [M+H]+ 400.2137.
[ 00205J ( lr,4r)-4-((5-Methyl-4-(6-(pyridin-3-ylamino)imidazo| l ,2-a|pyridin-3-yl)pyrimidin-2- yl)amino)cyclohexan- 1 -ol (106) and ( lr,4r)-4-((4-(Imidazo[ 1 ,2-a1pyridin-3-yl)-5-methylpyrimidin-2- yl)amino)cvclohexan- l -ol (107). ( 1 r,4r)-4-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)amino)cyclohexan- l -ol (200 mg, 0.50 mmol) and pyridin-3-amine (47.0 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give: 106 as a yellow solid (40 mg, 19%). 1 H-NMR (MeOD-i¾: δ 1.4- 1.29 (m, 4H), 1.89- 1.91 (m, 2H), 1.98-2.00 (m, 2H), 2.39 (s, 3H), 3.61 -3.65 (m, 3H), 7.22 (s, 1H), 7.30-7.32 (m, 2H), 7.79 (d, 1 H, J = 9.5 Hz), 8.09 (s, 2H), 8.20 (s, 1 H), 8.25 (s, 1 H), 8.44 (s, 1H), 9.90 (s, 1H) (one secondary amine proton (NH) signal not observed). HRMS (ESI) m/z [M+H]+ 416.2198. 107 as a white solid (40 mg, 28%). 1 H-NMR (DMSO-J6): δ 1.25- 1.35 (m, 4H), 1.89 (d, 2H, / = 10.5 Hz), 1.97 (d, 2H, / = 10.0 Hz), 2.34 (s, 3H), 3.43-3.45 (m, 1H), 3.68-3.69 (m, 1H), 4.58 (s, 1H), 6.99 (d, 1H, / = 8.0 Hz), 7.09 (t, 1H, J = 7.0 Hz), 7.49 (t, 1H, J = 7.5 Hz), 7.77 (d, 1H, J = 9.0 Hz), 8.24 (s, lH), 8.25 (s, lH), 9.90 (s, 1H). HRMS (ESI) m/z. [M+H]+ 324.1826.
[00206] ( lr,4r)-4-((5-Methyl-4-(6-(pyrimidin-5-ylamino
yl)amino)cvclohexan- 1 -ol (108). ( 1 r,4r)-4-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin- 2-yl)amino)cyclohexan- l-ol (200 mg, 0.50 mmol) and pyrimidin-5 -amine (48.0 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 108 as an orange solid (35 mg, 17%). Ή-NMR (MeOO-d4): δ 1.28-1.33 (m ,4H), 1.87-1.90 (m, 2H), 1.98-2.00 (m, 2H), 2.38 (s, 3H), 3.38 (s, 1H), 3.51- 3.56 (m, 1H), 3.65-3.67 (m, 1H), 7.47 (d, 1H, J = 9.5 Hz), 7.72 (d, 1H, J = 9.5 Hz), 8.17 (s, 1H), 8.18 (s, 1H), 8.58 (s, 2H), 8.63 (s, 1H), 9.91 (s, 1H) (two secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 417.2149.
[00207] N'-Methyl-N4-(5-Methyl-4-(6-(pyrinddin-5-ylamino)imidazo[ l ,2-a1pyridin-3- yl)pyrirnidin-2-yl)cyclohexane-l ,4-diarnine (109). N1-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)-N4-methylcyclohexane- 1 ,4-diamine ( 100 mg, 0.24 mmol) and pyrimidin-5 -amine (23.0 mg, 0.24 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 109 as a yellow solid (60 mg, 58%). Ή-NMR (MeOD-i¾): δ 1.39- 1.46 (m, 2H), 1.65- 1.67 (m, 1 H), 1.78- 1.82 (m, 1 H), 1.88 (br s, 1 H), 1 .97- 1 .99 (m, 2H), 2. 15 (br s, 2H), 2.35-2.37 (m, 3H), 3.05-3.09 (m, 1 H), 3.72-3.74 (m, 1 H), 3.93-3.95 (m, 1 H), 7.42 (d, 1 H, J = 9.5 Hz), 7.69 (t, 1H, / = 9.0 Hz), 8. 1 1 -8.21 (m, 2H), 8.55-8.64 (m, 3H), 9.83 (s, 1 H) (three secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 430.2468.
L00208J ( ls,3r,5R,7S)-3-((5-Fluoro-4-(6-phenylimidazo| l ,2-alpyridin-3-yl)pyrimidin-2- yl)amino)-5,7-dimethyladamantan- 1 -ol (110). ( ,3r,5R,7S)-3-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)- 5-fluoropyrimidin-2-yl)amino)adamantan- l -ol (80 mg, 0. 18 mmol) and 4,4,5,5-tetramethyl-2-phenyl- 1 ,3,2-dioxaborolane (36.0 mg, 0.18 mmol) were reacted according to general synthetic procedure C to give 110 as a yellow solid (80.0 mg, 92%). Ή-NMR (DMSO- 6): δ 1.21 - 1.23 (m, 2H), 1.38- 1.40 (m, 4H), 1.82- 1.92 (m, 6H), 2.01 -2.04 (m, 2H), 3. 18-3. 19 (m, 1 H), 4.40 (s, 1 H), 6.94 (s, 1 H), 7.45 (t, 1 H, J = 7.0 Hz), 7.53 (t, 2H, J = 7.0 Hz), 7.58 (d, 2H, J = 7.0 Hz), 7.83 (d, 1 H, J = 9.0 Hz), 7.90 (d, 1 H, J = 9.0 Hz), 8.30 (s, 1H), 8.45 (s, 1H), 9.90 (s, 1H). HRMS (ESI) m/z | M+HJ+ 484.2513.
[00209] ( l s.3r.5R.7S)-3-((5-Fluoro-4-(6-(pyrimidin-5-ylamino)imidazon .2-a1pyridin-3- yl)pyrimidin-2-yl)amino)-5,7-dimethyladamantan- 1 -ol (111). ( ls,3r,5R,7S)-3-((4-(6-Bromoimidazo[ l ,2- a]pyridin-3-yl)-5-fluoropyrimidin-2-yl)amino)adamantan- l -ol ( 120 mg, 0.26 mmol) and pyrimidin-5- amine (25.0 mg, 0.26 mmol) were reacted according to general synthetic procedure B to give 111 as a yellow solid (60.0 mg, 46%). Ή-NMR (DMSO-<¾): δ 1.42- 1.56 (m, 6H), 1.91 -2.07 (m, 8H), 3. 17-3. 19 (m, 3H), 4.10-4.1 1 (m, 1H), 4.55 (s, 1H), 6.53 (s, 1H), 7.50 (d, 1H, J = 9.0 Hz), 7.80 (d, 1H, J = 9.5 Hz), 8.27 (d, 1H, J = 4.0 Hz), 8.41 (d, 1H, J = 3.0 Hz), 8.59 (s, 2H), 8.60 (s, 1H), 8.68 (s, 1H), 9.91 (s, 1H). HRMS (ESI) m/z. [M+H]+ 501.2526.
[00210] N 1 -(5-Methyl-4-( 6-( pyrimidin-5-ylamino)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2-yl)-N4-
(2,2,2-trifluoroethyl)cyclohexane- l ,4-diamine (112). Nl-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5- methylpyrinrddin-2-yl)-A^-(2,2,2-trifluoroethyl)cyclohexane- l ,4-diamine ( 100 mg, 0.21 mmol) and pyrimidin-5 -amine (20.0 mg, 0.21 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 112 as a yellow solid (20 mg, 19%). 'H-NMR (MeOD-£¾: δ 1.10-1.12 (m, 2H), 1.30-1.37 (m, 2H), 1.92- 1.94 (m, 2H), 2.05-2.07 (m, 2H), 2.41 (s, 3H), 2.57 (t, 1H, J = 12.5 Hz), 3.25 (q, 2H, J = 13.5 Hz), 3.72 (t, 1H, J = 12.5 Hz), 7.50 (d, 1H, J = 9.0 Hz), 7.75 (d, 1H, J = 9.0 Hz), 8.20 (s, 2H), 8.22 (s, 1H), 8.57 (s, 2H), 8.67 (s, 1H), 9.90 (s, 1H) (two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 498.2339.
[0021 1] N-(4-((5-Methyl-4-(6-(pyrimidin-5-ylamino)imidazo[ l ,2-a1pyridin-3-yl)pyrimidin-2- yl)amino)cyclohexyl)acetamide (113). To a solution of (lr,4r)-N1-(5-methyl-4-(6-(pyrimidin-5- ylamino)imidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine (380 mg, 0.92 mmol) and triethylamine ( 1 mL) in dioxane (3 niL) was added acetyl chloride (71 μί, 1.00 mmol). The reaction was stirred overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 6% MeOH + 1 % NH3 (32% in water).to give 113 as a yellow solid (200 mg, 48%). Ή-NMR (MeOD-i/4): δ 1.22- 1.24 (m, 2H), 1 .31 - 1 .36 (m, 2H), 1 .86- 1.89 (m, 2H), 1.94 (s, 3H), 2.00-2.04 (m, 2H), 2.32 (s, 3H), 3.61 -3.64 (m, 2H), 7.46 (d, 1 H, J = 9.0 Hz), 7.70 (d, 1 H, J = 9.5 Hz), 8.14 (s, 3H), 8.55 (s, 2H), 8.64 (s, 1 H), 9.83 (s, 1H) (two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 458.241 8.
[00212] ( lr,4r)-N'-(4-(6-Bromo-7-(trifluoromethyl)imidazo[ 1 ,2-alpyridin-3-yl)-5-methylpyrimidin-2- vDcyclohexane- 1 ,4-diamine (114). 6-Bromo-3-(2-chloro-5-methylpyrimidin-4-yl)-7-(trifluoromethyl) imidazo[ l ,2-a]pyridine (200 mg, 0.5 1 mmol) and ( l ,4r)-cyclohexane- l ,4-diamine ( 176 mg, 1.54 mmol) were reacted according to general synthetic procedure A(ii) to give 114 as a yellow powder (80.0 mg, 34%). Ή-NMR (CDC13): δ 1.34- 1.36 (m, 4H), 1.94- 1.96 (m, 2H), 2. 18-2.20 (m, 2H), 2.37 (s, 3H), 2.73- 2.76 (m, 1 H), 3.8 1 -3.83 (m, 1 H), 5.00 (d, 1 H, 7 = 7.5 Hz), 8.1 1 (s, 1 H), 8.22 (s, 1 H), 8.24 (s, 1 H), 10.09 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z | M+HJ+ 469.0962.
[00213] ( lr,4r)-N'-(5-Methyl-4-(6-(pyrimidin-5-ylamino)imidazo[ l ,2-alpyridin-3-yl)pyrimidin-2- vDcyclohexane- 1 ,4-diamine (115). ( 1 r,4r)-/V'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (400 mg, 1.00 mmol) and pyrimidin-5-amine (96 mg, 1.00 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 115 as a yellow solid (290 mg, 70%). Ή-NMR (DMSO- 6): δ 1.26- 1.29 (m, 4H), 1.88- 1.92 (m, 4H), 2.33 (s, 3H), 2.91-2.93 (m, 1H), 3.60-3.63 (m, 1H), 6.83 (s, 1H), 7.41 (d, 1H, J = 9.5 Hz), 7.76 (d, 1H, / = 9.5 Hz), 8.20 (s, 1H), 8.24 (s, 1H), 8.55 (s, 2H), 8.59 (s, 1H), 8.64 (s, 1H), 9.69 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z LM+HJ+ 416.2310.
[00214] ( lr,4r)-N'-(5-Methyl-4-(6-(pyrirmdin-4-ylamino)irm
vDcyclohexane- 1 ,4-diamine (116). ( 1 r,4r)-Nl -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (200 mg, 0.50 mmol) and pyrimidin-4-amine (47 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 116 as a yellow solid (20 mg, 19%). Ή-NMR (MeOO-d4): δ 1.43- 1.45 (m, 4H), 2.02-2.05 (m, 2H), 2.20-2.22 (m, 2H), 2.41 (s, 3H), 3.10-3.13 (m, 1H), 3.90-3.93 (m, 1H), 6.90 (d, 1H, J = 6.0 Hz), 7.55 (d, 1H, J = 10.0 Hz), 7.70 (d, 1H, J = 9.5 Hz), 8.13 (s, 1H), 8.28 (s, 1H), 8.30 (s, 1H), 8.49 (s, 1H), 8.67 (s, 1H), 10.60 (s, 1H) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 416.231 1.
[00215] (4-(3-(2-((( lr,4r)-4-Aminocyclohexyl)amino)-5-fluoropyrim
yl)phenyl)(piperazin- l-yl)methanone (117). ( 1 r,4r)-N1-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin- fluoropyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.37 mmol) and tert-butyl 4-(4-(4,4,5,5- tetramethyl-l ,3,2-dioxaborolan-2-yl)benzoyl)piperazine-l-carboxylate (154 mg, 0.37 mmol) ) were reacted according to general synthetic procedure C to give tert-butyl 4-(4-(3-(2-((( 1 r,4r)-4-amino cyclohexyl)amino)-5-fluoropyrimidin-4-yl)imidazo[ l ,2-fl]pyridin-6-yl)benzoyl)piperazine- l-carboxylate (205 mg). The latter was heated at reflux in 3M HCl (4 mL) and MeOH (4 mL) for 6 h, basified with 2M NaOH, and extracted with DCM (3 X 100 mL). Organic extracts were combined, concentrated under reduced pressure and purified by preparative HPLC to give 117 as a yellow solid (90 mg, 47%). Ή-NMR (DMSO-i¾): δ 1.04- 1.07 (m, 2H), 1.20- 1.27 (m, 2H), 1.65- 1.69 (m, 2H), 1.91 - 1.94 (m, 2H), 2.27-2.29 (m, 3H), 3.33-3.36 (m, 4H), 3.74-3.80 (m, 3H), 7.27 (t, 1H, J = 6.5 Hz), 7.33-7.38 (m, 5H), 7.73 (d, 1H, J = 9.5 Hz), 8.13 (s, 1H), 8.24 (s, 1H), 10.38 (s, 1H). HRMS (ESI) m/z LM+HJ+ 515.2685.
[00216] ( lr,4r)-N'-(5-Chloro-4-(7-(pyrimidin-5-ylamino)imidazo[ 1 ,2-alpyridin-3-yl)pyrimidin-2- vDcyclohexane- 1 ,4-diamine (118). ( 1 r,4r)-N'-(4-(7-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-chloro pyrimidin-2-yl)cyclohexane- l ,4-diamine (200 mg, 0.48 mmol) and pyrimidin-5-amine (45 mg, 0.48 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 118 as a yellow solid (110 mg, 53%). Ή-NMR (DMSO-J6): δ 1.17-1.22 (m, 2H), 1.33-1.35 (m, 2H), 1.83-1.85 (m, 2H), 1.97-2.00 (m, 2H), 2.60-2.62 (m, 1H), 3.65-3.67 (m, 1H), 6.93 (s, 1H), 7.24 (s, 1H), 7.42 (d, 1H, J = 8.0 Hz), 8.34 (s, 1H), 8.64 (s, 1H), 8.81 (s, 2H), 8.86 (s, 1H), 9.28 (s, 1H), 9.86 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z. LM+HJ+ 436.1763.
[00217] 3-(2-((( 1 r,4r)-4-( Aziridin- 1 -yl)cyclohexyl)amino)-5-methylpyrimidin-4-yl)-N-(pyrimidin-5- yDimidazol l,2-a|pyridin-7-amine (119). A suspension of N'-(5-methyl-4-(6-(pyrimidin-5-ylamino) imidazo[l,2-Jpyridin-3-yl)pyrimidin-2-yl)cyclohexane-l,4-diamine (160 mg, 0.39 mmol) and K3P04 (409 mg, 1.93 mmol) in l-bromo-2-chloroethane (0.5 mL) and MeCN (3 mL) was heated in a pressurised tube at 120 °C for 3 h, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 5% MeOH + 0.5% NH3 (32% in water) to afford 119 as a yellow powder (20 mg, 12%). Ή-NMR (MeOD-i¾: δ 1.15-1.37 (m, 6H), 1.70-1.72 (m, 2H), 1.86-1.88 (m, 2H), 2.00-2.04 (m, 2H), 2.37 (s, 3H), 3.68-3.73 (m, 1H), 7.45 (dd, 1H, J = 9.5 & 2.0 Hz), 7.71 (d, 1H, J = 9.5 Hz), 8.14 (s, 1H), 8.18 (s, 1H), 8.56 (s, 2H), 8.61 (s, 1H), 9.85 (d, 1H, J = 2.0 Hz) (two secondary amine (NH) protons and one CH proton signals not observed). HRMS (ESI) m/z [M+H]+ 442.2466.
[00218] N1-(4-(6-((5-Fluoropyridin-3-yl)amino)imidazo[l,2-a1pyridin-3-yl)-5-methylpyrimidin- 2-yl)-N4,N4-dimethylcyclohexane- 1 ,4-diamine (120). N1-(4-(6-Bromoimidazo[l,2- ]pyridin-3-yl)-5- methylpyrimidin-2-yl)-N4,N4-dimethylcyclohexane-l,4-diamine (100 mg, 0.23 mmol) and 5- fluoropyridin-3-amine (26 mg, 0.23 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 120 as a yellow solid (50 mg, 47%). 1 H-NMR (MeOD-i/4): δ 1.25-1.34 (m4H), 1.83-1.85 (m, 2H), 2.10-2.12 (m, 2H), 2.21 (s, 6H), 2.30 (t, 1H,7 = 11.5 Hz), 2.40 (s, 3H), 3.68 (t, 1H,7 = 11.0 Hz), 7.27 (dt, 1H,7 = 11.0 & 2.5 Hz), 7.48 (dd, 1H, 7 = 9.5 & 2.5 Hz), 7.73 (d, 1H, 7= 9.5 Hz), 7.91 (t, 1H, 7=2.5 Hz), 8.17 (s, 1H), 8.18 (s, 1H), 8.20 (s, 1H), 9.91 (s, 1H). HRMS (ESI) m/z [M+H]+ 460.2503.
[00219] (lr,4r)-N1-Isopropyl-N4-(5-methyl-4-(6-(pyrimidin-5-ylamino)imidazo[L
yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (121). ( 1 r,4r)- -(5-Methyl-4-(6-(pyrimidin-5-ylamino) imidazo[l,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane-l,4-diamine (85 mg, 0.20 mmol) and acetone (73 μΕ, 1.00 mmol) were reacted according to general synthetic procedure D to give 121 as a white powder (40 mg, 45%). Ή-NMR (MeOd-i¾): δ 1.08-1.11 (m, 8H), 1.30-1.34 (m, 2H), 1.93-1.95 (m, 2H), 2.04- 2.07 (m, 2H), 2.40 (s, 3H), 2.61-2.63 (m, 1H), 2.96-2.98 (m, 1H), 3.68-3.70 (m, 1H), 7.49 (dd, 1H, 7 = 9.5
62.0 Hz), 7.74 (d, 1H,7 = 9.5 Hz), 8.18 (s, 1H), 8.21 (s, 1H), 8.56 (s, 2H), 8.65 (s, 1H), 9.87 (d, 1H,7 = 2.0 Hz) (three secondary amine proton (NH) signals not observed). HRMS (ESI) m/z. [M+H]+ 443.2545.
[00220J (lr,4r)-N'-(5-Methyl-4-(6-(methyl(pyridin-3-yl)amino)imidazo|l,2-a|pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (122). ( 1 r,4r)-jV'-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (220 mg, 0.55 mmol) and jV-methylpyridin-3-amine (56 μί, 0.55 mmol) were reacted according to general synthetic procedure B to give 122 as a yellow solid (30 mg, 13%). Ή-NMR (CDC13): δ 1.01 (br s, 2H), 1.23 (q, 2H,7= 14.5 Hz), 1.79 (d, 2H,7= 12.0 Hz), 2.06 (d, 2H,7= 12.0 Hz), 2.38 (s, 3H), 2.60 (t, 1H,7= 10.0 Hz), 3.38 (s, 3H), 3.70 (t, 1H,7= 10.0 Hz), 4.85 (d, 1H, 7= 8.0 Hz), 7.12-7.18 (m, 2H), 7.22 (dd, 1H, 7= 9.5 & 2.0 Hz), 7.73 (d, 1H, 7= 9.5 Hz), 8.12 (d, 1H, 7= 5.0 Hz), 8.14 (s, 1H), 8.19 (s, 1H), 8.30 (s, 1H), 9.66 (s, 1H) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z [M+H\+ 429.2518.
[00221] (lr.4r)-N'-(4-(6-((6-Fluoropyridin-3-yl)amino)imidazo[l,2-alpyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (123). ( 1 r,4r)-Nl -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3- yl)-5-methylpyrimidin-2-yl)cyclohexane-l,4-diamine (200 mg, 0.50 mmol) and 6-fluoropyridin-3-amine (56 mg, 0.50 mmol) were reacted according to general synthetic procedure B to give 123 as an orange solid (90 mg, 42%). Ή-NMR (MeOD-<¾: δ 1.18 (br s, 2H), 1.33 (q, 2H, 7 = 11.5 Hz), 1.87 (d, 2H, 7 = 10.0 Hz), 2.02 (d, 2H,7= 11.0 Hz), 2.36 (s, 3H), 2.69 (br s, 1H), 3.65 (t, 1H,7= 11.0 Hz), 6.98 (dd, 1H,
7 = 9.0 & 3.0 Hz), 7.38 (dd, 1H, 7 = 9.5 & 2.0 Hz), 7.62-7.69 (m, 2H), 7.99 (br s, 1H), 8.10 (s, 1H), 8.17 (s, 1H), 9.72 (d, 1H, 7= 2.0 Hz). HRMS (ESI) m/z [M+H]+ 432.2190.
[00222] 8-(4-(Imidazo[l,2-a1pyridin-3-yl)-5-methylpyrimidin-2-yl)-2,8-diazaspiro[4.5]decan-l- on (124).8-(4-(6-Bromoimidazo[l,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)-2,8-diazaspiro[4.5]decan- 1-one (200 mg, 0.45 mmol) and pyrimidin-5 -amine (44 mg, 0.45 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 124 as a yellow solid (50 mg, 31%). Ή-NMR (CDC13): δ 1.54 (d, 2H,7= 13.5 Hz), 1.96 (ddd, 2H,7= 14.0, 11.5 & 4.5 Hz), 2.15 (t, 2H, J = 7.0 Hz), 2.35 (s, 3H), 3.29 (ddd, 2H, J = 13.5, 1 1.0 & 3.0 Hz), 3.40 (t, 2H, J = 7.0 Hz), 4.54 (td, 2H, / = 13.5 & 4.0 Hz), 6.96 (dt, 1H, J = 7.0 & 0.5 Hz), 7.01 (s, 1H), 7.39 (ddd, 1H, J = 7.5, 7.0 & 0.5 Hz), 7.82 (d, 1 H, J = 9.0 Hz), 8.20 (s, 1 H), 8.26 (s, 1 H), 9.49 (d, 1 H, J = 7.0 Hz). HRMS (ESI) m/z [M+H]+ 363.1972.
[00223] 8-(5-Methyl-4-(6-phenylimidazor i ,2-alpyri
1 -one (125). 8-(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)-2,8- diazaspiro[4.5]decan- l -one ( 100 mg, 0.23 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (46.0 mg, 0.23 mmol) were reacted according to general synthetic procedure C to give 125 as a yellow solid (50.0 mg, 50%). Ή-NMR (DMSO-ifc): δ 1.40 (d, 2H, J = 13.5 Hz), 1.69 (dt, 2H, J = 13.0 & 4.0 Hz), 2.06 (t, 2H, / = 6.5 Hz), 2.38 (s, 3H), 3. 16-3.28 (m, 4H), 4.50 (td, 2U, J = 13.5 & 3.5 Hz), 7.44 (t, \ U, J = 7.5 Hz), 7.50 (t, 2H, J = 7.0 Hz), 7.63 (s, 1 H), 7.70 (d, 2H, J = 7.0 Hz), 7.82 (dd, 1 H, J = 9.0 & 1.5 Hz), 7.87 (d, 1H, / = 9.0 Hz), 8.30 (s, 1H), 8.38 (s, 1 H), 9.91 (s, 1 H). HRMS (ESI) m/z [M+H]+ 439.2245.
[ 00224J N-( ( lr,4r)-4-( (5-Methyl-4-(6-(pyrirmdin-5-ylamino)imidazo| 1 ,2-a lpyridin-3- yl)pyrimidin-2-yl)amino)cyclohexyl)methanesulfonamide (126). To a solution of ( l r,4r)-iV'-(5-methyl-4- (6-(pyrimidin-5-ylamino)imidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (80 mg, 0.19 mmol) and triethylamine (32 μΐ., 0.39 mmol) in DCE (5 mL) cooled on an ice bath was added methanesulfonyl chloride (32 μΐ., 0.39 mmol). The reaction was stirred overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 6% MeOH + 1 % NH3 (32% in water).to give 126 as a white solid (20 mg, 21 %). Ή-NMR (DMSO-i¾): δ 1.25- 1.28 (m, 4H), 1.85- 1.88 (m, 4H), 2.33 (s, 3H), 2.90 (s, 3H), 3.01 -3.04 (m, 1 H), 3.52-3.54 (m, 1 H), 6.91 (s, 2H), 7.41 (d, 1H, J = 9.0 Hz), 7.76 (d, 1Η, / = 9.5 Hz), 8.18 (s, 1H), 8.25 (s, 1H), 8.59 (s, 3H), 8.67 (s, 1H), 9.73 (s, 1H). HRMS (ESI) m/z [M+H]+ 494.2088.
[00225] ( 1 r.4r)-N ' -(4-(6-((6-Methoxypyridin-3-yl)amino)imidazo [ 1 ,2-alpyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (127). ( 1 r,4r)- V' -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3- yl)-5-methylpyrimidin-2-yl)cyclohexane- l ,4-diamine (600 mg, 1.50 mmol) and 6-methoxypyridin-3- amine ( 186 mg, 2.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 127 as an orange solid (200 mg, 30%). Ή-NMR (MeOD- d4): δ 1.26-1.55 (m, 4H), 2.06 (dd, 4H, J = 27.0 & 12.0 Hz), 2.35 (s, 3H), 3.02-3.15 (m, 1H), 3.60-3.74 (m, 1H), 3.90 (s, 3H), 6.81 (d, 1H, J = 8.5 Hz), 7.32 (dd, 1H, J = 9.5 & 2.0 Hz), 7.60 (d, 1H, J = 9.5 Hz), 7.63 (dd, 1H, J = 9.0 & 3.0 Hz), 8.01 (d, 1H, J = 3.0 Hz), 8.03 (s, 1H), 8.19 (s, 1H), 8.45 (s, 1H), 9.39 (s, 1H). HRMS (ESI) m/z [M+H]+ 445.2463.
[00226] ( lr,4r)-Nl-(5-Methyl-4-(6-(pyridin-2-ylanrdno)imidazo[ l ,2-a1pyridin-3-yl)pyrinrddi yl)cyclohexane-1.4-diamine (128). (lr,4r)-N1-(4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine (150 mg, 0.38 mmol) and pyridin-2-amine (35 mg, 0.38 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 128 as an orange solid (40 mg, 25%). Ή-NMR (MeOO-d4): δ 1.03 (br s, 2H), 1.26- 1.33 (m, 2H), 1.78 (br s, 2H), 2.08 (d, 2H, J = 1 1.5 Hz), 2.39 (s, 3H), 2.60 (t, 1 H, J = 1 1.0 Hz), 3.87 (br s, 1 H), 6.79 (dd, 1 H, J = 7.0 & 5.5 Hz), 6.86 (d, 1H, J = 8.5 Hz), 7.47 (d, 1 H, J = 9.0 Hz), 7.59 (ddd, 1H, J = 9.0, 8.0 & 2.0 Hz), 7.61 (d, 1 H, 7 = 9.5 Hz), 8.04 (s, 1 H), 8.14 (d, 1 H, J = 4.0 Hz), 8.23 (s, 1 H), 8.45 (br s, 1 H), 10.47 (d, 1H, / = 1.5 Hz) (two primary amine protons (NH2) and one secondary amine proton (NH) signals not observed). HRMS (ESI) m/z. [M+H]+ 415.2357.
[ 00227J ( lr,4r)-N'-(2-Methoxyethyl)-N4-(5-methyl-4-(6-phenylirnidazor i ,2-a1pyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (129) and ( l s,4s)-N'-(2-Methoxyethyl)-N4-(5-methyl-4-(6- phenylimidazoi 1 ,2-alpyridin-3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (130). 4-((5-Methyl-4-(6- phenylimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexan- l -one ( 130 mg, 0.33 mmol) and 2- methoxyethan- 1 -amine (29 μί, 0.38 mmol) were reacted according to general synthetic procedure D. The product was purified by preparative HPLC to give: 129 as a white solid (25 mg, 17%). 1 H-NMR (CDC13): δ 1.01 (br s, 2H), 1.20 (q, 2H, / = 12.5 Hz), 1.60 (br s, 2H), 2. 14 (d, 2H, / = 1 1.5 Hz), 2.39 (s, 3H), 2.74 (br s, 1H), 2.87 (s, 2H), 3.38 (s, 3H), 3.58 (s, 2H), 3.71 (br s, 1H), 5.18 (br s, 1H), 7.42 (t, 1H, / = 7.0 Hz), 7.49 (t, 2H, J = 7.5 Hz), 7.55-7.61 (m, 3H), 7.80 (d, 1H, J = 9.0 Hz), 8.14 (s, 1H), 8.18 (s, 1H), 8.40 (s, 1H), 9.85 (s, 1H). HRMS (ESI) m/z. | M+HJ+ 457.2714. 130 as a white solid ( 15 mg, 10%). 1 H-NMR (CDC13): δ 1.60 (br s, 2H), 1.72 (br s, 4H), 1.87 (br s, 2H), 2.39 (s, 3H), 2.85 (br s, 1H), 2.99 (s, 2H), 3.35 (s, 3H), 3.60 (s, 2H), 4.14 (br s, 1H), 5.84 (br s, 1H), 7.40 (t, 1H, J = 7.5 Hz), 7.46 (t, 2H, J = 7.0 Hz), 7.57 (d, 2H, J = 7.5 Hz), 7.60 (dd, 1H, J = 9.0 & 1.5 Hz), 7.79 (d, 1H, J = 9.5 Hz), 8.16 (s, 2H), 8.43 (br s, 1H), 9.96 (br s, 1H). HRMS (ESI) m/z [M+H]+ 457.2715.
[00228] ( lr.4r)-N'-Ethyl-N4-(5-methyl-4-(6-phenylimidazon .2-alpyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (131) and ( ls,4s)-N'-ethyl-N4-(5-Methyl-4-(6-phenylimidazo| 1 ,2-alpyridin- 3-yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (132). 4-((5-Methyl-4-(6-phenylimidazoL l ,2- Jpyridin-3- yl)pyrimidin-2-yl)amino)cyclohexan- l-one (150 mg, 0.38 mmol) and ethanamine (2M in THF, 130 μL·, 0.33 mmol) were reacted according to general synthetic procedure D. The product was purified by preparative HPLC to give: 131 as a white solid (30 mg, 19%). Ή-NMR (CDC13): δ 1.10- 1.40 (m, 7H), 1.94 (br s, 2H), 2.16 (d, 2H, J = 1 1.0 Hz), 2.38 (s, 3H, CH3), 2.78 (br s, 2H), 3.76 (s, 1H), 4.93 (d, 1H, J = 7.0 Hz), 7.40 (t, 1H, J = 7.5 Hz), 7.48 (t, 2H, J = 7.5 Hz), 7.57 (d, 3H, J = 7.5 Hz), 7.78 (d, 1H, J = 9.5 Hz), 8.10 (s, 1H), 8.21 (s, 1H), 8.47 (s, 1H), 9.71 (s, 1H). HRMS (ESI) m/z [M+H]+ 427.2609.
132 as a white solid (25 mg, 16%). Ή-NMR (CDC13): δ 1.31 (t, 3H, J = 7.0 Hz), 1.45-2.00 (m, 8H), 2.36 (s, 3H), 2.80-2.98 (m, 2H), 3.60-3.70 (m, 1H), 4.14 (br s, 1H), 5.94 (d, 1H, J = 7.0 Hz), 7.38 (t, 1H, J = 7.0 Hz), 7.45 (t, 2H, J = 7.0 Hz), 7.56 (d, 2H, J = 9.0 Hz), 7.59 (dd, 1H, / = 1 1.5 & 1.5 Hz), 7.78 (d, 1H, / = 9.0 Hz), 8.14 (s, 1H), 8.15 (s, 1H), 8.53 (s, 1H), 9.96 (s, 1H). HRMS (ESI) m/z. [M+H]+ 427.2607. [00229] ( lr,4r)-N'-Methyl-N4-(5-methy^^
vDcyclohexane- 1 ,4-diamine (133). 4-((5-Methyl-4-(6-phenylimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2- yl)amino)cyclohexan- 1 -one ( 150 mg, 0.38 mmol) and methanamine hydrochloride (26 mg, 0.38 mmol) were reacted according to general synthetic procedure D. The product was purified by preparative HPLC to give 133 as a white solid (30 mg, 19%). Ή-NMR (CDC13): δ 1 . 10- 1 .40 (m, 4H), 1.94 (br s, 2H), 2. 17 (d, 2H, J = 9.0 Hz), 2.39 (s, 3H), 2.42 (s, 3H), 2.75 (br s, 1 H), 3.77 (br s, 1 H), 4.99 (br s, 1 H), 7.41 (t, 1 H, / = 7.0 Hz), 7.48 (t, 2H, J = 8.0 Hz), 7.53-7.62 (m, 3H), 7.79 (d, 1 H, J = 9.0 Hz), 8. 1 1 (s, 1 H), 8.21 (s, 1H), 8.46 (s, 1 H), 9.71 (s, 1 H). HRMS (ESI) m/z. [M+H]+ 413.2453.
[00230] ( lr,4r)-N'-(5-Methyl-4-(6-(pyridin-4-ylamino)imidazo[ 1 ,2-a1pyridin-3-yl)pyrimidin-2- vDcyclohexane- 1 ,4-diamine (134). ( 1 r,4r)- -(4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 150 mg, 0.38 mmol) and pyridin-4-amine (35 mg, 0.38 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 134 as an orange solid (40 mg, 25%). Ή-NMR (DMSO- 6): ί 1 .3 1 (br s, 4H), 1.92 (br s, 4H), 2.33 (s, 3H), 2.92 (br s, 1 H), 3.65 (br s, 1 H), 6.70 (br s, 1 H), 6.95 (d, 1 H, J = 8.0 Hz), 7.41 (d, 1H, J = 9.5 Hz), 7.78 (d, 1H, J = 9.5 Hz), 8.21 (s, 2H), 8.26 (s, 1H), 8.33 (br s, 2H), 9.04 (br s, 1H), 9.67 (s, 1H). HRMS (ESI) m/z LM+HJ+ 415.2357.
[00231 ] N-( ( 1 r,4r)-4-( Azetidin- 1 -yl)cyclohexyl)-5-methyl-4-( 6-phenylimidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-amine (135) and N-(( l s,4s)-4-(azetidin- l -yl)cyclohexyl)-5-methyl-4-(6- phenylimidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2-amine (136). 4-((5-Methyl-4-(6-phenylimidazo[ 1 ,2- a]pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexan- l -one ( 150 mg, 0.38 mmol) and azetidine (25 μί, 0.38 mmol) were reacted according to general synthetic procedure D. The product was purified by preparative HPLC to give: 135 as a yellow solid (45 mg, 27%). Ή-NMR (CDC13): δ 1.00- 1.30 (m, 4H), 1.66 (br s, 2H), 2.14 (d, 2H, J = 7.0 Hz), 2.30-2.40 (m, 2H), 2.37 (s, 3H), 2.58 (br s, 1H), 3.74 (br s, 5H), 5.33 (br s, 1H), 7.39 (t, 1H, J = 7.0 Hz), 7.48 (t, 2H, J = 7.5 Hz), 7.55 (d, 2H, J = 7.5 Hz), 7.57 (dd, 1H, J = 9.0 & 1.5 Hz), 7.79 (d, 1H, J = 9.5 Hz), 8.10 (s, 1H), 8.18 (s, 1H), 9.64 (s, 1H). HRMS (ESI) m/z [M+H]+ 439.2610. 136 as a yellow solid ( 15 mg, 10%). Ή-NMR (CDC13): δ 1.52 (br s, 4H), 1.62- 1.78 (m, 2H), 1.84-1.96 (m, 2H), 2.25-2.35 (m, 2H), 2.39 (s, 3H), 2.52 (br s, 1H), 3.20-4.10 (m, 4H), 4.17 (br s, 1H), 5.89 (d, 1H, J = 8.0 Hz), 7.38-7.43 (m, 1H), 7.47 (t, 2H, J = 7.5 Hz), 7.56-7.64 (m, 3H), 7.78 (d, 1H, J = 9.0 Hz), 8.15 (s, 1H), 8.20 (s, 1H), 9.96 (s, 1H). HRMS (ESI) m/z [M+H]+ 439.2609.
[00232] 5-Fluoro-4-(6-phenylimidazo[ l ,2-a1pyridin-3-yl)-N-(( lr,4r)-4-(pyrrolidin- l -yl)cyclohexyl) pyrimidin-2-amine (137). ( 1 ,4r)-N1-(5-Fluoro-4-(6-phenylimidazo[ 1 ,2- ]pyridin-3-yl)pyrimidin-2- yl)cyclohexane-l ,4-diamine (95 mg, 0.24 mmol) and 1 ,4-dibromobutane (30 μί, 0.25 mmol) were reacted according to general synthetic procedure E to give 137 as a yellow solid (40 mg, 37%). 'H-NMR (CDC13): δ 1.24- 1.31 (m, 2H), 1.49- 1.52 (m, 2H), 1.97 (s, 2H), 2.14-2.17 (m, 2H), 2.23-2.25 (m, 2H), 2.31-2.34 (m, 2H), 2.64 (br s, 2H), 309-3.14 (m, 1H), 3.61 (br s, 2H), 3.75-3.77 (m, 1H), 4.89 (d, 1H, J = 7.5 Hz), 7.47 (t, 1H, J = 7.5 Hz), 7.55 (t, 2H, J = 7.0 Hz), 7.62-7.65 (m, 3H), 7.84 (d, 1H, J = 9.5 Hz), 8.24 (d, 1 H, J = 3.5 Hz), 8.48 (d, 1 H, / = 3.5 Hz), 10.1 1 (s, 1 H). HRMS (ESI) m/z. [M+H]+ 457.2516.
[00233] N-(( lr,4r)-4-(Azetidin- 1 -yl)cyclohexyl)-5-fluoro-4-(6-phenylimidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-amine (138). ( 1 r,4r)-Nl -(5-Fluoro-4-(6-phenylimidazo [ 1 ,2-a]pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine (80 mg, 0.20 mmol) and l -bromo-3-chloropropane (22 μΕ, 0.22 mmol) were reacted according to general synthetic procedure E to give 138 as a yellow solid ( 15 mg, 17%). Ή-NMR (CDC13): δ 1.00- 1.40 (m, 4H), 1.70- 1.80 (m, 2H), 2.24 (d, 2H, J = 1 1.0 Hz), 2.28-2.43 (m, 2H), 2.56-2.70 (m, 1 H), 3.75 (br s, 4H), 4.95 (d, 1 H, J = 7.0 Hz), 7.44 (t, 1 H, J = 7.5 Hz), 7.53 (t, 2H, J = 7.5 Hz), 7.60 (d, 2H, 7 = 8.5 Hz), 7.62 (dd, 1 H, J = 9.5 & 2.0 Hz), 7.84 (d, 1 H, J = 9.0 Hz), 8.21 (d, 1 H, 7 = 3.5 Hz), 8.46 (d, 1H, / = 3.5 Hz), 8.49 (s, 1 H), 10.3 (s, 1 H). HRMS (ESI) m/z [M+H]+ 443.2357.
[ 00234J 3-( 2-( ( ( lr,4r)-4-(Azetidin- 1 -yl)cyclohexyl)amino)-5-methylpyrimidin-4-yl)-N-(5- fluoropyridin-3-yl)imidazo[ 1 ,2-alpyridin-6-amine (139). ( l r,4r)-Ar'-(4-(7-((5-Fluoropyridin-3- yl)amino)imidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 160 mg, 0.37 mmol) and 1 -bromo-3-chloropropane (44 μΕ, 0.44 mmol) were reacted according to general synthetic procedure E to give 139 as a yellow solid (20 mg, 12%). Ή-NMR (MeOO-d4): δ 1. 10- 1.45 (m, 4H), 1.96 (br s, 2H), 2.13 (d, 2H, J = 12.0 Hz), 2.37 (s, 3H), 2.35-2.50 (m, 2H), 3.04 (br s, 1H), 3.66-3.78 (m, 1 H), 4.02 (t, 4H, J = 1.5 Hz), 7.28 (td, 1 H, / = 1 1.0 & 2.5 Hz), 7.45 (dd, 1 H, / = 9.5 & 2.0 Hz), 7.70 (d, 1 H, / = 9.5 Hz), 7.91 (d, 1H, J = 2.5 Hz), 8.14 (s, 1H), 8.18 (s, 1H), 8.21 (s, 1H), 8.54 (s, 1H), 9.74 (s, 1H). HRMS (ESI) m/z [M+H]+ 473.2577.
[00235] 5-Methyl-4-(6-phenylimidazor i .2-alpyridin-3-yl)-N-(( l r,4r)-4-(pyrrolidin- l - yl)cyclohexyl)pyrimidin-2-amine (140). ( 1 r,4r)- V'-(5-Methyl-4-(6-phenylimidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine ( 160 mg, 0.38 mmol) and 1 ,4-dibromobutane (67 μΕ, 0.56 mmol) were reacted according to general synthetic procedure E. The product was further purified by preparative HPLC to give 140 as a yellow solid (90 mg, 52%). Ή-NMR (CDC13): δ 1.20- 1.40 (m, 4H), 1.85 (br s, 2H), 1.95 (s, 4H), 2.18 (d, 2H, J = 8.5 Hz), 2.39 (s, 3H), 2.88 (s, 2H), 3.01 (br s, 2H), 3.72 (br s, 1H), 5.59 (br s, 1H), 7.40 (t, 1H, J = 7.0 Hz), 7.48 (t, 2H, J = 7.5 Hz), 7.58 (d, 2H, J = 7.5 Hz), 7.60 (dd, 1H, 7 = 9.5 &1.5 Hz), 7.82 (d, 1H, J = 9.0 Hz), 8.13 (s, 1H), 8.17 (s, 1H), 8.38 (s, 2H), 9.78 (s, 1H). HRMS (ESI) m/z [M+H]+ 453.2766.
[00236] 3-(2-((( 1 r,4r)-4-( Azetidin- 1 -yl)cyclohexyl)amino)-5-methylpyrimidin-4-yl)-N-
(pyrirrddin-5-yl)imidazo[ l ,2-a1pyridin-6-amine (141). ( l r,4r)-N'-(5-Methyl-4-(7-(pyrimidin-5- ylamino)irddazo[ l ,2-a]pyridin-3-yl)pyrirrddin-2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.36 mmol) and l-bromo-3-chloropropane (54 μΐ^, 0.54 mmol) were reacted according to general synthetic procedure E to give 141 as a yellow solid (30 mg, 18%). Ή-NMR (MeOO-d4): δ 1.20-1.42 (m, 4H), 1.99 (d, 2H, J = 7.0 Hz), 2.12 (d, 2H, J = 1 1.5 Hz), 2.34 (s, 3H), 2.45 (br s, 2H), 3.06-3.20 (m, 1H), 3.66-3.75 (m, 1H), 4.1 1 (t, 4H, / = 8.0 Hz), 7.43 (dd, 1H, J = 9.5 & 2.0 Hz), 7.68 (d, 1H, J = 9.0 Hz), 8.1 1 (s, 1H), 8.18 (s, 1H), 8.33 (s, 2H), 8.57 (s, 2H), 8.62 (s, 1 H), 9.75 (s, 1 H). HRMS (ESI) m/z [M+H]+ 456.2625.
[00237] 3-(5-Methyl-2-( ( ( lr,4r)-4-(pyrrolidin- 1 -yl)cyclohexyl)amino)pyrimidin-4-yl)-N-
(pyrimidin-5-yl)imidazo[ 1 ,2-alpyridin-6-amine (142). ( lr,4r)-N1-(5-Methyl-4-(7-(pyrimidin-5- ylamino)imidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine ( 150 mg, 0.36 mmol) and
I , 4-dibromobutane (65 μL·, 0.54 mmol) were reacted according to general synthetic procedure E. The product was further purified by preparative HPLC to give 142 as a yellow solid (30 mg, 18%). Ή-NMR (MeOO-d4): δ 1.30- 1.44 (m, 2H), 1.46- 1.64 (m, 2H), 2.06 (s, 4H), 2.15 (d, 4H, J = 10.5 Hz), 2.34 (s, 3H, CH3), 3.1 1 (t, 1 H, J = 1 1.5 Hz), 3.22-3.42 (m, 2H), 3.67-3.78 (m, 1 H), 7.42 (dd, 1 H, J = 9.5 & 2.0 Hz), 7.67 (d, 1 H, J = 9.5 Hz), 8.10 (s, 1 H), 8. 17 (s, 1 H), 8.39 (s, 2H), 8.57 (s, 2H), 8.62 (s, 1 H), 9.76 (s, 1 H). HRMS (ESI) m/z [M+H]+ 470.2780.
[ 00238 J 5-Fluoro-4-(6-phenylimidazo| l ,2-alpyridin-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine
(143). tert- uty\ 4-((4-(6-bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-fluoropyrimidin-2-yl)amino)piperidine- 1 - carboxylate (860 mg, 1.76 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (359 mg, 1.76 mmol) were reacted according to general synthetic procedure C to give teri-butyl 4-((5-fluoro-4-(6- phenylimidazo[ l ,2-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine- l -carboxylate (800 mg). The latter was stirred at room temperature in 6 M HC1 ( 10 mL) overnight, basified with 6 M NaOH, and extracted with DCM (2 x 400 mL). Organic extracts were combined, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 4% MeOH + 0.05% NH3 (32% in water) to afford 143 as a white solid (550 mg, 81 %). Ή-NMR (CDC13): δ 1.32- 1.44 (m, 2H), 2.05 (d, 2H, J = 10.5 Hz), 2.41 (br s, 2H), 2.95 (d, 2H, / = 12.5 Hz), 3.82-3.93 (m, 1H), 5.02 (d, 1H, J = 8.0 Hz), 7.45 (t, 1H, / = 7.5 Hz), 7.51 (t, 2H, / = 7.0 Hz), 7.59-7.66 (m, 3H), 7.83 (d, 1H, J = 9.5 Hz), 8.21 (d, 1H, J = 3.5 Hz), 8.50 (d, 1H, J = 4.0 Hz), 10.20 (s, 1H). HRMS (ESI) m/z [M+H]+ 389.1887.
[00239] 5-Fluoro-N-( l-Methylpiperidin-4-yl)-4-(6-phenylirmdazo[ l ,2-a1pyridin-3-yl)pyrimidin- 2-amine (144). 4-(6-Bromoimidazo[ l ,2-a]pyridin-3-yl)-5-fluoro-N-( l-methylpiperidin-4-yl)pyrimidin-2- amine (100 mg, 0.25 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (359 mg, 1.76 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 144 as a beige solid (65 mg, 65%). Ή-NMR (CDC13): δ 1.74-1.90 (m, 2H), 2.15 (d, 3H, J =
I I .5 Hz), 2.36 (s, 3H), 3.06 (br s, 2H), 3.87 (br s, 1H), 5.26 (d, 1H, J = 6.5 Hz), 7.48 (t, 1H, J = 7.0 Hz), 7.55 (t, 2H, J = 7.5 Hz), 7.59-7.66 (m, 3H), 7.85 (d, 1H, J = 9.0 Hz), 8.22 (d, 1H, J = 3.5 Hz), 8.40 (s, 1H), 8.52 (d, 1H, J = 4.0 Hz), 10.19 (s, 1H). HRMS (ESI) m/z [M+H]+ 403.2044.
[00240] N-( 1 -(Cyclopropylmethyl)piperidin-4-yl)-5-fluoro-4-(6-phenylimidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-amine (145). A solution of 5-fluoro-4-(6-phenylimidazo[l ,2-a]pyridin-3-yl)-N-(piperidin- 4-yl)pyrimidin-2-amine ( 100 mg, 0.26 mmol), (bromomethyl)cyclopropane (89 μί, 0.78 mmol), Triethylamine (0.2 mL, 2.27 mmol) in DMF (5 mL) was stirred at 90 °C overnight. The reaction mixture was concentrated under reduced pressure and purified by purified by flash column chromatography starting with 100% DCM ramping to 3% MeOH to afford 145 as a white solid ( 15 mg, 13%). Ή-NMR (CDC13): δ 0.25 (s, 2H), 0.60-0.70 (m, 2H), 0.96 (br s, 1 H), 1 .85-2. 10 (m, 2H), 2.21 (d, 2H, J = 12.0 Hz), 2.58 (br s, 2H), 3.44 (br s, 2H), 3.94 (br s, 1 H), 4.94 (s, 2H), 5.61 (s, 1 H), 7.45 (t, 1 H, J = 7.0 Hz), 7.54 (t, 2H, J = 7.5 Hz), 7.59-7.66 (m, 3H), 7.86 (d, 1 H, J = 9.5 Hz), 8.22 (d, 1 H, J = 3.5 Hz), 8.52 (d, 1 H, J = 3.5 Hz), 10.21 (s, 1 H). HRMS (ESI) m/z [M+H]+ 443.2360.
[00241 ] N-( 1 -(Cyclopentylmethyl)piperidin-4-yl)-5-fluoro-4-(6-phenylimidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-amine (146). 5-Fluoro-4-(6-phenylimidazo[ 1 ,2-a]pyridin-3-yl)-N-(piperidin-4- yl)pyrimidin-2-amine ( 100 mg, 0.26 mmol) and cyclopropanecarbaldehyde (28 μί, 0.26 mmol) were reacted according to general synthetic procedure D to give 146 as a white solid ( 100 mg, 82%). Ή-NMR (CDCI3): δ 1.09- 1.21 (m, 2H), 1.45- 1.65 (m, 6H), 1.66- 1.78 (m, 2H), 1.82 ( br s, 1H), 1.90-2.00 (m, 1 H), 2.05 (s, 3H), 2. 10-2.23 (m, 2H), 2.76 (br s, 2H), 3.70-3.85 (m, 1 H), 5.1 1 (d, 1 H, J = 4.0 Hz), 7.44 (t, 1 H, / = 7.5 Hz), 7.52 (t, 2H, J = 7.5 Hz), 7.59-7.65 (m, 3H), 7.84 (d, 1H, J = 9.0 Hz), 8.20 (d, 1H, J = 4.0 Hz), 8.50 (d, 1H, J = 3.5 Hz), 10.21 (s, 1H). HRMS (ESI) m/z, [ M+HJ+ 471.2672.
[00242] 5-Fluoro-N-( 1 -(methylsulfonyl)piperidin-4-yl)-4-(6-phenylimidazo[ 1 ,2-alpyridin-3- yl)pyrimidin-2-amine (147). To a solution of 5-fluoro-4-(6-phenylimidazo[ l ,2-a]pyridin-3-yl)-/V- (piperidin-4-yl)pyrimidin-2-amine ( 130 mg, 0.33 mmol) and triethylamine (44 μί, 0.50 mmol) in DCM ( 10 mL) cooled on an ice bath was added methanesulfonyl chloride (57 μΐ^, 0.98 mmol). The reaction was stirred overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 3% MeOH. The product was further purified by preparative HPLC to give 147 as a yellow solid (40 mg, 26%). Ή-NMR (DMSO-J6): δ 1.54 (q, 2H, / = 10.0 Hz), 1.99 (d, 2H, J = 1 1.0 Hz), 2.68 (br s, 2H), 2.31-2.38 (m, 2H), 3.75-3.92 (m, 1H), 7.44 (d, 1H, J = 8.0 Hz), 7.47 (t, 1H, J = 7.5 Hz), 7.57 (t, 2H, J = 7.5 Hz), 7.79 (d, 2H, J = 7.5 Hz), 7.84 (d, 1H, J = 9.0 Hz), 7.92 (d, 1H, J = 9.0 Hz), 8.39 (d, 1H, J = 4.0 Hz), 8.48 (d, 1H, J = 3.5 Hz), 10.16 (s, 1H) (three methyl protons signals not observed). HRMS (ESI) m/z [M+H]+ 467.1668.
[00243] 4-(3-(5-Fluoro-2-(( l-methylpiperidin-4-yl)arrdno)pyrimidin-4-yl)imidazo[ l ,2-alpyridin- 6-yl)-N,N-dimethylbenzenesulfonamide (148) . 4-(6-Bromoimidazo[ l ,2- ]pyridin-3-yl)-5-fluoro-N-( l- methylpiperidin-4-yl)pyrimidin-2-amine ( 100 mg, 0.25 mmol) and N,N-dimethyl-4-(4,4,5,5-tetramethyl- l ,3,2-dioxaborolan-2-yl)benzenesulfonamide (78 mg, 0.25 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 148 as a yellow solid ( 1 10 mg, 86%). Ή-NMR (DMSO-£¾: δ 1.52 (br s, 4H), 1.85-1.93 (m, 2H), 2.03 (br s, 2H), 2.54- 2.74 (s, 6H), 3.64 (br s, 1H), 7.37 (d, 1H, J = 7.0 Hz), 7.86-8.00 (m, 4H), 8.06 (d, 2H, J = 8.0 Hz), 8.40 (d, IH, J = 4.0 Hz), 8.47 (d, IH, 7 = 3.5 Hz), 10.24 (s, IH) (three methyl protons signals not observed). HRMS (ESI) m/z. [M+H]+ 510.2088.
[00244] 3-(5-Fluoro-2-((l-methylpiperidin-4-yl)annno)pyrirnidin-4-yl)-N-(pyrirni
yl)imidazo[ l,2-alpyridin-6-amine (149). 4-(6-Bromoimidazo[l ,2-a]pyridin-3-yl)-5-fluoro-N-( 1 - methylpiperidin-4-yl)pyrimidin-2-amine (200 mg, 0.50 mmol) and pyrimidin-5 -amine (48 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 149 as a grey solid (65 mg, 31 %). Ή-NMR (CDC13): δ 2.1 1 -2.15 (m, 2H), 2.27-2.30 (m, 2H), 2.75 (s, 3H), 2.89 (br s, 2H), 3.47 (br s, 2H), 4.05 (br s , 1H), 7.37-7.39 (m, IH), 7.76 (d, IH, 7 = 9.5 Hz), 8.16 (d, IH, 7 = 3.5 Hz), 8.40 (s, IH), 8.44 (d, IH, 7 = 3.5 Hz), 8.55 (s, 2H), 8.76 (s, IH), 10.06 (s, IH) (one secondary amine proton (NH) not observed). HRMS (ESI) m/z. [M+H]+ 467.1668. HRMS (ESI) m/z [M+H]+ 420.2061.
[00245J (lr,4r)-Nl-(5-Methyl-4-(6-phenyl-7-(trifluoromethyl)imidazo| l,2-alpyridin-3- yl)pyrimidin-2-yl)cyclohexane- 1 ,4-diamine (150). ( l r,4r)-.V'-(4-(6-Bromo-7-
(trifluoromethyl)imidazo[ 1 ,2-a]pyridin-3-yl)-5-methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 100 mg, 0.21 mmol) and phenylboronic acid (26 mg, 0.21 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 150 as a white solid (45 mg, 46%). Ή-NMR (CDC13): δ 1.08- 1.22 (m, 2H), 1.29 (br s, 2H), 1.85-2.15 (m, 4H), 2.86-3.00 (m, IH), 3.66 (br s, IH), 5.13 (br s, IH), 6.06 (br s, 4H), 7.36-7.48 (m, 5H), 8.16 (s, IH), 8.20 (s, IH), 8.22 (s, IH), 9.37 (s, IH) (two primary amine protons (NH2) not observed. HRMS (ESI) m/z, [M+H]+ 467.2172.
[00246J 5-Methyl-N-((lr,4r)-4-methylcyclohexyl)-4-(6-phenylimidazo| l ,2-a|pyridin-3- yl)pyrimidin-2-amine (151). 4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methyl-/V-(( 1 r,4r)-4- methylcyclohexyl)pyrimidin-2-amine ( 100 mg, 0.25 mmol) and phenylboronic acid (31 mg, 0.25 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 151 as a white solid (60 mg, 61 %). Ή-NMR (DMSO-i¾): δ 0.47 (br s, IH), 0.62 (s, 4H), 1.05-1.25 (m, 3H), 1.39 (s, 2H), 1.89 (d, 2H, 7 = 1 1.0 Hz ), 2.36 (s, 3H), 3.53 (br s, IH), 6.92 (d, 1H, 7 = 7.5 Hz), 7.44 (t, IH, J = 7.0 Hz), 7.52 (t, 2H, 7 = 7.5 Hz), 7.70-7.78 (m, 3H), 7.85 (d, IH, 7 = 9.0 Hz), 8.25 (s, IH), 8.26 (s, IH), 9.99 (s, IH). HRMS (ESI) m/z. [M+H]+ 398.2345.
[00247] 3-(5-Methyl-2-((( lr,4r)-4-methylcyclohexyl)amino)pyrimidin-4-yl)-N-(pyrimidin-5-yl) imidazo[ l,2-a1pyridin-6-amine (152). 4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-methyl-/V-(( 1 r,4r)-4- methylcyclohexyl)pyrimidin-2-amine (200 mg, 0.50 mmol) and pyrimidin-5-amine (48 mg, 0.50 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 152 as an orange solid (70 mg, 34%). Ή-NMR (DMSO-i/6): δ 0.64 (br s, 2H), 1.05-1.35 (m, 2H), 1.47 (br s, 2H), 1.86 (d, 2H, 7 = 6.0 Hz), 2.34 (s, 3H), 3.19 (d, 3H, 7 = 5.5 Hz), 3.50 (br s, IH), 4.11 (q, IH, 7 = 5.5 Hz), 6.82 (br s, IH), 7.42 (dd, 1H, 7 = 9.5 & 2.0 Hz), 7.78 (d, IH, 7 = 9.5 Hz), 8.22 (d, 2H, J = 1 1.5 Hz), 8.51 (s, 2H), 8.58 (s, IH), 8.63 (s, IH), 9.85 (br s, IH). HRMS (ESI) m/z. [M+Hf 415.2357.
[00248] 2-((( lr,4r)-4-((5-Methyl-4-(6-(pyrirmdin-5-yk
yl)aimno)cyclohexyl)amino)acetamide (153) and 2,2'-((( lr,4r)-4-((5-Methyl-4-(6-(pyrimidin-5- ylamino)imidazo[ 1 ,2-alpyridin-3-yl)pyrirnidin-2-yl)amino)cyclohexyl)azanediyl)diacetami (154). A suspension of ( 1 r,4r)-N'-(5-methyl-4-(6-(pyrimidin-5-ylamino)imidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2- yl)cyclohexane- l ,4-diamine ( 100 mg, 0.24 mmol), 3-bromopropanamide (50 mg, 0.36 mmol) and K2C03 (50 mg, 0.36 mmol) in DMF was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 8% MeOH + 1 % NH3 (32% in water). The products were further purified by preparative HPLC to give: 153 as a yellow solid (30 mg, 26%). Ή-NMR (MeOD-<¾: δ 1.37- 1 .48 (m, 4H), 2.09-2. 16 (m, 4H), 3.38 (s, 3H), 3.09 (t, I H, J = 12.5 Hz), 3.73-3.77 (m, 3H), 7.45 (dd, I H, J = 9.0 & 2.0 Hz), 7.71 (d, I H, 7 = 9.5 Hz), 8.14 (s, I H), 8.22 (s, I H), 8.34 (s, 2H), 8.60 (s, 2H), 8.64 (s, IH), 9.76 (br s, I H) (two primary amine protons (NH2) and one secondary amine (NH) signals not observed). HRMS (ESI) m/z LM+HJ+ 473.2743. 154 as a brown solid ( 15 mg, 12%). 'H-NMR (MeOD-J4): δ 1.15-1.40 (m, 4H), 1.70- 1.92 (m, 2H), 2.00-2.15 (m, 2H), 2.38 (s, 3H), 2.45-2.62 (m, IH), 3.16 (br s, 4H), 3.54-3.63 (m, IH), 7.45 (dd, IH, J = 9.0 & 2.0 Hz), 7.72 (d, IH, 7 = 9.5 Hz), 8.16 (s, IH), 8.19 (s, IH), 8.57 (s, 2H), 8.63 (s, IH), 9.86(d, IH, J = 1.5 Hz) (four primary amine protons (NH2) and two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 530.2741.
[00249] N-(4,4-Difluorocyclohexyl)-5-methyl-4-(6-phenylimidazo[ l ,2-alpyridin-3-yl)pyrimidin- 2-amine (155). 4-(6-BromoimidazoL 1 ,2-a]pyridin-3-yl)-N-(4,4-difluorocyclohexyl)-5-methylpyrimidin-2- amine ( 160 mg, 0.38 mmol) and phenylboronic acid (45 mg, 0.38 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 155 as a white solid (65 mg, 41 %). Ή-NMR (CDC13): δ 1.35-1.55 (m, 2H), 1.50-1.62 (m, 2H), 1.80-1.95 (m, 2H), 1.95-2.10 (m, 2H), 2.42 (s, 3H), 3.80-3.92 (m, IH), 5.35 (br s, IH), 7.41-7.46 (m, IH), 7.46-7.52 (m, 2H), 7.54-7.59 (m, 2H), 7.61 (dd, IH, J = 2.0 & 9.5 Hz), 7.82 (dd, IH, J = 1.0 & 9.5 Hz), 8.18 (s, IH), 8.20 (s, IH), 9.93 (s, IH). HRMS (ESI) m/z [M+H]+ 420.1998.
[00250] N-(4,4-Difluorocyclohexyl)-4-(irridazo[ l ,2-a1pyridin-3-yl)-5-m (156). 4-(6-Bromoirrddazo[l ,2- ]pyridin-3-yl)-N-(4,4-difluorocyclohexyl)-5-methylpyrirmdin-2-amine (240 mg, 0.57 mmol) and pyrimidin-5 -amine (55 mg, 0.57 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 156 as a white solid (30 mg, 15%). Ή-NMR (CDC13): δ 1.65-1.75 (m, 2H), 1.83-2.03 (m, 2H), 2.10-2.23 (m, 4H), 2.34 (s, 3H), 3.95- 4.05 (m, IH), 4.94 (d, IH, J = 7.5 Hz), 6.94 (dt, IH, J = 7.0 & 1.0 Hz), 7.33-7.39 (m, IH), 7.74 (d, IH, J = 9.0 Hz), 8.14 (s, IH), 8.23 (s, IH), 9.66 (d, IH, J = 7.0 Hz). HRMS (ESI) m/z [M+H]+ 344.1688. [00251] Methyl ( lr,4r)-4-((5-methyl-4-(6-(pyrimidin-5- yl)pyrimidin-2-yl)amino)cvclohexane- l-carboxylate (157). Methyl ( l r,4r)-4-((4-(6-bromoimidazo[ l ,2- a]pyridin-3-yl)-5-methylpyrimidin-2-yl)aniino)cyclohexane- l -carboxylate (600 mg, 1.35 mmol) and pyrimidin-5-amine ( 130 mg, 1 .35 mmol) were reacted according to general synthetic procedure B. The product was further purified by preparative HPLC to give 157 as an orange solid (200 mg, 32%). Ή- NMR (MeOD-i¾: δ 1.27- 1 .3 1 (m, 4H), 1.85-2.00 (m, 2Η), 2.00-2. 15 (m, 2Η), 2.20-2.35 (m, I H), 2.40 (s, 3H), 3.62-3.70 (m, 4H), 7.47 (dd, I H, J = 9.0 & 2.0 Hz), 7.73 (d, I H, J = 9.5 Hz), 8. 19 (s, I H), 8.20 (s, I H), 8.5 1 (s, 2H), 8.61 (s, I H), 9.98 (s, I H) (two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z. [M+H]+ 459.2258.
[00252] ( lr,4r)-4-((5-Methyl-4-(6-(pyrimidin-5-ylamino)imidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2- yl)amino)cyclohexane- l -carboxylic acid (158). A solution of methyl ( 1 r,4r)-4-((5-methyl-4-(6- (pyrimidin-5-ylamino)imidazo[ 1 ,2-a]pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexane- 1 -carboxylate ( 135 mg, 0.29 mmol) in 2M NaOH (8 mL) and MeOH (8 mL) was stirred at room temperature overnight. The reaction mixture was washed with DCM (2 x 100 mL). The aqueous phase was acidified to pH 3. The resulting precipitate was filtered, and purified by preparative HPLC to give 158 as a yellow solid (50 mg, 39%). Ή-NMR (DMSO-£/6): δ 0.90-1.40 (m, 4H), 1.60-2.10 (m, 4H), 2.07 (s, IH), 2.34 (s, 3H), 3.53 (br s, IH), 6.82 (s, IH), 7.39 (d, IH, / = 8.5 Hz), 7.76 (d, IH, / = 9.5 Hz), 8.19 (s, IH), 8.25 (s, IH), 8.54 (s, 2H), 8.59 (s, IH), 8.64 (s, IH), 9.81 (s, IH), 12.05 (br s, IH). HRMS (ESI) m/z LM+H]+ 445.2099.
[00253] ( lr,4r)-N'-(4-(7-Fluoro-6-phenylimidazo[ l ,2-a1pyridin-3-yl)-5-methylpyrimidin-2- vDcyclohexane- 1 ,4-diamine (159). ( 1 r,4r)-/V"'-(4-(6-Bromo-7-fluoroimidazo[ 1 ,2-a]pyridin-3-yl)-5- methylpyrimidin-2-yl)cyclohexane- 1 ,4-diamine ( 100 mg, 0.24 mmol) and phenylboronic acid (29 mg, 0.24 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 159 as a white solid (20 mg, 20%). Ή-NMR (CDC13): δ 1.17-1.21 (m, 4H), 1.92 (br s, 2H), 2.09-2.1 1 (m, 2H), 2.37 (s, 3H), 2.88 (br s, IH), 3.72 (br s, IH), 5.1 1 (br s, IH), 7.45-7.53 (m, 6H), 8.10 (s, IH), 8.18 (s, IH), 9.68 (d, IH, J = 7.5 Hz) (two primary amine protons (NH2) signals not observed). HRMS (ESI) m/z, [M+H]+ 417.2204.
[00254] ( lr.4r)-N'-(5-Fluoro-4-(6-phenylimidazor i .2-alpyridin-3-yl)pyrirnidin-2-yl)-N4-( l- methylpiperidin-4-yl)cyclohexane- 1 ,4-diamine (160). ( 1 r^^-N'-iS-Fluoro^-^-phenylimidazof 1 ,2- ]pyridin-3-yl)pyrirnidin-2-yl)cyclohexane-l ,4-diamine ( 100 mg, 0.25 mmol) and l-methylpiperidin-4- one (29 μί, 0.25 mmol) were reacted according to general synthetic procedure D. The product was further purified by preparative HPLC to give 160 as a yellow sticky liquid (50 mg, 40%). 'H-NMR (CDC13): δ 0.82-0.89 (m, 2H), 1.16- 1.25 (m, 2H), 1.75-1.83 (m, 4H), 2.01-2.04 (m, 2H), 2.17-2.19 (m, 2H), 2.54-2.67 (m, 5H), 2.88 (br s, 2H), 3.23 (br s, 2H), 3.71 (s, IH), 5.08 (br s, IH), 7.44 (t, IH, J = 7.5 Hz), 7.53 (t, 2H, J = 7.5 Hz), 7.61-7.64 (m, 3H), 7.85 (d, IH, J = 9.0 Hz), 8.20 (d, IH, J = 3.5 Hz), 8.50 (d, IH, J = 3.5 Hz), 10.19 (s, IH) (one secondary amine proton (NH) not observed). HRMS (ESI) m/z.
[M+H]+ 500.2938.
[00255] ( lr,4r)-N'-(5-fluoro-4-(6-phenylimidazo[ 1 ,2-a1pyridin-3-yl)pyrirnidin-2-yl)-N4-
(tetrahydro-2H-pyran-4-yl)cyclohexane- 1 ,4-diamine (161). ( 1 r,4r)-Nl -(5-Fluoro-4-(6-phenylimidazo [ 1 ,2- a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine ( 100 mg, 0.25 mmol) and tetrahydro-4H-pyran-4- one (23 μΐ^, 0.25 mmol) were reacted according to general synthetic procedure D. The product was further purified by preparative HPLC to give 161 as a yellow solid (55 mg, 45%). Ή-NMR (CDC13): δ 1.21 - 1.34 (m, 4H), 1.73- 1.80 (m, 2H), 1.85- 1.88 (m, 2H), 1.99-2.01 (m, 2H), 2.22-2.24 (m, 2H), 2.92 (br s, IH), 3.06 (br s, I H), 3.35-3.40 (m, 2H), 3.76 (br s, I H), 4.01 -4.04 (m, 2H), 4.99 (s, I H), 7.45 (t, I H, J = 7.0 Hz), 7.54 (t, 2H, J = 7.0 Hz), 7.61 -7.64 (m, 3H), 7.84 (d, I H, J = 9.5 Hz), 8.21 (d, I H, J = 3.5 Hz), 8.47 (d, IH, / = 4.0 Hz), 10.09 (s, IH) (one secondary amine proton (NH) not observed). HRMS (ESI) m/z. [M+H]+ 487.2622.
[00256J N-( l-(Ethylsulfonyl)piperidin-4-yl)-5-fluoro-4-(6-phenylimidazo| l ,2-a|pyridin-3- yl)pyrimidin-2-amine (163). To a solution of 5-fluoro-4-(6-phenylimidazo[ l ,2-a]pyridin-3-yl)-/V- (piperidin-4-yl)pyrimidin-2-amine (92 mg, 0.24 mmol) and triethylamine (32 μΕ, 0.36 mmol) in DCM ( 10 mL) cooled on an ice bath was added ethanesulfonyl chloride (68 μΕ, 0.72 mmol). The reaction was stirred overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 3% MeOH to give 163 as a yellow solid (65 mg, 56%). Ή-NMR (DMSO-i ): 5 1.17 (t, 3H, 7 = 7.0 Hz), 1.47- 1.5 1 (m, 2H), 1.97 (d, 2H, / = 10.5 Hz), 2.82 (br s, 2H), 3.45 (br s, 2H), 3.82 (br s, I H), 7.44-7.49 (m, 2H), 7.58 (t, 2H, J = 7.5 Hz), 7.78 (d, 2H, J = 7.5 Hz), 7.82-7.85 (m, IH), 7.92 (d, IH, J = 9.0 Hz), 8.39 (d, IH, J = 3.5 Hz), 8.47 (d, IH, J = 3.5 Hz), 10.16 (s, IH). HRMS (ESI) m/z [M+H]+ 481.1822.
[00257] ( lr,4r)-4-((5-Chloro-4-(6-(4-fluorophenyl)imidazor i .2-alpyridin-3-yl)pyrimidin-2- yl)amino)cvclohexan- 1 -ol (165). ( 1 r,4r)-4-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)amino)cyclohexan- l -ol ( 150 mg, 0.36 mmol) and (4-fluorophenyl)boronic acid (50 mg, 0.36 mmol) were reacted according to general synthetic procedure C to give 165 as a white solid ( 1 15 mg, 73%). Ή- NMR (DMSO-rfe): δ 0.73 (br s , 1H), 1.27 (br s, 3H), 1.57 (br s, IH), 1.86 (br s, 3H), 3.22 (br s, IH), 3.56 (br s, IH), 4.38 (s, IH), 7.33-7.36 (m, 2H), 7.46 (s, IH), 7.79-7.82 (m, 3H), 7.87 (d, IH, J = 9.0 Hz), 8.44 (s, IH), 8.56 (s, IH), 9.81 (s, IH). HRMS (ESI) m/z [M+H]+ 438.1498.
[00258] ( lr.4r)-4-((5-Chloro-4-(6-(pyridin-3-yl)imidazor i .2-alpyridin-3-yl)pyrimidin-2- yl)amino)cyclohexan- 1 -ol ( 166). ( 1 r,4r)-4-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5-chloropyrimidin- 2-yl)amino)cyclohexan- l -ol ( 150 mg, 0.36 mmol) and pyridin-3-ylboronic acid (44 mg, 0.36 mmol) were reacted according to general synthetic procedure C to give 166 as a white solid (95 mg, 63%). Ή-NMR (DMSO-i/6): δ 0.68 (br s , 1H), 1.24- 1.27 (m, 3H), 1.51 (br s, IH), 1.85-1.93 (m, 3H), 3.22 (br s, IH), 3.56 (br s, IH), 4.33 (s, IH), 7.48 (s, IH), 7.53-7.56 (m, IH), 7.87-7.93 (m, 2H), 8.20 (d, IH, J = 7.5 Hz), 8.45 (s, IH), 8.58 (s, IH), 8.63-8.65 (m, IH), 9.00 (s, IH), 9.89 (s, IH). HRMS (ESI) m/z. [M+H]+ 421.1544.
[00259] ( lr,4r)-4-((5-Chloro-4-(6-(6-methoxypyridin-3-yl)iiffld
2-yl)amino)cyclohexan- l-ol (167). ( 1 r,4r)-4-((4-(6-Bromoimidazo[ 1 ,2-a]pyridin-3-yl)-5- chloropyrirrudin-2-yl)arnino)cyclohexan-l-ol (500 mg, 1.19 mmol) and (6-methoxypyridin-3-yl)boronic acid ( 1 82 mg, 1 .19 mmol) were reacted according to general synthetic procedure C to give 167 as a white solid (430 mg, 80%). Ή-NMR (DMSO-rf6): δ 0.75 (br s , 1 H), 1 .28 (br s, 3H), 1.56 (br s, I H), 1 .87 (br s, 3H), 3.28 (br s, I H), 3.57 (br s, I H), 3.93 (s, 3H), 4.33 (s, I H), 6.97 (d, I H, J = 8.5 Hz), 7.47 (s, I H), 7.8 1 -7.90 (m, 2H), 8. 1 1 (d, I H, J = 7.5 Hz), 8.44 (s, IH), 8.59 (s, I H), 9.89 (s, IH) (one secondary amine proton (NH) not observed). HRMS (ESI) m/z. [M+H]+ 45 1. 1650.
[ 00260J 4-(4-((5-Methyl-4-(6-(pyrirmdin-5-ylamino)imidazo| l,2-alpyridin-3-yl)pyrimidin-2- yl)amino)cyclohexyl)piperazin-2-one (168). 4-((5-Methyl-4-(6-(pyrimidin-5-ylamino)imidazo[ 1 ,2- a]pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexan- l -one (200 mg, 0.48 mmol) and piperazin-2-one (48 mg, 0.48 mmol) were reacted according to general synthetic procedure D. The product was further purified by preparative HPLC to give 168 as a yellow solid (30 mg, 13%). Ή-NMR (MeOD-<¾): δ 1.26- 1.36 (m, 2H), 1.59 (br s, 2H), 1.74- 1.76 (m, I H), 1.87- 1.88 (m, 2H), 2. 12-2. 14 (m, I H), 2.36 (br s, I H), 2.42 (s, 3H), 2.66 (s, I H), 2.77-2.80 (m, I H), 3. 19 (s, I H), 3.28 (s, I H), 3.28-3.30 (m, I H), 3.66-3.69 (m, IH), 3.90-3.92 (m, IH), 7.47-7.52 (m, IH), 7.75 (d, IH, J = 9.5 Hz), 8.21-8.24 (m, 2H), 8.58 (s, 2H), 8.65 (s, IH), 9.94 (s, IH) (three secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 499.2682.
[00261 ] l -Methyl-3-(( lr.4r)-4-((5-methyl-4-(6-phenylimidazor i .2-a1pyridin-3-yl)pyrimidin-2- yl)amino)cvclohexyl)urea (169). A solution of ( l r,4r)-Af'-(5-Methyl-4-(6-phenylimidazo[ l ,2-a]pyridin-3- yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine (50 mg, 0.13 mmol), methylcarbamic chloride ( 18 mg, 0.15 mmol) and Triethylamine (35 μί, 0.25 mmol) in DCM ( 10 mL) was stirred at room temperature for 2 h. The reaction mixture was purified by preparative HPLC to give 169 as a yellow solid (40 mg, 68%). Ή- NMR (DMSO- 6): δ 0.86 (br s, 2H), 1.25- 1.34 (m, 2H), 1.64 (br s, 2H), 1.89-1.91 (m, 2H), 2.34 (s, 3H), 3.18 (br s, IH), 3.32 (br s, IH), 3.67 (br s, IH), 5.64 (d, IH, 7 = 4.5 Hz), 6.96 (d, IH, J = 8.0 Hz), 7.46 (t, IH, J = 7.5 Hz), 7.53 (t, 2H, J = 7.0 Hz), 7.73-7.78 (m, 2H), 7.85 (d, IH, J = 9.0 Hz), 8.16 (s, IH), 8.23 (s, IH), 8.28 (s, IH), 9.82 (s, IH). HRMS (ESI) m/z [M+H]+ 456.2510.
[00262] 5-Fluoro-4-(7-phenylimidazo[ l ,2-a1pyridin-3-yl)-N-(piperidin-4-yl)pyrimidin-2-amine (170). 4-(7-Chloroimidazo[ l ,2- ]pyridin-3-yl)-5-fluoro-N-(piperidin-4-yl)pyrimidin-2-amine ( 147 mg, 0.42 mmol) and 4,4,5,5-tetramethyl-2-phenyl- l ,3,2-dioxaborolane (86 mg, 0.42 mmol) were reacted according to general synthetic procedure C. The product was further purified by preparative HPLC to give 170 as a white solid ( 100 mg, 61 %). Ή-NMR (DMSO-i/6): δ 1.50- 1.54 (m, 2H), 2.03-2.05 (m, 2H), 3.1 1-3.16 (m, 2H), 3.28-3.33 (m, 1H), 4.61-4.63 (m, 2H), 7.49 (t, 1H, J = 7.5 Hz), 7.56 (t, 2H, J = 7.5 Hz), 7.72-7.74 (m, 1H), 7.95 (d, 1H, J = 7.5 Hz), 8.18 (s, 1H), 8.35 (s, 1H), 8.42 (d, 1H, J = 3.5 Hz), 8.54 (d, 1 H, J = 3.5 Hz), 9.8 1 (d, 1 H, J = 7.5 Hz) (two secondary amine protons (NH) signals not observed). HRMS (ESI) m/z. [M+H]+ 389.1888.
[00263] 5-Fluoro-N-( l-(methylsulfonyl)piperidin-4-yl)-4-(7-phenylimidazo[ l ,2-a1pyridin-3- yl)pyrimidin-2-amine (171). To a solution of 5-fluoro-4-(7-phenylimidazo[ l ,2-a]pyridin-3-yl)-/V- (piperidin-4-yl)pyrimidin-2-amine (70 mg, 0.18 mmol) and triethylamine (24 μΕ, 0.27 mmol) in DCM ( 10 mL) cooled on an ice bath was added methanesulfonyl chloride (32 μΕ, 0.55 mmol). The reaction was stirred overnight, concentrated under reduced pressure and purified by flash column chromatography starting with 100% DCM ramping to 3% MeOH. The product was further purified by preparative HPLC to give 171 as a yellow solid (55 mg, 66%). Ή-NMR (DMSO- 6): δ 1.47- 1.54 (m, 2H), 1.99-2.02 (m, 2H), 2.99 (s, 3H), 3.22-3.27 (m, 2H), 3.52-3.54 (m, 1 H), 4.48-4.51 (m, 2H), 7.19 (d, 1 H, J = 7.0 Hz), 7.49 (t, 1 H, / = 7.5 Hz), 7.57 (t, 2H, J = 7.5 Hz), 7.73-7.75 (m, 1 H), 7.95-7.97 (m, 2H), 8.18 (d, 1 H, J = 1.5 Hz), 8.42 (d, 1 H, J = 3.5 Hz), 8.53 (d, 1 H, J = 3.5 Hz), 9.82 (d, 1 H, J = 7.5 Hz). HRMS (ESI) m/z.
LM+HJ+ 467.1666.
[00264] 1 -Methyl-3-( ( 1 r,4r)-4-( (5-methyl-4-( 6-(pyrimidin-5-ylamino)imidazo[ 1 ,2-a]pyridin-3- yl)pyrimidin-2-yl)amino)cyclohexyl)urea (172). ( l r,4r)-N'-(5-methyl-4-(6-(pyrimidin-5- ylamino)imidazo[ l ,2-fl]pyridin-3-yl)pyrimidin-2-yl)cyclohexane- l ,4-diamine ( 128 mg, 0.31 mmol), methylcarbamic chloride (44 mg, 0.46 mmol) and Triethylamine ( 130 μΕ, 0.93 mmol) in DCM ( 10 mL) was stirred at room temperature for 2 h. The resulting solid was filtered, washed with H20 and MeOH to give 172 as a beige solid ( 100 mg, 68%). Ή-NMR (DMSO-rf6): S 0.84 (br s, 2H), 1.10- 1.17 (m, 2H), 1.63-1.85 (m, 4H), 2.33 (s, 1H), 2.55 (d, 3H, / = 4.5 Hz), 3.26 (br s, 1H), 3.53-3.59 (m, 1H), 5.64 (br s, 2H), 6.68 (s, 1H), 7.40 (d, 1H, J = 9.0 Hz), 7.76 (d, 1H, J = 9.5 Hz), 8.18 (s, 1H), 8.25 (s, 1H), 8.55-8.57 (m, 3H), 8.66 (s, 1H), 9.76 (s, 1H) (two secondary amine proton (NH) signals not observed). HRMS (ESI) m/z [M+H]+ 473.2528
Example 2 Biological Activity
Kinase assays
[00265] Eurofins Pharma Discovery or Reaction Biology Corporation Kinase Profiler services were used to measure inhibition of CDKs and other kinases by radiometric assay. Inhibition of CDK4/D 1 ,
CDK6/D3 and CDK9/T1 were also determined in-house using ADP Glo Kinase assays (Promega Corporation, Madison, USA). Briefly, the kinase reaction for CDK4/D1 and CDK6/D3 was performed with kinase reaction buffer (40 nM Tris base pH 7.5, 20 mM MgCl2, 0.4 mM DTT), 0.1 mg/ml BSA and RB-CTF substrate (retinoblastoma proteinl C-terminal fraction). For CDK9/CyclinTl , the kinase reaction was performed with standard assay buffer and Kinase Dilution Buffer and RBER-IRStide substrate. Serial dilutions of 1 :3 were prepared for test compounds for 10 concentrations (from 10 μΜ to 0.5 riM). The kinase reactions were started by addition of ATP, incubated for 40 min at 37° C and then stopped by adding 10 μΐ^ of ADP Glo reagent. After incubation at room temperature in the dark for 40 min, 20 μΐ^ of kinase detection reagent was added per well and incubated for 40 min. Luminescence was measured using an EnVision Multilabel plate reader (PerkinElmer, Buckinghamshire, UK). Positive and negative controls were performed in the presence and absence of CDK kinases, respectively. Half-maximal inhibition (IC50) values were calculated using a 4-parameter logistic non-linear regression model with Graphpad prism (Version 6.0). Apparent inhibition constants (K ) values were calculated from Km (ATP) and TC50 values for the respective kinases. The results are shown in Table 2.
Cell viability assay
[00266] Compounds from Example 1 were subjected to a standard MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) and resazurin assays on solid tumour cell lines and leukemia cell lines, respectively, as previously reported (Wang S et al., J Med Chem 47: 1662- 1675, 2004 and Diab S. et al. CheMedChem 9:962-972, 2014). Compound concentrations required to inhibit 50% of cell growth (GI50) were calculated using non-linear regression analysis. The results are shown in Tables 2 and 3.
Table 2 Inhibition of cyclin-dependant kinases and anti-proliferative activity (72 h, GI50 μΜ)
of representative compounds
72 h Growth inhibition
CDK inhibition, K, (μΜ)/ or residual activity (%) at 10 μΜ
Cmpd Glso (μΜ)
CDK1 B CDK2A CDK4D1 CDK6D3 CDK7H CDK9T1 MV4-1 1
1 0.077 0.018 0.025 23% 0.026 0.006 0.046 + 0.005
2 0.085 0.012 - 5% 0.034 0.005 0.006 ± 0.001
3 0.084 0.023 0% 46% 0.019 0.006 < 0.001
4 1 % 2% 0% 2% - 0.003 0.004 + 0.001
5 0.014 0.006 0% 16% 0.075 0.002 0.003 ± 0.001
6 0.013 0.009 1 1 % 16% 0.016 0.003 0.002 + 0.0005
7 0.42 0.24 0.691 1.71 0.73 0.006 0.075 ± 0.01 1
8 3.81 0.35 1 1 % 34% 0.38 0.035 0.066 ± 0.007
9 0.266 0.08 45% 58% 0.23 0.009 0.008 ± 0.002
10 1.53 0.43 2.62 1.54 0.60 0.008 0.059 ± 0.008
11 75% 63% 40% 27% 26% 0.291 0.009 + 0.001
12 0.121 0.013 4% 41 % 0.032 0.008 0.006 ± 0.001
13 0.329 0.063 0% 59% 0.052 0.024 0.022 ± 0.002 0.755 0.115 3% 17% 0.040 0.007 0.368 ± 0.129
0.070 0.027 0% 13% 0.15 0.014 0.050 ± 0.009
0.000 0.001 - 32% 50% 0.029 0.010 ± 0.001
0.004 0.0004 1% 26% 0.001 0.062 < 0.001
0.028 0.007 9% 41% 0.001 0.148 6.108 + 1.141
0.795 0.527 0.004 - 0.27 0.078 0.084 ± 0.008
56% 54% 29% - 1.75 0.829 0.092 ± 0.010
0.479 0.321 -11% - 0.60 0.069 0.003 + 0.001
1.06 1.12 2% 42% 0.437 0.095 0.041 ± 0.012
0.258 0.155 0% 39% 0.885 0.063 0.280 ± 0.049
-1% -1% -16% 18% 0.281 0.141 0.506 ± 0.104
3% 2% 4% 4% 1% 0.003 < 0.001
7% 5% 9% 24% 0% 0.003 < 0.001
-1% 4% 4% 15% 2% 0.003 < 0.001
4% 8% 95% 100% 2% 0.85 0.042 ± 0.017
3.57 1.83 17% 45% 2.73 0.051 0.101 ± 0.039
67% 49% 17% 39% 13% 0.12 0.017 ± 0.006
32% 145 45 11% 13% 0.018 0.005 ± 0.002
>10 0.63 16% 36% 5.39 0.094 0.066 ±0.014
11% 13% 7% 12% 7% 0.022 0.004 ±0.001
2.16 0.09 2.80 1.05 2.24 0.005 0.095 ±0.031
0.88 0.26 0.79 0.394 0.27 0.007 0.011 ±0.002
0.065 0.016 4% 48% 0.094 0.016 0.004 ±0.001
0.17 0.044 7% 96% 1.18 0.12 0.013 ±0.002
2.56 0.91 0% 80% 0.58 0.065 0.052 ±0.011
7.36 4.74 36% 100% 5.60 0.165 0.082 ±0.020
0.88 0.73 30% 72% 0.038 0.014 0.005 ±0.001
2.66 0.059 40% 55% 0.958 0.045 0.013 ±0.002
0.460 0.046 0% 45% 0.024 0.061 0.007 ±0.001
4% 1% 0% 2% 3% 0.008 0.004 ±0.001
0% 0% 2% 1% 2% 0.007 < 0.001
0% 0% 5% 0% 2% 0.006 < 0.001 0% 0% 0% 1% 3% 0.004 < 0.001
5% 2% 4% 16% 0.075 0.004 0.003 ± 0.001
13% 3% 4% 45% 8% 0.004 0.002 ± 0.000
1% 0% 0% 5% 3% 0.003 -
1% 0% 14% 4% 4% 0.003 -
4% 4% 0% 22% 6% 0.006 0.001 + 0.000
6% 7% 4% 21% 6% 0.013 0.008 ± 0.003
18% 3% 0% 0% 5% 0.049 0.002 + 0.001
29% 5% 0% 0% 6% 0.110 0.018 ± 0.004
24% 5% 5% 2% 8% 0.069 0.558 ± 0.130
39% 12% 0% 5% 22% 0.051 -
47% 31% 45% 39% 17% 0.069 0.067 ± 0.014
71% 70% 69% 86% 22% 0.17 0.177 ± 0.005
2.68 0.92 55% 91% 2.39 0.072 0.274 ± 0.064
57% 62% 115 89% 37% 0.41 0.057 ± 0.006
79% 63% 17% 89% 37% 0.49 0.083 ± 0.035
87% 72% 63% 87% 60% 0.497 0.025 ± 0.009
18% 6% 38% 29% 18% 0.054 0.095 ± 0.031
2.37 0.59 1% 38% 1.44 0.016 0.155 ± 0.054
32% 12% 125 24% 31% 0.024 -
1.26 0.18 0.76 0.33 3.25 0.007 -
38% 10% 31% 29% 52% 0.017 0.128 ± 0.04
2.18 0.35 37% 23% 0.71 0.033 0.127 ± 0.002
2.95 0.61 24% 25% 0.95 0.023 0.199 ± 0.02
4.32 1.42 31% 70% 3.28 0.62 0.212 ± 0.104
6.05 2.66 35% 66% 5.19 0.203 0.383 + 0.119
69% 52% 77% 85% 57% 0.194 1.457 ± 0.476
75% 62% 53% 49% 63% 0.469 0.752 ± 0.055
39% 11% 41% 46% 50% 0.020 0.349 ± 0.086
52% 22% 41% 46% 50% 0.034 -
72% 59% 91% 89% 92% 0.485 -
5% 0% 5% 6% 3% 0.011 78 7% 0% 10% 3% 3% 0.019 -
79 0.27 0.071 13% 80% 0.079 0.004 0.008 + 0.001
80 - - 61 % 54% - 0.200 0.243 ± 0.053
81 2.01 0.51 1.58 1.01 0.21 0.008 0.025 ± 0.01 1
82 0.82 0.22 20% 99% 0.15 0.018 0.054 ± 0.015
83 2.56 0.91 27% 80% 0.58 0.065 0.052 ± 0.01 1
84 51 % 39% 9% 12% 10% 0.033 0.035 + 0.006
85 7.44 0.77 75% 43% 0.048 0.13 1.324 ± 0.549
86 2.64 0.25 25% 47% 0.044 0.216 0.086 ± 0.005
87 31 % 19% 73% 39% 14% 0.073 0.135 + 0.057
88 0.16 0.019 0.06 0.034 1.26 0.002 -
89 10% 7% 21 % 225 12% 0.027 0.003 ± 0.001
90 57% 44% 24% 80% 295 0.21 1 0.229 + 0.015
91 5% 7% 17% 41 % 1 % 0.082 0.014 ± 0.007
92 22% 27% 37% 58% 27% 0.089 0.179 + 0.061
93 35% 31 % 28% 69% 49% 0.071 0.336 + 0.082
94 20% 12% 25% 45% 10% 0.388 0.748 ± 0.063
95 59% 28% 76% 76% 33% 0.198 0.646 + 0.129
96 63% 37% 49% 90% 63% 0.193 > 10
97 28% 32% 54% 39% 9% 0.016 0.058 + 0.002
98 1.50 0.31 0.78 0.53 1.67 0.004 0.153 ± 0.021
99 1.66 0.48 1.16 0.51 3.10 0.006 0.265 ± 0.034
100 87% 79% 96% 84% 98% >5 > 10
101 60% 41 % 97% 100% 85% 0.561 > 10
102 36% 22% 73% 100% 85% 0.109 0.059 + 0.019
103 4% 1 % 30% 45% 40% 0.203 > 10
104 4% 2% 70% 73% 57% 0.155 4.76 ± 1.16
105 7% 3% 93% 94% 15% 0.188 0.748 + 0.063
106 5% 2% 43% 71 % 25% 0.042 0.851 ± 0.048
107 47% 5% 37% 54% 34% 0.161 1.416 ± 0.652
108 0.16 0.035 70% 68% 4.76 0.018 > 10
109 1.26 0.18 0.94 0.21 > 10 0.008 110 66% 61% 99% 100% 87% >5 -
111 20% 11% 29% 89% 86% 0.108 -
112 1.73 0.49 > 5 45% >5 0.205 2.55 ± 1.70
113 0.82 0.45 28% 39% 2.59 1.01 > 10
114 53% 28% 8% 40% 0.075 0.005 0.026 + 0.009
115 1.35 0.14 1.24 1.11 4 0.006 0.552 ± 0.166
116 - - 18% 86% - 0.106 0.885 + 0.137
117 10% 4% 0% 12% 5% 0.004 0.045 + 0.004
118 0.154 0.026 0% 6% 0.018 0.036 -
119 0.623 0.14 0.64 0.54 0.12 0.004 -
120 31% 4% 0.87 - 29% 0.015 0.023 + 0.010
121 0.78 0.86 2.21 47% 3.86 0.032 -
122 1.71 1.15 71% 44% 1.16 0.30 -
123 1.53 0.30 31% 155 0.89 0.011 -
124 87% 34% - - 91% >5 > 5
125 >5 3.94 100% 92% 4.56 2.88 -
126 2% 0.089 14% - 94% 0.111 > 5
127 34% 0% 32% - 39% 0.045 -
128 45% 0.706 38% - 34% 0.31 0.068 ± 0.006
129 42% 0% 32% - 18% 0.12 -
130 25% 23% 23% - 40% 1.12 0.172 + 0.001
131 29% 44% 24% - 20% 0.320 0.132 ± 0.059
132 25% 23% 16% - 40% 1.12 0.012 + 0.008
133 22% 40% 60% - 10% 0.14 -
134 43% 22% 11% - 28% 0.12 -
135 61% 57% 28% - 13% 1.14 0.564 + 0.047
136 22% 59% 48% - 36% 2.77 0.297 ± 0.001
137 3% 0% 7% - 0.040 0.003 < 0.01
138 0.076 0.111 6% - 0% 0.006 < 0.001
139 31% 4% 14% - 15% 0.044 -
140 39% 61% 65% - 0.597 0.53 0.242 ± 0.132
141 0.532 0.064 15% 30% 0.011 142 23% 15% 8% 39% 0.025 0.064 ± 0.017
143 3% 4% 4% 0.088 0.108 0.003 + 0.001
144 0.047 8% 20% 0.072 0.138 0.005 ± 0.003
145 0.222 22% 41% 0.199 0.402 0.0.011 + 0.001
146 16% 34% 34% 0.37 1.823 0.026 + 0.003
147 0.334 0.015 70% 54% 0.711 0.620 + 0.260
148 27% 46% 70% 18% 0.261 0.023 + 0.007
149 9% 20% 3% 0.313 0.178 0.145 + 0.001
150 45% 11% 21% 0.372 0.149 0.420 ± 0.020
151 96% 87% 93% 94% >5 8.643 + 0.010
152 34% 5% 20% 55% 0.181 2.856 + 0.290
153 0.632 14% 0% 49% 0.010 9.317 ± 0.730
154 14% 7% 3% 37% 0.022 > 10
155 100% 100% 96% 99% >5 7.003 ± 2.030
156 77% 34% 51% 80% >5 3.301 + 0.310
157 69% 38% 32% 90% 0.527 2.399 + 0.090
158 94% 85% 92% 98% 0.185 > 10
159 31% 11% 43% 20% 0.061 -
160 3% 7% 0% 0.099 0.014 -
161 0.074 6% 3% 0.094 0.016 -
163 - 0% 61% 5% 4.57 -
165 - 51% 61% 24% 0.93 -
166 - 8% 54% 33% 1.28 -
167 - 4% 66% 49% 0.49 -
168 - 11% 22% 55% 0.181 -
169 - 31% 81% 35% 1.88 -
170 - 7% 5% 18% >5 -
171 - 35% 47% 65% >5 -
172 2% 6% 21% 0.005 Antiproliferative activity of representative compounds
Figure imgf000090_0001
[00267J Throughout the specification and the claims that follow, unless the context requires otherwise, the words "comprise" and "include" and variations such as "comprising" and "including" will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.
[00268J The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement of any form of suggestion that such prior art forms part of the common general knowledge.
[00269] It will be appreciated by those skilled in the art that the invention is not restricted in its use to the particular application described. Neither is the present invention restricted in its preferred embodiment with regard to the particular elements and/or features described or depicted herein. It will be appreciated that the invention is not limited to the embodiment or embodiments disclosed, but is capable of numerous rearrangements, modifications and substitutions without departing from the scope of the invention as set forth and defined by the following claims.
[00270] Please note that the following claims are provisional claims only, and are provided as examples of possible claims and are not intended to limit the scope of what may be claimed in any future patent applications based on the present application. Integers may be added to or omitted from the example claims at a later date so as to further define or re-define the invention.

Claims

1. A compound of formula I:
(1)
Figure imgf000091_0001
wherein:
A is a cycloalkyl or heterocycloalkyl, optionally substituted by one or more R6 groups such that m is an integer from 0 to 5 inclusive, and wherein said heterocycloalkyl comprises at least one but no more than two heteroatoms selected from N, O and S; and wherein
R, R1, R2, R3, R4, R5 and R6 are each independently selected from the group consisting of H, alkyl, alkyl-R7, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH2-heteroaryl, aralkyl, halogen, N02, CN, CF3, OH, O-alkyl, O-alkyl-R7, O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O- heteroaryl, O-R9, NH2, NH-alkyl, NH-alkyl-R7, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH -heteroaryl, NH-R7, NHO-aryl, NH)-heteroaryl, NHCH2-aryl, N-(alkyl)2, N- (heteroalkyl)2, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N-(R7)(R8), N- (alkyl)(R7), N-(heteroalkyl)(R7), N-(cycloalkyl)(R7), N-(heterocycloalkyl)(R7), N-(aryl)(R7), N- (heteroaryl)(R7), SH-alkyl, SH-alkyl-R7, SH-heteroalkyl, SH-cycloalkyl, SH-heterocycloalkyl, SH- aryl, SH-heteroaryl, S-(alkyl)2, S-heteroalkyl, S-(cycloalkyl)2, S-(heterocycloalkyl)2, S-(aryl)2, S- (heteroaryl)2, S-(alkyl)(aryl), SH-R7, S-(R7)(R8), S-(alkyl)(R7), S-(heteroaryl)(R7), S-(cycloalkyl)(R7), S-(heterocycloalkyl)(R7), S-(aryl)(R7), S-(heteroaryl)(R7), COOH, CONH2, CONH-alkyl, CONH-aryl, CON-(alkyl)(R7), CON(aryl)(R7), CON(heteroaryl)(R7), CONH-R7, CON-(R7)(R8), S03H, S02-alkyl, S02-alkyl-R7, S02-aryl, S02-aryl-R7, S02NH2, S02NH-R7, S02N-(R7)(R8), CO-alkyl, CO-alkyl-R7, CO-aryl, CO-aryl-R7, CO-R7, COOR7, and R9,
and wherein R7 and R9 are each independently selected from the group consisting of H, alkyl, alkyl- R10, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, halogen, N02, CN, CF3, OH, O-alkyl, O-alkyl-R10, O-heteroalkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, O-R10, NH2, NH-alkyl, NH-alkyl-R10, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH- heteroaryl, NH-R10, N-(alkyl)2, N-(heteroalkyl)2, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N- (heteroaryl)2, N-(R10)(Rn), N-(alkyl)(R10), N-(heteroalkyl)(R10), N-(cycloalkyl)(R10), N- (heterocycloalkyl)(R10), N-(aryl)(R10), N-(heteroaryl)(R10), SH-alkyl, SH-alkyl-R10, SH-heteroalkyl, SH-cycloalkyl, SH-heterocycloalkyl, SH-aryl, SH-heteroaryl, S-(alkyl)2, S-(cycloalkyl)2, S- (heterocycloalkyl)2, S-(aryl),, S -(heteroaryl )2, S-(alkyl)(aryl), SH-R10, S-CR^XR1 1), S-(alkyl)(R10), S- (heteroaryl)(R10), S-(cycloalkyl)(R10), S-(heterocycloalkyl)(R10), S-(aryl)(R10), S-(heteroaryl)(R10), COOH, COO-alkyl, ( N I I... CONH-alkyl, CONH-aryl, CON-(alkyl)(R10), CON(aryl)(R10),
CON(heteroaryl)(R1()), CONH-R10, CON-(Rl0)(Rn), S03H, S02-alkyl, S02-alkyl-R1(), S02-aryl, S02- aryl-R10, S02NH2, S02NH-R10, SO2N-(R10)(Rn), CO-alkyl, CO-alkyl-R10, CO-aryl, CO-aiyl-R10, CO- R10, and COOR10, and R9,
and wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl,
heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, CN, OH, O-methyl, NH2, COOH, CONH2, CF3 and S02N(CH3)2; and R9, R^ and R11 are independently selected from water solubilising groups;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
2. A compound according to claim 1 , wherein A is a 5- to 7-membered cycloalkyl or heterocycloalkyl group optionally substituted with one or more R6 groups.
3. A compound according to claim 1 , wherein R and/or R4 is H.
4. A compound according to claim 1 , wherein R, R1, R2, R' and R4 are each independently selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH2- heteroaryl, halogen, N02, CF3, OH, O-alkyl, O-heteroalkyl, 0-C3.8 cycloalkyl, O-aryl, O-heteroaryl, NH2, NH-alkyl, NH-heteroalkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH- CioO-aryl, NHO-aryl, NHO-heteroaryl, NHCH2-aryl, N(alkyl)2, N(cycloalkyl)2, N(heterocycloalkyl)2, N-(alkyl)(aryl), SH-alkyl, SH-aryl, SH-heteroaryl, S-heteroalkyl, S-C3.8 cycloalkyl, and R9; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl, CN, OH, O-methyl, O-ethyl, 0-CF2, NH2, COOH, CONH2, heterocycloalkyl, CO- heterocycloalkyl, CF3 and S02N(CH3)2.
5. A compound according to claim 1 , wherein R3 is H, alkyl, O-alkyl, CN or halogen.
6. A compound according to claim 1, wherein m is an integer selected from 1 , 2 and 3.
7. A compound according to claim 1, wherein R6 is independently selected from the group consisting of H, alkyl, OH, halogen, O-alkyl, C02-alkyl, COOH, Ci_3-heterocycloalkyl, O-heteroalkyl, NH2, NH-alkyl, NH-heteroalkyl, NH-cycloalkyl, NH-R9 where R9 is CO(NH-alkyl), S02-alkyl, NH- alkyl-R9 where R9 is CF3, O-alkyl, CO(NH2) or C02-alkyl, N-(alkyl)2, N-(alkyl)(R9) where R9 is heteroalkyl, S02-alkyl, S02NH2, alkyl-R9 where R9 is C02-alkyl, and COOR9 where R9 is a CU3 alkyl or C] _6 alkyl; wherein said heterocycloalkyl and heteroaryl groups comprises at least one but no more than two heteroatoms selected from N, S and O, and wherein said alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl, CN, OH, O-methyl, O-ethyl, 0-CF2, NH2, COOH, CONH2, heterocycloalkyl, CO-heterocycloalkyl, CF3 and S02N(CH3)2.
8. A compound according to claim 1 , wherein A is cyclohexane, adamantane, tetrahydro-2H- pyran or piperidine optionally substituted with at least one of R6.
9. The use of a compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating cancer or another proliferative cell disease or condition.
10. A method of treating cancer or another proliferative cell disease or condition in a subject, the method comprising administering to said subject a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, diluent and/or excipient.
1 1. The use of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating cancer or another proliferative cell disease or condition.
12. A pharmaceutical composition or medicament comprising a compound according to any one of claims 1 to 8 and a pharmaceutically acceptable earner, diluent and/or excipient.
13. A method of modulating protein kinase activity in a cell, comprising introducing to or contacting said cell with an effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
14. The use of a compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a disease or condition in a subject characterised by over-expression of one or more CD enzyme and/or by one or more aberrant CDK activity.
15. A method of treating a disease or condition in a subject characterised by over-expression of one or more CDK. enzyme and/or by one or more aberrant CDK activity, the method comprising administering to said sub ject a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, solvate or prodrug thereof, optionally in combination with a pharmaceutically acceptable earner, diluent and/or excipient.
16. The use of a compound according to claim 1 , or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treating a disease or condition in a subject characterised by over-expression by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity.
PCT/AU2018/000011 2017-02-01 2018-02-01 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS WO2018141002A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3051604A CA3051604A1 (en) 2017-02-01 2018-02-01 Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
SG11201907095UA SG11201907095UA (en) 2017-02-01 2018-02-01 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
EP18748523.0A EP3577116A4 (en) 2017-02-01 2018-02-01 Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as thereapeutic agents
JP2019541271A JP7113528B2 (en) 2017-02-01 2018-02-01 N-Cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine derivatives as therapeutic agents
US16/482,867 US11111245B2 (en) 2017-02-01 2018-02-01 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
CN201880015860.9A CN110418789B (en) 2017-02-01 2018-02-01 Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents
AU2018214431A AU2018214431B2 (en) 2017-02-01 2018-02-01 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900290A AU2017900290A0 (en) 2017-02-01 Pyrimidin-2-amine derivatives as therapeutic compounds
AU2017900290 2017-02-01

Publications (2)

Publication Number Publication Date
WO2018141002A2 true WO2018141002A2 (en) 2018-08-09
WO2018141002A3 WO2018141002A3 (en) 2018-11-22

Family

ID=63039275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2018/000011 WO2018141002A2 (en) 2017-02-01 2018-02-01 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS

Country Status (8)

Country Link
US (1) US11111245B2 (en)
EP (1) EP3577116A4 (en)
JP (1) JP7113528B2 (en)
CN (1) CN110418789B (en)
AU (1) AU2018214431B2 (en)
CA (1) CA3051604A1 (en)
SG (1) SG11201907095UA (en)
WO (1) WO2018141002A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362852A (en) * 2018-12-25 2020-07-03 浙江瑞博制药有限公司 Preparation method of drug intermediate 1-tert-butyloxycarbonyl-3-azetidinone
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
WO2021003517A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
WO2021030537A1 (en) * 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US12084438B2 (en) 2018-01-29 2024-09-10 Merck Patent Gmbh GCN2 inhibitors and uses thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022596A1 (en) 1995-12-18 1997-06-26 Zeneca Limited Quinazoline derivatives
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
WO1998013354A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
WO1999002166A1 (en) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Use of colchinol derivatives as vascular damaging agents
WO2000040529A1 (en) 1999-01-07 2000-07-13 Angiogene Pharmaceuticals Ltd. Colchinol derivatives as vascular damaging agents
WO2000041669A2 (en) 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Benzimidazole vascular damaging agents
WO2000047212A1 (en) 1999-02-10 2000-08-17 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2001094341A1 (en) 2000-06-06 2001-12-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
WO2010049731A1 (en) 2008-10-29 2010-05-06 Astrazeneca Ab Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors
WO2015154039A2 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2017020065A1 (en) 2015-08-04 2017-02-09 University Of South Australia N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1518550A (en) * 2001-06-21 2004-08-04 ʷ��˿�������ȳ�ķ���޹�˾ Imidazo [1,2-A] pyridine derivatives for prophylaxis and treatment of herpes viral infections
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
EP1432712B1 (en) * 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
JP2008519260A (en) * 2004-10-29 2008-06-05 トレック インコーポレイテッド Ion balance monitor
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US8569306B2 (en) * 2009-02-24 2013-10-29 Hoffmann-La Roche, Inc. JNK modulators
BR112012030814A2 (en) * 2010-06-04 2019-09-24 Hoffmann La Roche jnk inhibitors
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022596A1 (en) 1995-12-18 1997-06-26 Zeneca Limited Quinazoline derivatives
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
WO1998013354A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
WO1999002166A1 (en) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Use of colchinol derivatives as vascular damaging agents
WO2000040529A1 (en) 1999-01-07 2000-07-13 Angiogene Pharmaceuticals Ltd. Colchinol derivatives as vascular damaging agents
WO2000041669A2 (en) 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Benzimidazole vascular damaging agents
WO2000047212A1 (en) 1999-02-10 2000-08-17 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2001094341A1 (en) 2000-06-06 2001-12-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
WO2010049731A1 (en) 2008-10-29 2010-05-06 Astrazeneca Ab Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors
WO2015154039A2 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2017020065A1 (en) 2015-08-04 2017-02-09 University Of South Australia N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 1994
"Prodrugs: challenges and rewards", 2007, SPRINGER
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING CO.
ARAKI ET AL., PLAS ONE, vol. 10, no. 1, 2015, pages e0116929
ASGHAR ET AL., NAT REV DRUG DISCOV, vol. 14, no. 2, 2015, pages 130 - 46
BERGE ET AL., JPHARM SCI, vol. 66, 1977, pages 1 - 19
CHINN ET AL., J CANCER RES CLIN ONCOL, vol. 140, no. 7, 2014, pages 1137 - 1349
DE FALCO ET AL., CANCER BIOL THER, vol. 4, no. 3, 2005, pages 277 - 281
DESAI ET AL., PLOS ONE, vol. 8, no. 3, 2013, pages e59588
DIAB S. ET AL., CHEMEDCHEM, vol. 9, 2014, pages 962 - 972
GARY ET AL., ONCOTARGET, vol. 7, no. 25, 2016, pages 38598 - 38611
GREGORY ET AL., LEUKEMIA, vol. 29, no. 6, 2015, pages 1437 - 1441
HARTSINK SEGERS ET AL., LEUKEMIA, vol. 27, no. 3, 2013, pages 560 - 568
HITOSHI ET AL., NAGOYA JMED SCI, vol. 77, no. 1-2, 2015, pages 7 - 17
HU ET AL., MOL CANCER THER, vol. 14, no. 7, 2015, pages 1532 - 1539
JAIN ET AL., CURR DRUG TARGETS, vol. 15, no. 5, 2014, pages 539 - 50
LAPENNA ET AL., NAT REV DRUG DISCOV, vol. 8, no. 7, 2009, pages 547 - 66
LEINWEBER FJ, DRUGMETAB REV, vol. 18, 1987, pages 379 - 439
LI ET AL., CURR CANCER DRUG TARGETS, vol. 15, no. 3, 2015, pages 196 - 204
MACARULLA ET AL., RECENT PAT ANTICANCER DRUG DISCOV, no. 2, 2008, pages 114 - 22
MICHAELIS ET AL., PLOS ONE, vol. 9, no. 9, 2014, pages el08758
MITA ET AL., CLIN BREAST CANCER, vol. 14, no. 3, 2014, pages 169 - 176
PALLER ET AL., CANCER MED, vol. 3, no. 5, 2014, pages 1322 - 1335
RAHAMAN ET AL., ENDOCR RELAT CANCER, 2016, pages ERC-16 - 0299
SCHWARTZ ET AL., INVEST NEW DRUGS, vol. 31, no. 2, 2013, pages 370 - 80
See also references of EP3577116A4
SIMONE ET AL., CELL DEATH AND DIFFER, vol. 14, no. 1, pages 192 - 195
STEPHENSON ET AL., LUNG CANCER, vol. 83, no. 2, 2014, pages 219 - 223
STERN ET AL., CRITICAL REVIEWS IN ONCOLOGY/HAEMATOLOGY, vol. 54, 2005, pages 1 - 29
TRIFONOV ET AL., CURR OPIN BIOTECHNOL, vol. 24, no. S 1, 2013, pages S114 - S115
WALSBY ET AL., LEUKEMIA, vol. 25, no. 3, 2011, pages 411 - 419
WALSBY ET AL., ONCOTARGET, vol. 5, no. 17, 2014, pages 7691 - 7704
WANDER ET AL., THER ADV HEMATOL, vol. 5, no. 3, 2014, pages 65 - 77
WANG S ET AL., J MED CHEM, vol. 47, 2004, pages 1662 - 1675
WANG, S ET AL., TRENDS PHARMACOL SCI, vol. 29, no. 6, 2008, pages 302 - 313
YAMAMOTO ET AL., J CLIN INVEST, vol. 124, no. 8, 2014, pages 3479 - 3488

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12084438B2 (en) 2018-01-29 2024-09-10 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
US11352356B2 (en) 2018-03-13 2022-06-07 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN111362852A (en) * 2018-12-25 2020-07-03 浙江瑞博制药有限公司 Preparation method of drug intermediate 1-tert-butyloxycarbonyl-3-azetidinone
CN111362852B (en) * 2018-12-25 2023-06-16 浙江瑞博制药有限公司 Preparation method of medicine intermediate 1-tert-butoxycarbonyl-3-azetidinone
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN114269742A (en) * 2019-07-10 2022-04-01 常州千红生化制药股份有限公司 Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents
WO2021003517A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2021030537A1 (en) * 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US12065448B2 (en) 2019-09-18 2024-08-20 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Also Published As

Publication number Publication date
AU2018214431A1 (en) 2019-08-29
CN110418789A (en) 2019-11-05
EP3577116A2 (en) 2019-12-11
US11111245B2 (en) 2021-09-07
EP3577116A4 (en) 2020-12-02
JP2020505419A (en) 2020-02-20
WO2018141002A3 (en) 2018-11-22
CA3051604A1 (en) 2018-08-09
JP7113528B2 (en) 2022-08-05
CN110418789B (en) 2022-03-25
SG11201907095UA (en) 2019-08-27
AU2018214431B2 (en) 2021-07-29
US20200231586A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
AU2018214431B2 (en) Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
US11970491B2 (en) N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
EP3630749B1 (en) 2-quinolone derived inhibitors of bcl6
DK3149008T3 (en) Specific protein kinase inhibitors
CA3150689A1 (en) Heterocyclic compounds as kinase inhibitors
MX2014014112A (en) New compounds.
CN114502555B (en) Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridin-3-yl) pyrimidin-2-amine for the treatment of proliferative diseases and disorders
TWI793877B (en) Heterocyclic compound as diacrylglycerol kinases inhibitor and use thereof
CN114269742B (en) Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18748523

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3051604

Country of ref document: CA

Ref document number: 2019541271

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018214431

Country of ref document: AU

Date of ref document: 20180201

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018748523

Country of ref document: EP

Effective date: 20190902